Johnson & Johnson (JNJ)

Company ID: 8 | CIK: 0000200406
10-Q view:
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-K data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-K data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-K data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
Segments are charted by their disclosed metrics (revenue, segment profit, etc.). Each line is a single segment. Reconciliation/corporate items are excluded. Major customers are shown as a percentage of revenue. Operational KPIs are grouped by metric concept; sub-metrics appear as separate lines.

Geographic Segments

No 10-Q data
No 10-Q data

Business Unit / Product Segments

Major Customers (% of Revenue)

No 10-Q data

Operational KPIs

Plan assets (aum)

No 10-Q data

Vaccine manufacturing sites (capacity)

No 10-K data

Voluntary turnover rate (churn)

No 10-Q data

Pending plaintiffs (claims_count)

No 10-K data

Stockholders of record (customers)

No 10-Q data

Employee survey participation (engagement)

No 10-Q data

Full-time equivalent positions (headcount)

Acquisition/divestiture impact on growth (other)

No 10-K data

Actelion shares tendered (other)

No 10-K data

Advertising expense (other)

No 10-Q data

Advertising expenses (other)

No 10-Q data

Alleged PROPULSID deaths (other)

No 10-K data

Amortization expense (other)

No 10-K data

Annual cost savings (other)

No 10-K data

Antibody-mediated PRCA reports (other)

No 10-K data

Average shares outstanding (other)

No 10-K data

COVID-19 vaccine commitments (other)

No 10-K data

COVID-19 vaccine supply commitments (other)

No 10-K data

Cash and cash equivalents (other)

No 10-K data

Cash and marketable securities (other)

No 10-K data

Cash collateral paid (other)

No 10-K data

Cash dividend per share (other)

No 10-K data

Cash dividends per share (other)

No 10-K data

Cash, cash equivalents and marketable securities (other)

No 10-K data

Commercial paper balance (other)

No 10-K data

Commercial paper outstanding (other)

No 10-K data

Commercial paper rate (other)

No 10-K data

Commercial paper weighted average interest rate (other)

No 10-K data

Commercial paper weighted average maturity (other)

No 10-K data

Common Shares Outstanding (other)

No 10-Q data

Common Stock Outstanding (other)

No 10-Q data

Common Stock Shares Outstanding (other)

No 10-K data

Common Stock outstanding (other)

No 10-Q data

Common shares outstanding (other)

Common stock outstanding (other)

Common stock record holders (other)

No 10-Q data

Common stock shares outstanding (other)

No 10-K data

Consecutive dividend increase years (other)

No 10-K data

Consecutive years of dividend increases (other)

No 10-K data

Consumer franchise sales (other)

No 10-K data

Contract manufacturing commitments (other)

No 10-K data

Countries of Operation (other)

No 10-Q data

Countries of operation (other)

No 10-Q data

Countries where products sold (other)

No 10-Q data

Countries with manufacturing (other)

No 10-Q data

Countries with operations (other)

No 10-Q data

Countries with sales (other)

No 10-Q data

Countries with subsidiaries (other)

No 10-Q data

Credit facility availability (other)

No 10-K data

Credit facility available (other)

No 10-K data

Credit facility capacity (other)

No 10-K data

Credo survey participation (other)

No 10-Q data

Cross currency swap notional (other)

No 10-K data

Cumulative shares repurchased (other)

No 10-K data

Currency impact on sales (other)

No 10-K data

Currency impact on sales growth (other)

No 10-K data

DePuy shares tendered (other)

No 10-K data

Debt to total capital (other)

No 10-K data

Debt to total capital ratio (other)

No 10-K data

Derivative notional amount (other)

No 10-K data

Derivative notional outstanding (other)

No 10-K data

Device franchise sales (other)

No 10-K data

Diluted EPS (other)

No 10-K data

Diluted average shares outstanding (other)

No 10-K data

Dividends paid per share (other)

No 10-Q data

Drug-eluting stent sales share (other)

No 10-K data

Drugs over $100M sales (other)

No 10-Q data

Drugs over $50M sales (other)

No 10-Q data

Drugs with sales above $100 million (other)

No 10-Q data

Drugs with sales above $50 million (other)

No 10-Q data

Drugs with sales over $100 million (other)

No 10-Q data

Drugs with sales over $100M (other)

No 10-Q data

Drugs with sales over $50 million (other)

No 10-Q data

Drugs with sales over $50M (other)

No 10-Q data

EPREX patient-years (other)

No 10-K data

ESOP unallocated shares (other)

No 10-Q data

Effective income tax rate (other)

No 10-K data

Effective tax rate (other)

No 10-K data

Employee survey participation (other)

No 10-Q data

Employees separated (other)

No 10-K data

Fixed Interest Fund yield (other)

No 10-Q data

Forward FX contract notional (other)

No 10-K data

Global Supply Chain expected annual savings (other)

No 10-K data

Global Supply Chain expected total charges (other)

No 10-K data

Global Supply Chain total project costs (other)

No 10-K data

Health care reform rebate impact (other)

No 10-K data

Hepatitis C sales headwind (other)

No 10-K data

International sales growth (other)

No 10-K data

J&J shares held in plan (other)

No 10-Q data

Kenvue ownership stake (other)

No 10-K data

Largest product revenue share (other)

No 10-Q data

Manufacturing plants (other)

No 10-K data

Marketable securities (other)

No 10-K data

MedDev franchise sales (other)

No 10-K data

Medical devices franchise sales (other)

No 10-K data

Mesothelioma cases resolved (other)

No 10-K data

Net cash (other)

No 10-K data

Net cash position (other)

No 10-K data

Net debt (other)

No 10-K data

Net debt position (other)

No 10-K data

Net debt ratio (other)

No 10-K data

Net debt to net capital (other)

No 10-K data

New product sales contribution (other)

No 10-Q data

New product sales mix (other)

No 10-Q data

New product sales share (other)

No 10-Q data

New products sales share (other)

No 10-Q data

New products share of sales (other)

No 10-Q data

Number of Reportable Segments (other)

Operating Companies (other)

No 10-Q data

Operating companies (other)

No 10-Q data

Operating countries (other)

No 10-Q data

Operational sales growth (other)

No 10-K data

Opioid cases pending (other)

No 10-K data

Opioid cases remaining (other)

No 10-K data

Opioid lawsuits (other)

No 10-K data

Opioid settlement contribution (other)

No 10-K data

Opioid settlement paid (other)

No 10-K data

PRCA reporting rate (other)

No 10-K data

PROPULSID plaintiffs (other)

No 10-K data

Participant loans outstanding (other)

No 10-Q data

Pending PROPULSID cases (other)

No 10-K data

Pending U.S. plaintiffs (other)

No 10-K data

Pending claims (other)

No 10-K data

Pending lawsuit plaintiffs (other)

No 10-K data

Pending lawsuits (other)

No 10-K data

Pending liability plaintiffs (other)

No 10-K data

Pending plaintiffs (other)

No 10-K data

Pending product liability claimants (other)

No 10-K data

Pending product liability claims (other)

No 10-K data

Pending product liability lawsuits (other)

Pending product liability plaintiffs (other)

Pharmaceutical product sales (other)

No 10-K data

Plaintiffs in pending lawsuits (other)

No 10-K data

Plaintiffs in product liability lawsuits (other)

No 10-K data

Plan net assets available (other)

No 10-Q data

Planned employee separations (other)

No 10-K data

Positions eliminated (other)

Positions to be eliminated (other)

Positions to eliminate (other)

No 10-Q data

Practitioners trained (other)

No 10-K data

Prescription drugs marketed (other)

No 10-Q data

Product liability claimants (other)

Product revenue concentration (other)

No 10-Q data

Propulsid litigation - alleged deaths (other)

No 10-K data

Propulsid litigation - lawsuits filed (other)

No 10-K data

Propulsid litigation - named individuals (other)

No 10-K data

Quarterly cash dividend per share (other)

No 10-K data

Quarterly dividend per share (other)

No 10-K data

R&D Expenditure (other)

No 10-Q data

R&D Expenditures (other)

No 10-Q data

R&D as percent of sales (other)

No 10-Q data

R&D expense (other)

No 10-Q data

R&D intensity (other)

No 10-Q data

R&D percent of sales (other)

No 10-Q data

RISPERDAL market share (other)

No 10-K data

Record holders of Common Stock (other)

No 10-Q data

Record holders of common stock (other)

No 10-Q data

Remaining opioid cases (other)

No 10-K data

Remaining repurchase authorization (other)

No 10-K data

Remaining shares authorized for repurchase (other)

No 10-K data

Remicade revenue share (other)

No 10-Q data

Research and Development Costs (other)

No 10-Q data

Research and Development Expenditures (other)

No 10-Q data

Research and Development Expense (other)

No 10-Q data

Research and development costs (other)

No 10-Q data

Research and development expense (other)

No 10-Q data

Research and development facilities (other)

No 10-Q data

Research expense (other)

No 10-Q data

Research facilities (other)

No 10-Q data

Research facility countries (other)

No 10-Q data

Restricted stock and RSUs outstanding (other)

No 10-K data

Restricted stock outstanding (other)

No 10-K data

Restricted stock units outstanding (other)

No 10-K data

Restructuring accrual (other)

No 10-K data

Restructuring accrual remaining (other)

No 10-K data

Restructuring cash outlays (other)

No 10-K data

Restructuring charges (other)

No 10-K data

Restructuring charges recorded (other)

No 10-K data

Restructuring cost savings (other)

No 10-K data

Restructuring positions eliminated (other)

Restructuring positions planned (other)

No 10-K data

Restructuring program charges (other)

No 10-K data

Restructuring reserve (other)

No 10-K data

Restructuring reserve balance (other)

No 10-K data

Restructuring severance reserve (other)

No 10-K data

STELARA biosimilar headwind (other)

No 10-K data

STELARA decline impact (other)

No 10-K data

Sales from new products (other)

No 10-Q data

Severance reserve balance (other)

No 10-K data

Share repurchase program authorized (other)

No 10-K data

Share repurchase program remaining (other)

No 10-K data

Shareowners of record (other)

No 10-Q data

Shares exercised under stock option plans (other)

No 10-K data

Shares granted under stock option plans (other)

No 10-K data

Shares outstanding (other)

No 10-K data

Shares repurchased (other)

No 10-K data

Shares repurchased under buyback program (other)

No 10-K data

Stock options exercisable (other)

No 10-K data

Stock options outstanding (other)

No 10-K data

Stock repurchase program size (other)

No 10-K data

Stockholders of record (other)

No 10-Q data

Subsidiaries (other)

No 10-Q data

Supplier finance obligations (other)

No 10-K data

Suspected PRCA reports (other)

No 10-K data

Synthes acquisition net earnings (other)

No 10-K data

Synthes acquisition sales (other)

No 10-K data

Talc claimants (other)

No 10-Q data

Talc litigation plaintiffs (other)

No 10-K data

Talc litigation reserve (other)

No 10-K data

Talc plaintiffs (other)

No 10-K data

Talc reserve (other)

No 10-K data

Talc trust reserve (other)

No 10-K data

Top product revenue share (other)

No 10-Q data

Total borrowings (other)

No 10-K data

Total debt (other)

No 10-K data

Total debt percentage of total capital (other)

No 10-K data

Total debt position (other)

No 10-K data

Total debt ratio (other)

No 10-K data

Total debt to total capital (other)

No 10-K data

Treasury shares (other)

No 10-K data

Unrecognized tax benefits (other)

No 10-K data

Vaccine manufacturing sites (other)

No 10-K data

Voluntary turnover rate (other)

No 10-Q data

Weighted average diluted shares (other)

No 10-K data

Weighted average effective interest rate (other)

No 10-K data

Weighted average shares outstanding (other)

No 10-K data

Year 2000 compliance costs (other)

No 10-K data

Year 2000 cost estimate (other)

No 10-K data

Year 2000 costs estimate (other)

No 10-K data

Year 2000 costs expensed (other)

No 10-K data

Year 2000 costs incurred (other)

No 10-K data

Year 2000 readiness costs (other)

No 10-K data

Year 2000 total cost estimate (other)

No 10-K data

Year 2000 total estimated cost (other)

No 10-K data

Manufacturing facilities (properties)

Voluntary turnover rate (retention)

No 10-Q data

PRCA reports (safety_incidents)

No 10-K data

Common Stock Outstanding (shares)

No 10-Q data

Manufacturing square footage (square_footage)

No 10-Q data

Plan participants (users)

No 10-Q data
Human capital disclosures. Workforce totals and demographics are point-in-time. Flow metrics use the year-to-date period for 10-Q and full year for 10-K. Workforce actions (RIFs, restructurings, acquisition-related changes) are listed in the table at the bottom.

Workforce Totals

No 10-Q data
No 10-Q data

Demographics

No demographic data found.

Workforce Breakdowns

No 10-Q data

HCM Metrics — Point-in-Time

No 10-Q data

HCM Metrics — Flow (Annual / YTD)

No 10-Q data

Workforce Actions

Period EndTypeStatusAffected% WorkforceAnnouncedExpected CompletionGeographySegment / FunctionChargeSourceNote
2026-06-28restructuringin_progress2026-042029-12-31Innovative Medicine — supply chain / manufacturing locationsUSD 200 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		New supply chain restructuring program initiated in fiscal Q2 2026 to exit certain manufacturing locations; estimated total costs $650-$750 million including site and supplier exit costs, decommissioning and asset impairments. Q2 2026 charge of $200 million primarily asset impairments ($18M in cost of products sold, $182M in other income/expense).
2026-06-28restructuringin_progress20252026-12-31MedTech — Surgery franchiseUSD 59 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program to exit certain non-strategic product lines and optimize select sites; Q2 2026 pre-tax expense $59 million ($31M restructuring, $4M cost of products sold, $24M other income/expense), primarily product exits. Total program costs estimated $0.6-$0.7 billion; ~$0.3 billion recorded to date.
2026-06-28restructuringin_progress20232026-12-31MedTech — Orthopaedics franchiseUSD 17 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program to exit certain markets, product lines and distribution network arrangements; Q2 2026 pre-tax expense $17 million ($3M restructuring, $13M cost of products sold, $1M other income/expense). Total project cost approximately $1.0 billion; ~$0.8 billion recorded to date. Related: Orthopaedics business separation announced October 2025.
2026-06-28restructuringin_progress2026-06-282029-12-31Innovative MedicineUSD 650 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Supply chain program initiated in fiscal Q2 2026 to exit certain manufacturing locations; estimated total program cost of $650-750 million. $200 million recorded in Q2 2026, primarily asset impairments. No employee count disclosed.
2026-06-28restructuringin_progress2025-01-012026-12-31MedTech — Surgery franchiseUSD 650 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program initiated in fiscal 2025 to exit non-strategic product lines and optimize sites; estimated total cost $0.6-0.7 billion, ~$0.3 billion recorded to date. Announcement date approximate (fiscal 2025, month not disclosed). No employee count disclosed.
2026-06-28restructuringin_progress2023-01-012026-12-31MedTech — Orthopaedics franchiseUSD 1,000 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program initiated in fiscal 2023 to exit markets, product lines and distribution arrangements; ~$0.8 billion recorded to date, total ~$1.0 billion at completion in fiscal Q4 2026. Announcement date approximate (fiscal 2023, month not disclosed). No employee count disclosed.
2026-06-28acquisition_additionannounced2026-06-082026-09-30Innovative MedicineUSD 1,000 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Firefly Bio, Inc. for $1 billion in cash; closing expected in fiscal Q3 2026 subject to regulatory approvals. Headcount added not disclosed.
2026-06-28divestiture_reductionannounced2025-10-012027-10-01MedTech — OrthopaedicsMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Intention to separate the Orthopaedics business announced October 2025 (day not disclosed); targeted completion within 18 to 24 months of announcement. Headcount impact not disclosed.
2026-06-28restructuringin_progress2026-03-292029-12-31WorldwideInnovative MedicineUSD 200 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Supply chain restructuring program to exit certain manufacturing locations. Estimated total costs $650M-$750M. Q2 2026 charge of $200M primarily related to asset impairments. Employee count not disclosed.
2026-06-28restructuringin_progress2025-01-012026-12-31WorldwideMedTech - SurgeryUSD 59 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Surgery franchise restructuring to exit non-strategic product lines and optimize sites. Estimated total costs $600M-$700M. Q2 2026 pre-tax expense $59M. Employee count not disclosed.
2026-06-28restructuringin_progress2023-01-012026-12-31WorldwideMedTech - OrthopaedicsUSD 17 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Orthopaedics franchise restructuring to exit certain markets and product lines. Estimated total cost ~$1.0B. Q2 2026 pre-tax expense $17M. Employee count not disclosed.
2026-06-28restructuringin_progressUSD 34,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-06-28restructuringin_progressSeparation Related Costs [Member] / Innovative Medicine [Member]USD 200,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-06-28restructuringin_progressInnovative Medicine [Member]USD 200,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-06-28restructuringin_progressOperating Segments [Member] / Innovative Medicine [Member]USD 200,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-06-28restructuringin_progressOperating Segments [Member] / MedTech Surgery Franchise [Member]USD 59,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-06-28restructuringin_progressOperating Segments [Member] / MedTech [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-06-28restructuringin_progressOperating Segments [Member]USD 276,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-06-28restructuringin_progressMedTech Surgery Franchise [Member]USD 31,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-06-28restructuringin_progressMedTech [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-29restructuringin_progress2025-01-012026-12-31MedTech — Surgery franchiseUSD 55 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program initiated in fiscal 2025 to exit non-strategic product lines and optimize sites; Q1 2026 pre-tax charge of $55 million primarily for product exits ($30M in Restructuring, $20M in Cost of products sold, $5M in Other income/expense). Approximately $0.3 billion of project costs recorded to date; total program estimated at $0.9-$1.0 billion, expected substantially complete by end of fiscal 2026. No employee counts disclosed.
2026-03-29restructuringcompleted2023-01-012025-12-31MedTech — Orthopaedics franchiseUSD 7 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program initiated in fiscal 2023 to exit certain markets, product lines and distribution arrangements; substantially completed in fiscal 2025. Q1 2026 pre-tax charge of $7 million primarily for market and product exits. Approximately $0.8 billion of total project costs recorded since announcement. No employee counts disclosed.
2026-03-29divestiture_reductionannounced2025-10-01MedTech — OrthopaedicsUSD 100 (millions)MD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Company announced intention in October 2025 to separate its Orthopaedics business, targeting completion within 18-24 months of announcement; multiple separation paths still being explored. Q1 2026 included approximately $0.1 billion of Orthopaedics separation-related charges. No headcount impact quantified.
2026-03-29restructuringin_progress20252026-12-31MedTech — Surgery franchiseUSD 55 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program initiated in fiscal 2025 to exit non-strategic product lines and optimize sites. Q1 2026 pre-tax expense of $55M comprises $30M in Restructuring, $20M in Cost of products sold, $5M in Other (income)/expense. Total program cost estimated at $0.9B–$1.0B; ~$0.3B recorded to date. No employee counts disclosed.
2026-03-29restructuringcompleted20232025MedTech — Orthopaedics franchiseUSD 7 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program initiated in fiscal 2023 covering market, product line and distribution network exits; filer states it was substantially completed in fiscal 2025, yet $7M of pre-tax expense was still recorded in Q1 2026. ~$0.8B total project costs recorded since announcement. No employee counts disclosed.
2026-03-29divestiture_reductionin_progress2025-10MedTech — OrthopaedicsMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Announced intention to separate the Orthopaedics business; filer targeting completion within 18 to 24 months of the October 2025 announcement (i.e., between approximately 2027-04 and 2027-10). No headcount impact disclosed; a $0.1B Orthopaedics separation-related charge was recorded in Other (income)/expense in Q1 2026.
2026-03-29restructuringin_progress2025-01-012026-12-31MedTech Segment Surgery franchiseUSD 55 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program initiated in fiscal 2025 to simplify operations by exiting non-strategic product lines. Q1 2026 pre-tax expense of $55 million primarily related to product exits. Total program costs estimated between $0.9 billion and $1.0 billion.
2026-03-29restructuringcompleted2023-01-012025-12-31MedTech Segment Orthopaedics franchiseUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program initiated in fiscal 2023 to streamline operations. Substantially completed in fiscal 2025. Q1 2026 pre-tax expense of $7 million primarily related to market and product exits.
2026-03-29restructuringin_progressUSD 32,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-29restructuringin_progressSeparation Related Costs [Member] / MedTech [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-29restructuringin_progressOperating Segments [Member] / MedTech Surgery Franchise [Member]USD 55,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-29restructuringin_progressOperating Segments [Member] / MedTech [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-29restructuringin_progressOperating Segments [Member]USD 62,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-29restructuringin_progressRestructuring Charges [Member] / MedTech Surgery Franchise [Member]USD 30,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-29restructuringin_progressCosts of Goods and Services Sold [Member] / MedTech Surgery Franchise [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-29restructuringin_progressOther Income Expense Net [Member] / MedTech Surgery Franchise [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-12-28restructuringin_progress20252026GlobalMedTech — Surgery franchiseUSD 205 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Program initiated in fiscal 2025 to exit certain non-strategic product lines and optimize select sites. FY2025 pre-tax expense of $205 million (recorded across Restructuring, Other income/expense and Cost of products sold); estimated total program cost $0.9–$1.0 billion, expected substantially complete by end of fiscal 2026. Employee headcount impact not disclosed.
2025-12-28restructuringcompleted20232025GlobalMedTech — Orthopaedics franchiseUSD 307 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year program initiated fiscal 2023 to exit certain markets, product lines and distribution arrangements. FY2025 pre-tax expense of $307 million; cumulative program cost approximately $0.8 billion. Substantially completed in fiscal 2025. Employee headcount impact not disclosed. (Prior-year charges of $167M in 2024 and $319M in 2023 excluded per current-year-only rule.)
2025-12-28divestiture_reductionannounced2025-102027-04GlobalMedTech — Orthopaedics (to be named DePuy Synthes)Item_1_Business
f5-10k / GLM-5.3-flash-HTML		Company announced intention to separate its Orthopaedics business, exploring multiple separation paths with targeted completion 18–24 months after announcement (approximately April–October 2027). In connection, $1.7 billion of DePuy Synthes trademarks were reclassified to indefinite-lived intangibles. No headcount or separation charge quantified in this filing.
2025-12-28acquisition_additioncompleted2025-04-022025-04-02GlobalInnovative Medicine — NeuroscienceUSD 15 (billions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition of Intra-Cellular Therapies completed April 2, 2025 for $14.5 billion in an all-cash merger (adds CAPLYTA and neuroscience pipeline; funded partly by $9.2 billion senior notes issued Q1 2025). Acquisition-related pre-tax costs of $0.4 billion in fiscal 2025. Employee headcount added through the acquisition not disclosed.
2025-12-28acquisition_additioncompleted2025-12-262025-12-26GlobalInnovative Medicine — OncologyUSD 3 (billions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		All-cash acquisition of Halda Therapeutics, a clinical-stage biotechnology company with a RIPTAC platform for solid tumors including prostate cancer; $3.05 billion net of cash acquired, including $0.2 billion acquisition-related costs. Employee headcount added through the acquisition not disclosed.
2025-12-28restructuringin_progress2026-12-31WorldwideMedTech — Surgery franchiseUSD 205 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Program initiated in fiscal 2025 to simplify operations by exiting non-strategic product lines and optimizing select sites; $205M pre-tax FY2025 expense ($76M in Restructuring, $122M in Other income/expense, $7M in Cost of products sold). Estimated total program cost $0.9B–$1.0B, substantially complete by end of fiscal 2026. Employees affected not disclosed.
2025-12-28restructuringcompleted2023WorldwideMedTech — Orthopaedics franchiseUSD 307 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year program initiated fiscal 2023 (exit certain markets, product lines, distribution arrangements); only FY2025 activity captured ($307M pre-tax: $152M Restructuring, $84M Cost of products sold, $71M Other income/expense). Program substantially completed in fiscal 2025; cumulative program costs of approximately $0.8B since announcement. Employees affected not disclosed.
2025-12-28acquisition_additioncompleted2025-04-02United StatesInnovative Medicinebusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Intra-Cellular Therapies, Inc. (CAPLYTA) for $14.5B total consideration; headcount added not disclosed.
2025-12-28acquisition_additioncompleted2025-12-26United StatesInnovative Medicinebusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		All-cash acquisition of Halda Therapeutics OpCo, Inc. for approximately $3.05B net of cash acquired; headcount added not disclosed.
2025-12-28otherannounced2025-10WorldwideMedTech — Orthopaedics (DePuy Synthes)Item_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Announced intention to separate the Orthopaedics business; multiple separation paths under exploration with targeted completion 18 to 24 months after the October 2025 announcement. No workforce impact quantified in the filing.
2025-12-28restructuringin_progress2025-01-012026-12-31WorldwideMedTech - SurgeryUSD 0 (billions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Program to simplify and focus operations by exiting non-strategic product lines and optimizing sites. Estimated total costs $0.9B-$1.0B. Substantially completed by end of fiscal 2026.
2025-12-28restructuringcompleted2023-01-012025-12-28WorldwideMedTech - OrthopaedicsUSD 0 (billions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Program to streamline operations by exiting markets, product lines and distribution networks. Total project costs approx $0.8B recorded since announcement. Substantially completed in fiscal 2025.
2025-12-28restructuringcompleted2023-01-012024-12-29WorldwideInnovative MedicineUSD 0 (billions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Prioritization of R&D investment resulting in exit of certain programs. Total project costs approx $0.6B. Completed in fiscal fourth quarter of 2024.
2025-12-28acquisition_additioncompleted2025-04-022025-04-02WorldwideInnovative MedicineUSD 15 (billions)business_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Intra-Cellular Therapies, Inc. closed April 2, 2025.
2025-12-28acquisition_additioncompleted2025-12-262025-12-26WorldwideInnovative MedicineUSD 3 (billions)business_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Halda Therapeutics OpCo, Inc. closed December 26, 2025.
2025-12-28restructuringin_progress2025-01-012026-12-31WorldwideMedTech - SurgeryUSD 205 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Program initiated in FY2025 to simplify operations by exiting non-strategic product lines. Total estimated costs $0.9B-$1.0B. Employee count not disclosed.
2025-12-28restructuringcompleted2023-01-012025-12-28WorldwideMedTech - OrthopaedicsUSD 307 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Program initiated in FY2023. Substantially completed in FY2025. Total project costs approx $0.8B. Employee count not disclosed.
2025-12-28restructuringcompleted2023-01-012024-12-29WorldwideInnovative Medicine - R&DUSD 0 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Program initiated in FY2023 to prioritize R&D investment. Completed in FY2024. No charge recorded in FY2025. Employee count not disclosed.
2025-12-28otherannounced2025-10-012027-04-01WorldwideMedTech - OrthopaedicsItem_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Announced intention to separate Orthopaedics business. Targeted completion within 18-24 months. Employee impact not quantified.
2025-12-28restructuringin_progressUSD 228,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-28restructuringin_progressOperating Segments [Member] / MedTech [Member]USD 500,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-28restructuringin_progressSurgery Restructuring Plan [Member]USD 200,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-28restructuringin_progressOrthopaedics Restructuring Plan [Member]USD 300,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-28restructuringin_progressOperating Segments [Member] / Medtech Surgery Franchise [Member]USD 205,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-28restructuringin_progressOperating Segments [Member] / Orthopaedics Restructuring Plan [Member]USD 307,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-28restructuringin_progressOperating Segments [Member] / Innovative Medicine [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-28restructuringin_progressOperating Segments [Member]USD 512,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-28restructuringin_progressRestructuring Charges [Member] / Medtech Surgery Franchise [Member]USD 76,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-28restructuringin_progressOther Income Expense Net [Member] / Medtech Surgery Franchise [Member]USD 122,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-28restructuringin_progressCosts of Goods and Services Sold [Member] / Medtech Surgery Franchise [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-28restructuringin_progressRestructuring Charges [Member] / Medtech Ortho Franchise [Member]USD 152,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-28restructuringin_progressOther Income Expense Net [Member] / Medtech Ortho Franchise [Member]USD 71,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-28restructuringin_progressCosts of Goods and Services Sold [Member] / Medtech Ortho Franchise [Member]USD 84,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-09-28restructuringin_progress2025-01-012026-12-31MedTech — Surgery franchiseUSD 157 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program initiated in fiscal 2025 to simplify operations by exiting non-strategic product lines and optimizing select sites; total estimated program cost $0.9-$1.0 billion; fiscal nine months 2025 pre-tax expense $157 million ($128 million in Q3), primarily asset impairments and market/product exits.
2025-09-28restructuringin_progress2023-01-012025-12-31MedTech — Orthopaedics franchiseUSD 145 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program initiated in fiscal 2023 to streamline operations by exiting certain markets, product lines and distribution arrangements; total estimated program cost $0.7-$0.8 billion with approximately $0.6 billion recorded to date; fiscal nine months 2025 pre-tax expense $145 million ($40 million in Q3).
2025-09-28otherannounced2025-10-14MedTech — Orthopaedics businesssubsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Company announced intention to separate its Orthopaedics business, exploring multiple paths, with targeted completion within 18 to 24 months of the announcement; no employee counts disclosed.
2025-09-28restructuringin_progress2026-12-31GlobalMedTech — Surgery franchiseUSD 900 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program initiated in fiscal 2025 to exit non-strategic product lines and optimize sites; estimated total program cost is $0.9B–$1.0B. Q3 2025 pre-tax expense $128M; YTD 2025 $157M. No employee count disclosed.
2025-09-28restructuringin_progress2025-12-31GlobalMedTech — Orthopaedics franchiseUSD 700 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program initiated in fiscal 2023; estimated total program cost $0.7B–$0.8B, with approximately $0.6B recorded since announcement. Q3 2025 pre-tax expense $40M; YTD 2025 $145M. No employee count disclosed.
2025-09-28acquisition_additioncompleted2025-04-02United StatesInnovative MedicineUSD 14,500 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Intra-Cellular Therapies acquisition closed 2025-04-02 for total consideration of $14.5B; no headcount added disclosed. Acquisition-related costs before tax of $0.3B in YTD 2025, including $0.1B of accelerated equity award compensation.
2025-09-28otherannounced2025-10-14GlobalMedTech — Orthopaedicssubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter announcement of intention to separate the Orthopaedics business, targeting completion within 18–24 months of announcement; no headcount or charge disclosed.
2025-09-28restructuringin_progress2025-01-012026-12-31GlobalMedTech - SurgeryUSD 128 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Program initiated in fiscal 2025 to simplify operations by exiting non-strategic product lines. Q3 2025 expense of $128 million primarily included asset impairments and market/product exits. Total program estimated costs $0.9 billion - $1.0 billion.
2025-09-28restructuringin_progress2023-01-012025-12-31GlobalMedTech - OrthopaedicsUSD 40 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Program initiated in fiscal 2023 to streamline operations. Q3 2025 expense of $40 million primarily included asset impairments and market/product exits. Total program estimated costs $0.7 billion - $0.8 billion.
2025-09-28otherannounced2025-10-142027-10-14GlobalMedTech - Orthopaedicssubsequent_events
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Company announced intention to separate Orthopaedics business. Targeted completion within 18 to 24 months after initial announcement.
2025-09-28restructuringin_progress2025-01-012026-12-31WorldwideMedTech - SurgeryUSD 128 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program initiated in fiscal 2025 to simplify operations by exiting non-strategic product lines. Q3 2025 pre-tax expense of $128 million primarily included asset impairments and market/product exits. Total estimated program costs between $0.9 billion and $1.0 billion.
2025-09-28restructuringin_progress2023-01-012025-12-31WorldwideMedTech - OrthopaedicsUSD 40 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program initiated in fiscal 2023 to streamline operations. Q3 2025 pre-tax expense of $40 million primarily included market and product exits. Total estimated program costs between $0.7 billion and $0.8 billion.
2025-09-28otherannounced2025-10-142027-04-14WorldwideMedTech - Orthopaedicssubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Company announced intention to separate Orthopaedics business. Targeted completion within 18 to 24 months after announcement.
2025-09-28restructuringin_progressUSD 63,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-28restructuringin_progressMedTech [Member]USD 200,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-28restructuringin_progressOperating Segments [Member] / MedTech Surgery Franchise [Member]USD 128,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-28restructuringin_progressOperating Segments [Member] / MedTech [Member]USD 40,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-28restructuringin_progressOperating Segments [Member] / Innovative Medicine [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-28restructuringin_progressOperating Segments [Member]USD 168,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-28restructuringin_progressRestructuring Charges [Member] / MedTech Surgery Franchise [Member]USD 35,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-28restructuringin_progressCosts of Goods and Services Sold [Member] / MedTech Surgery Franchise [Member]USD 93,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-28restructuringin_progressOther Income Expense Net [Member] / MedTech Surgery Franchise [Member]USD 93,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-28restructuringin_progressRestructuring Charges [Member] / MedTech [Member]USD 28,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-28restructuringin_progressCosts of Goods and Services Sold [Member] / MedTech [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-28restructuringin_progressOther Income Expense Net [Member] / MedTech [Member]USD 30,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-29restructuringin_progress2025-01-012027-06-29MedTech — Surgery franchiseUSD 29 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program initiated in fiscal 2025 to simplify operations by exiting non-strategic product lines and optimizing select sites; total estimated program cost $0.9-$1.0 billion, expected to be completed over the next two years. Q2 2025 charge of $29 million recorded in Restructuring. No employee counts disclosed.
2025-06-29restructuringin_progress2023-01-012025-12-29MedTech — Orthopaedics franchiseUSD 50 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program initiated in fiscal 2023 to streamline operations by exiting certain markets, product lines and distribution network arrangements. Q2 2025 pre-tax expense of $50 million ($35 million in Restructuring, $15 million in Cost of products sold); six-month 2025 expense $105 million. Total project costs approximately $0.6 billion recorded to date; total estimated program cost $0.7-$0.8 billion, expected to be substantially completed by end of fiscal 2025. No employee counts disclosed.
2025-06-29restructuringin_progress2025-01-012026-12-31GlobalMedTech — Surgery franchiseUSD 900 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program initiated in fiscal 2025 to exit non-strategic product lines and optimize sites; estimated total program cost of $0.9B–$1.0B, expected completion over two years. $29M recorded in Q2 2025. No employee count disclosed.
2025-06-29restructuringin_progress2023-01-012025-12-31GlobalMedTech — Orthopaedics franchiseUSD 750 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program initiated in fiscal 2023 to streamline operations by exiting markets, product lines, and distribution arrangements. Approximately $0.6B recorded to date; estimated total $0.7B–$0.8B, substantially complete by end of fiscal 2025. No employee count disclosed.
2025-06-29restructuringin_progress2025-01-012027-06-30GlobalMedTech - SurgeryUSD 29 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Program initiated in fiscal 2025 to simplify operations by exiting non-strategic product lines and optimizing sites. Estimated total costs $0.9B-$1.0B. $29M expense recorded in Q2 2025.
2025-06-29restructuringin_progress2023-01-012025-12-31GlobalMedTech - OrthopaedicsUSD 50 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Program initiated in fiscal 2023 to streamline operations by exiting markets, product lines, and distribution networks. $50M expense recorded in Q2 2025 (including asset impairments). Total project costs approx $0.6B recorded to date.
2025-06-29restructuringin_progress2025-01-012027-06-29MedTech Segment Surgery franchiseUSD 29 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program initiated in fiscal 2025 to simplify operations by exiting non-strategic product lines and optimizing sites. Estimated total costs $0.9B-$1.0B. Q2 2025 charge was $29M.
2025-06-29restructuringin_progress2023-01-012025-12-31MedTech Segment Orthopaedics franchiseUSD 50 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program initiated in fiscal 2023 to streamline operations. Estimated total costs $0.7B-$0.8B. Q2 2025 pre-tax expense was $50M (includes asset impairments and market exits).
2025-06-29restructuringin_progressUSD 64,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-29restructuringin_progressMedTech [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-29restructuringin_progressMedTech Surgery Franchise [Member]USD 29,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-29restructuringin_progressOperating Segments [Member] / MedTech Surgery Franchise [Member]USD 29,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-29restructuringin_progressOperating Segments [Member] / MedTech [Member]USD 50,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-29restructuringin_progressOperating Segments [Member] / Innovative Medicine [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-29restructuringin_progressOperating Segments [Member]USD 79,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-29restructuringin_progressRestructuring Charges [Member] / MedTech [Member]USD 35,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-29restructuringin_progressCosts of Goods and Services Sold [Member] / MedTech [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-29restructuringin_progressOther Income Expense Net [Member] / MedTech [Member]USD 30,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-30restructuringin_progress2023-01-012025-12-29MedTech — Orthopaedics franchiseUSD 55 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program initiated fiscal 2023 to exit certain markets, product lines and distribution arrangements. Q1 2025 pre-tax charge of $55 million ($17M in Restructuring, $8M in Cost of products sold, $30M in Other (Income)/Expense), primarily asset impairments and market/product exits. Approximately $0.5 billion of total project costs recorded to date; estimated total program cost $0.7-$0.8 billion, expected completion by end of fiscal 2025. No employee counts disclosed.
2025-03-30restructuringin_progress2023-01-012025-12-31GlobalMedTech — Orthopaedics franchiseUSD 55 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pre-tax restructuring expense of $55M in Q1 2025 ($17M in Restructuring, $8M in COGS, $30M in Other (Income)/Expense). Program initiated in fiscal 2023 to streamline operations via market, product line, and distribution network exits. Total project costs of approximately $0.5B recorded since announcement; estimated total program cost $0.7B–$0.8B. No employee headcount affected disclosed.
2025-03-30restructuringcompleted2023-01-012024-12-29GlobalInnovative Medicine — R&D portfolio prioritizationrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		R&D investment prioritization program completed in fiscal Q4 2024; no restructuring expense recorded in Q1 2025 (Q1 2024 charge was approximately $0.1B, covering partnered/non-partnered program terminations and asset impairments). No employee headcount affected disclosed.
2025-03-30acquisition_additionannounced2025-04-022025-04-02United StatesInnovative Medicine — Intra-Cellular Therapies, Inc.USD 14,600 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Subsequent-event acquisition of Intra-Cellular Therapies closed April 2, 2025 for approximately $14.6B equity value ($132.00/share cash). Headcount added not disclosed; results included in Innovative Medicine segment from acquisition date. Funded by cash on hand and Q1 2025 debt issuance (~$9.2B senior unsecured notes).
2025-03-30restructuringin_progress2023-01-012025-12-31GlobalMedTech - OrthopaedicsUSD 55 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Program initiated in fiscal 2023 to streamline Orthopaedics operations. Q1 2025 pre-tax expense of $55 million primarily for asset impairments and market exits. Total program costs approx $0.5 billion recorded to date; estimated total $0.7-$0.8 billion.
2025-03-30acquisition_additioncompleted2024-05-31GlobalMedTech - Cardiovascularbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Shockwave Medical Inc. completed May 31, 2024. Results included in MedTech segment. No specific headcount disclosed.
2025-03-30acquisition_additioncompleted2024-06-20GlobalInnovative Medicinebusiness_combinations_footnote
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Proteologix, Inc. completed June 20, 2024. Results included in Innovative Medicine segment. No specific headcount disclosed.
2025-03-30acquisition_additioncompleted2024-03-07GlobalInnovative Medicinebusiness_combinations_footnote
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Ambrx Biopharma, Inc. completed March 7, 2024. Results included in Innovative Medicine segment. No specific headcount disclosed.
2025-03-30acquisition_additionannounced2025-04-02GlobalInnovative Medicinesubsequent_events
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Subsequent to quarter end, Company completed acquisition of Intra-Cellular Therapies, Inc. on April 2, 2025 for approx $14.6 billion. Results will be included in Innovative Medicine segment. No specific headcount disclosed.
2025-03-30restructuringin_progress2023-01-012025-12-31WorldwideMedTech - OrthopaedicsUSD 55 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program initiated in fiscal 2023 to streamline Orthopaedics operations by exiting certain markets, product lines, and distribution networks. Q1 2025 pre-tax expense of $55 million primarily included asset impairments and market/product exit costs. Total program costs estimated between $0.7 billion and $0.8 billion. Employee count not disclosed.
2025-03-30acquisition_additionannounced2025-04-02WorldwideInnovative MedicineUSD 14,600 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Completed acquisition of Intra-Cellular Therapies, Inc. on April 2, 2025 for approximately $14.6 billion. Headcount added not disclosed.
2025-03-30restructuringin_progressUSD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-30restructuringin_progressInnovative Medicine [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-30restructuringin_progressMedTech [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-30restructuringin_progressOperating Segments [Member] / MedTech [Member]USD 55,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-30restructuringin_progressOperating Segments [Member] / Innovative Medicine [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-30restructuringin_progressOperating Segments [Member]USD 55,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-30restructuringin_progressRestructuring Charges [Member] / MedTech [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-30restructuringin_progressCosts of Goods and Services Sold [Member] / MedTech [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-30restructuringin_progressOther Nonoperating Income (Expense) [Member] / MedTech [Member]USD 30,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-12-29restructuringcompleted20232024-12-29Innovative Medicine — research and developmentUSD 102 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Fiscal 2024 portion of a program begun in 2023 to prioritize R&D investment, exiting programs primarily in infectious diseases and vaccines (including the RSV adult vaccine program) via termination of development programs, asset impairments and divestments. Total program costs approximately $0.6 billion since announcement; program completed in fiscal Q4 2024. Headcount impact not quantified.
2024-12-29restructuringin_progress20232025MedTech — OrthopaedicsUSD 167 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Program initiated in fiscal 2023 to streamline operations by exiting certain markets, product lines and distribution network arrangements. Fiscal 2024 pre-tax expense of $167 million ($132 million in the Restructuring line and $35 million in Cost of products sold). Cumulative program costs approximately $0.5 billion; total estimated program costs $0.7–0.8 billion; completion expected by end of fiscal 2025. Headcount impact not quantified.
2024-12-29acquisition_additioncompleted2024-05-31MedTech — Cardiovascular (intravascular lithotripsy)USD 13 (billions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		All-cash merger at $335.00 per share; total enterprise value approximately $13.1 billion. The Item 1 headcount footnote explicitly states Shockwave is included in the fiscal 2024 employee count; number of employees added not disclosed.
2024-12-29divestiture_reductioncompleted2024MedTech — Surgery (ENT device business)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Divestiture completed during fiscal 2024 with approximately $0.3 billion in proceeds and an approximately $0.2 billion gain recorded in 2024 (also cited in MD&A as offsetting General Surgery growth). Workforce impact not quantified.
2024-12-29acquisition_additionannounced2025Innovative Medicine (CNS disorders)USD 15 (billions)subsequent_events
f5-10k / GLM-5.3-flash-HTML		Definitive agreement announced after fiscal year-end to acquire Intra-Cellular Therapies, Inc. for $132.00 per share in cash, total equity value approximately $14.6 billion; to be funded with cash and debt and expected to close later in 2025 subject to regulatory and stockholder approvals. Headcount impact not disclosed.
2024-12-29restructuringcompleted20232024-12-29GlobalInnovative Medicine — R&D (primarily infectious diseases and vaccines)USD 102 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		R&D prioritization program announced in fiscal 2023; fiscal 2024 charge of $102M recorded in Restructuring. Cumulative program cost approximately $0.6B since announcement; program completed in fiscal Q4 2024. No employees-affected count disclosed.
2024-12-29restructuringin_progress20232025-12-31GlobalMedTech — Orthopaedics franchiseUSD 167 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Market, product line and distribution network exits; fiscal 2024 pre-tax expense of $167M ($132M in Restructuring, $35M in Cost of products sold). Cumulative approximately $0.5B recorded to date; total program estimated at $0.7B-$0.8B, expected completion by end of fiscal 2025. No employees-affected count disclosed.
2024-12-29acquisition_additioncompleted2024-03-072024-03-07United StatesInnovative Medicinebusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Ambrx Biopharma, Inc. for approximately $2.0B equity value ($1.8B net of cash acquired); headcount added not disclosed.
2024-12-29acquisition_additioncompleted2024-05-312024-05-31United StatesMedTech — Cardiovascularbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Shockwave Medical Inc. at $335.00 per share; total enterprise value approximately $13.1B. Shockwave included in fiscal 2024 headcount; headcount added not separately disclosed.
2024-12-29acquisition_additioncompleted2024-06-202024-06-20United StatesInnovative Medicinebusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Proteologix, Inc. for approximately $0.8B net of cash acquired, with potential additional milestone payment; headcount added not disclosed.
2024-12-29divestiture_reductioncompleted20242024-12-29GlobalMedTechdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Divestiture of Acclarent with approximately $0.3B proceeds; headcount removed not disclosed.
2024-12-29divestiture_reductioncompleted20242024-12-29International (outside United States)Innovative Medicinediscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Divestiture of Ponvory outside the U.S. with approximately $0.2B proceeds; headcount removed not disclosed.
2024-12-29acquisition_additionannouncedUnited StatesInnovative Medicinesubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Intra-Cellular Therapies, Inc. for $132.00 per share (~$14.6B equity value), announced after fiscal year-end 2024; to be funded with cash on hand and debt; closing expected later in 2025 subject to approvals. Announcement date not specified in filing; headcount added not disclosed.
2024-12-29restructuringcompleted2023-01-012024-12-29WorldwideInnovative MedicineUSD 0 (billions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Program completed in fiscal fourth quarter 2024. Total project costs approx $0.6 billion since announcement. 2024 charge was $0.1 billion pre-tax.
2024-12-29restructuringin_progress2023-01-012025-12-31WorldwideMedTechUSD 0 (billions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Orthopaedics franchise restructuring. Total project costs approx $0.5 billion since announcement. Estimated total program costs $0.7-0.8 billion. Expected completion by end of fiscal 2025.
2024-12-29restructuringcompleted2023-01-012024-12-29WorldwideInnovative MedicineUSD 102 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Prioritization of R&D investment to focus on most promising medicines. Exits primarily in infectious diseases and vaccines. Program completed in fiscal fourth quarter of 2024. Total project costs approx $0.6 billion since announcement.
2024-12-29restructuringin_progress2023-01-012025-12-31WorldwideMedTechUSD 167 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Orthopaedics franchise restructuring to streamline operations by exiting certain markets, product lines and distribution network arrangements. Expected to be completed by end of fiscal year 2025. Total project costs approx $0.5 billion since announcement.
2024-12-29acquisition_additioncompleted2024-05-312024-05-31WorldwideMedTechbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Shockwave Medical Inc. completed May 31, 2024. Headcount included in total employee count.
2024-12-29acquisition_additioncompleted2024-03-072024-03-07WorldwideInnovative Medicinebusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Ambrx Biopharma, Inc. completed March 7, 2024.
2024-12-29acquisition_additioncompleted2024-06-202024-06-20WorldwideInnovative Medicinebusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Proteologix, Inc. completed June 20, 2024.
2024-12-29acquisition_additioncompleted2024-10-082024-10-08WorldwideMedTechbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of V-Wave Ltd completed October 8, 2024.
2024-12-29acquisition_additioncompleted2024-07-112024-07-11WorldwideInnovative Medicinebusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Yellow Jersey (global rights to NM26) completed July 11, 2024.
2024-12-29restructuringin_progressUSD 234,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-29restructuringin_progressOperating Segments [Member] / Innovative Medicine [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-29restructuringin_progressOperating Segments [Member] / MedTech [Member]USD 200,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-29restructuringin_progressR&D Restructuring Plan [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-29restructuringin_progressOrthopaedics Restructuring Plan [Member]USD 200,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-29restructuringin_progressOperating Segments [Member]USD 269,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-29restructuringin_progressInnovative Medicine [Member]USD 102,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-29restructuringin_progressRestructuring Charges [Member] / MedTech [Member]USD 132,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-29restructuringin_progressCosts of Goods and Services Sold [Member] / MedTech [Member]USD 35,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-09-29restructuringin_progress2023-01-01Innovative Medicine — R&D program exits (infectious diseases and vaccines, including RSV adult vaccine, hepatitis and HIV development)USD 100 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Fiscal 2023 R&D prioritization program; pre-tax restructuring expense of $0.1 billion in fiscal nine months 2024 (immaterial in Q3 2024); cumulative project costs of approximately $0.6 billion since announcement; majority of program completed with minor charges expected in remainder of year. Employee counts not disclosed.
2024-09-29restructuringin_progress2023-01-012025-12-31MedTech — Orthopaedics franchise (exiting certain markets, product lines and distribution network arrangements)USD 100 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Pre-tax restructuring expense of $0.1 billion in fiscal nine months 2024 (immaterial in Q3 2024), primarily market and product exit costs; cumulative project costs of approximately $0.4 billion since announcement; estimated total program cost of $0.7-$0.8 billion. Employee counts not disclosed.
2024-09-29restructuringin_progress20232024-12-31Innovative Medicine — Research and DevelopmentUSD 100 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pre-tax restructuring expense for fiscal nine months 2024; program covers R&D program exits (RSV adult vaccine, hepatitis, HIV). Total project costs of approximately $0.6 billion since announcement; majority completed with minor charges expected in remainder of fiscal 2024. No employee count disclosed.
2024-09-29restructuringin_progress20232025-12-31MedTech — OrthopaedicsUSD 107 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pre-tax restructuring expense for fiscal nine months 2024 (includes $92 million in Restructuring and $15 million in Cost of products sold); market and product exits. Total program estimated at $0.7-0.8 billion, expected completion by end of fiscal 2025. No employee count disclosed.
2024-09-29restructuringin_progress2023-01-012025-12-31GlobalInnovative MedicineUSD 0 (billions)restructuring_footnote
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Prioritization of R&D investment; exit of certain programs in infectious diseases and vaccines. Fiscal nine months 2024 expense was $0.1 billion. Total project costs approx $0.6 billion. Majority completed, minor charges expected in remainder of year.
2024-09-29restructuringin_progress2023-01-012025-12-31GlobalMedTechUSD 0 (billions)restructuring_footnote
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Orthopaedics franchise streamlining; exiting certain markets, product lines, and distribution networks. Fiscal nine months 2024 expense was $0.1 billion. Total project costs approx $0.4 billion. Estimated total program costs $0.7-$0.8 billion.
2024-09-29restructuringin_progress2023-01-012024-12-31GlobalInnovative MedicineUSD 0 (billions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Prioritization of R&D investment; exit of certain programs in infectious diseases and vaccines. Pre-tax expense of $0.1 billion in Q3 2024. Total project costs approx $0.6 billion since announcement. Majority completed.
2024-09-29restructuringin_progress2023-01-012025-12-31GlobalMedTechUSD 0 (billions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Orthopaedics franchise restructuring; exiting certain markets, product lines, and distribution networks. Pre-tax expense of $0.1 billion in Q3 2024. Total project costs approx $0.4 billion since announcement. Estimated total program cost $0.7-$0.8 billion.
2024-09-29restructuringin_progressUSD 41,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-29restructuringin_progressInnovative Medicine [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-29restructuringin_progressMedTech [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-29restructuringin_progressR&D Restructuring Plan [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-29restructuringin_progressOrthopaedics Restructuring Plan [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-29restructuringin_progressOperating Segments [Member] / Innovative Medicine [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-29restructuringin_progressOperating Segments [Member] / MedTech [Member]USD 28,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-29restructuringin_progressOperating Segments [Member]USD 47,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-29restructuringin_progressRestructuring Charges [Member] / MedTech [Member]USD 22,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-29restructuringin_progressCosts of Goods and Services Sold [Member] / MedTech [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progress2023-01-01Innovative Medicine — R&D portfolio prioritization (infectious diseases and vaccines program exits)USD 0 (billions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Fiscal six months 2024 pre-tax restructuring expense of $0.1 billion; fiscal Q2 2024 recorded restructuring income of $0.1 billion from asset divestments. Total project costs of approximately $0.6 billion recorded since announcement; majority of program completed, minor charges expected in remainder of year. No employee counts disclosed.
2024-06-30restructuringin_progress2023-01-012025-12-31MedTech — Orthopaedics franchise (market, product line and distribution network exits)USD 0 (billions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Pre-tax restructuring expense of $0.1 billion in both fiscal Q2 and fiscal six months 2024, primarily market and product exit costs. Total project costs approximately $0.4 billion recorded since announcement; estimated total program cost $0.7-$0.8 billion, expected completion by end of fiscal 2025. No employee counts disclosed.
2024-06-30restructuringin_progress2024-12-31GlobalInnovative Medicine — Research & DevelopmentUSD -63 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		R&D portfolio prioritization announced in fiscal 2023 (program exits mainly in infectious diseases and vaccines). Q2 2024 shows pre-tax restructuring income of $63M from asset divestments; six-months expense was $81M. No employee counts disclosed; majority of program complete with minor charges expected in remainder of 2024.
2024-06-30restructuringin_progress2025-12-31GlobalMedTech — OrthopaedicsUSD 52 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Orthopaedics restructuring initiated fiscal 2023 to streamline operations via market, product-line and distribution-network exits. Q2 2024 charge of $52M ($50M in Restructuring line, $2M in cost of products sold); six-months charge $79M. Total program cost estimated at $0.7B–$0.8B, expected completion end of fiscal 2025. No employee counts disclosed.
2024-06-30restructuringin_progress2023-01-012024-12-31GlobalInnovative MedicineUSD -63 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Fiscal 2023 R&D prioritization program. Q2 2024 income of $63M includes asset divestments and termination of program costs. Total project costs approx $0.6B recorded since announcement. Majority completed, minor charges expected in remainder of year.
2024-06-30restructuringin_progress2023-01-012025-12-31GlobalMedTechUSD 52 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Fiscal 2023 Orthopaedics franchise restructuring. Q2 2024 expense of $52M primarily for market and product exits. Total project costs approx $0.4B recorded. Estimated total program costs $0.7B-$0.8B, expected completion by end of fiscal 2025.
2024-06-30restructuringin_progress2023-01-012024-12-31GlobalInnovative MedicineUSD -63 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		R&D prioritization program announced in FY2023. Q2 2024 recorded pre-tax income of $0.1 billion (reported as $(63) million in table) due to asset divestments and termination of program costs. Majority of program completed.
2024-06-30restructuringin_progress2023-01-012025-12-31GlobalMedTechUSD 52 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Orthopaedics franchise restructuring announced in FY2023. Q2 2024 recorded pre-tax expense of $0.1 billion (reported as $52 million in table) for market and product exits. Expected completion by end of FY2025.
2024-06-30restructuringin_progressUSD -13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressInnovative Medicine [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressMedTech [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressR&D Restructuring Plan [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressOrthopaedics Restructuring Plan [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressOperating Segments [Member] / Innovative Medicine [Member]USD -63,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressOperating Segments [Member] / MedTech [Member]USD 52,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressOperating Segments [Member]USD -11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressRestructuring Charges [Member] / MedTech [Member]USD 50,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressCosts of Goods and Services Sold [Member] / MedTech [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progress2023-01-01Innovative Medicine — R&D program exits (infectious diseases and vaccines)USD 144 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Pre-tax restructuring expense for Q1 2024 covering termination of partnered and non-partnered development program costs and asset impairments; program announced in fiscal 2023, majority completed with minor charges expected in remainder of year; total project costs approximately $0.6 billion since announcement; no employee count disclosed.
2024-03-31restructuringin_progress2023-01-012025-12-31MedTech — Orthopaedics franchiseUSD 27 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Pre-tax restructuring expense for Q1 2024, primarily market and product exit costs; program initiated in fiscal 2023 to streamline operations by exiting certain markets, product lines and distribution arrangements; total estimated program costs $0.7-$0.8 billion, expected complete by end of fiscal 2025; no employee count disclosed.
2024-03-31restructuringin_progressGlobalInnovative Medicine — Research & DevelopmentUSD 144 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pre-tax Q1 2024 charge of $144M for R&D program exits (infectious diseases/vaccines, RSV adult vaccine, hepatitis, HIV). Total project costs ~$0.6B since announcement; majority completed with minor charges expected for remainder of year. No employee count disclosed.
2024-03-31restructuringin_progress2025-12-31GlobalMedTech — OrthopaedicsUSD 27 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2024 pre-tax expense of $27M ($20M in Restructuring, $7M in Cost of products sold) for market/product exits and distribution network changes. ~$0.3B recorded to date; estimated total program cost $0.7B–$0.8B, expected completion by end of fiscal 2025. No employee count disclosed.
2024-03-31acquisition_additioncompleted2024-03-07United StatesInnovative Medicinebusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Ambrx Biopharma completed 2024-03-07 for ~$2.0B equity value ($1.8B net of cash). Headcount added not disclosed.
2024-03-31divestiture_reductioncompletedGlobalInnovative Medicineother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Divestiture of Ponvory completed in Q1 2024 with ~$0.2B proceeds. Headcount removed not disclosed.
2024-03-31acquisition_additionannounced2024-06-30United StatesMedTechsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement announced after quarter-end to acquire Shockwave Medical for $335.00/share (~$13.1B enterprise value); closing expected by mid-year 2024. Headcount addition not disclosed.
2024-03-31restructuringin_progress2024-12-31Innovative MedicineUSD 144 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		R&D program exits in infectious diseases and vaccines. Total project costs approx $0.6 billion. Majority completed.
2024-03-31restructuringin_progress2025-12-31MedTechUSD 27 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Orthopaedics franchise streamlining. Total project costs approx $0.3 billion. Expected completion by end of fiscal 2025.
2024-03-31restructuringin_progress2023-01-012024-12-31WorldwideInnovative MedicineUSD 144 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Prioritization of R&D investment; exit of certain programs in infectious diseases and vaccines. Total project costs approx $0.6B since announcement. Majority completed.
2024-03-31restructuringin_progress2023-01-012025-12-31WorldwideMedTechUSD 27 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Orthopaedics franchise restructuring; exiting certain markets, product lines, and distribution networks. Estimated total program costs $0.7B-$0.8B.
2024-03-31restructuringin_progressUSD 164,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressInnovative Medicine [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressR&D Restructuring Plan [Member]USD 144,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressOrthopaedics Restructuring Plan [Member]USD 27,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressOperating Segments [Member] / Innovative Medicine [Member]USD 144,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressOperating Segments [Member] / MedTech [Member]USD 27,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressOperating Segments [Member]USD 171,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressRestructuring Charges [Member] / MedTech [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressCosts of Goods and Services Sold [Member] / MedTech [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-12-31restructuringin_progress20232024-12-31Innovative Medicine — Research & Development (exits primarily in infectious diseases and vaccines, including RSV adult vaccine program, hepatitis and HIV development)USD 479 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Pre-tax charge recorded in fiscal 2023 ($449M in Restructuring line, $30M in cost of products sold); total program estimated at $500–600M; expected completion by end of fiscal 2024. Headcount affected not disclosed.
2023-12-31restructuringin_progress20232025-12-31MedTech — Orthopaedics franchiseUSD 319 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Program streamlines operations by exiting certain markets, product lines and distribution network arrangements. Fiscal 2023 pre-tax expense $319M ($40M in Restructuring line, $279M in cost of products sold), primarily inventory and instrument charges; total program estimated at $700–800M, completion by end of fiscal 2025. Headcount affected not disclosed.
2023-12-31divestiture_reductioncompleted2023-05-082023-08-23GlobalConsumer Health (Kenvue)USD 986 (millions)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Separation of Consumer Health business executed via Kenvue IPO (May 8, 2023) and exchange offer completed August 23, 2023, ceasing consolidation. Fiscal 2023 separation costs of $986M recorded in discontinued operations; $21.0B non-cash gain on exchange offer. Number of employees transferred to Kenvue not disclosed.
2023-12-31restructuringin_progress2024-12-31GlobalInnovative Medicine — Research & DevelopmentUSD 479 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Fiscal 2023 pre-tax expense for R&D portfolio prioritization, including program exits in infectious diseases/vaccines (RSV adult vaccine, hepatitis, HIV). $449M recorded in Restructuring and $30M in Cost of products sold; total program estimated at $500M–$600M. Employees affected not disclosed.
2023-12-31restructuringin_progress2025-12-31GlobalMedTech — OrthopaedicsUSD 319 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Fiscal 2023 pre-tax expense for streamlining the Orthopaedics franchise via exits of certain markets, product lines and distribution arrangements; primarily inventory and instrument charges. $40M in Restructuring and $279M in Cost of products sold; total program estimated at $700M–$800M. Employees affected not disclosed.
2023-12-31divestiture_reductioncompleted2023-08-23GlobalConsumer Health (Kenvue) — discontinued operationsdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Consumer Health separation completed via IPO (2023-05-08) and exchange offer (2023-08-23), deconsolidating the business and removing its workforce from continuing operations. Headcount removed not disclosed; separation costs of $986M incurred in fiscal 2023 (advisory, legal, accounting, contractor and other costs).
2023-12-31acquisition_additioncompleted2023-11-30United StatesMedTech — Interventional Solutions (Laminar, Inc.)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of privately held Laminar Inc. (left atrial appendage closure) closed 2023-11-30 for approximately $0.4B cash, accounted for as an asset acquisition of in-process R&D (approximately $0.5B of IPR&D asset acquisitions in total for fiscal 2023). Headcount added not disclosed.
2023-12-31acquisition_additionannounced2024-06-30United StatesInnovative Medicine (Ambrx Biopharma, Inc.)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Subsequent event: definitive agreement announced in fiscal first quarter 2024 for all-cash merger at $28.00 per share, total equity value approximately $2.0B ($1.9B net of estimated cash); closing expected in first half of 2024 subject to shareholder and antitrust approvals. Announcement date not specified beyond fiscal Q1 2024; headcount added not disclosed.
2023-12-31restructuringcompleted2023-01-012024-12-31WorldwideInnovative MedicineUSD 479 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Prioritization of R&D investment resulting in exit of certain programs. Estimated total costs $500-600 million.
2023-12-31restructuringin_progress2023-01-012025-12-31WorldwideMedTechUSD 319 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Orthopaedics franchise restructuring to streamline operations. Estimated total costs $700-800 million.
2023-12-31restructuringin_progress2023-01-012024-12-31WorldwideInnovative MedicineUSD 479 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Prioritization of R&D investment, exiting certain programs in infectious diseases and vaccines. Estimated total costs $500M-$600M.
2023-12-31restructuringin_progress2023-01-012025-12-31WorldwideMedTechUSD 319 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Orthopaedics franchise streamlining, exiting certain markets, product lines, and distribution networks. Estimated total costs $700M-$800M.
2023-12-31restructuringin_progressUSD 489,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressOperating Segments [Member] / Innovative Medicine [Member]USD 500,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressOperating Segments [Member] / MedTech [Member]USD 300,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressR&D Restructuring Plan [Member]USD 479,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressOrthopaedics Restructuring Plan [Member]USD 319,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressOperating Segments [Member]USD 798,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressRestructuring Charges [Member] / Innovative Medicine [Member]USD 449,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressCosts of Goods and Services Sold [Member] / Innovative Medicine [Member]USD 30,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressRestructuring Charges [Member] / MedTech [Member]USD 40,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressCosts of Goods and Services Sold [Member] / MedTech [Member]USD 279,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-10-01restructuringin_progress2023-01-022024-12-31Innovative Medicine — R&D portfolio prioritization (infectious diseases and vaccines program exits, including RSV adult vaccine, hepatitis and HIV development)USD 424 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Pre-tax restructuring expense of $424 million for the fiscal nine months ($149 million in Q3) covering termination of partnered and non-partnered development program costs and asset impairments; total estimated program cost $500-600 million, expected completion in fiscal 2024.
2023-10-01restructuringin_progress2023-07-032025-12-31MedTech — Orthopaedics franchise (exiting certain markets, product lines and distribution network arrangements)USD 235 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Pre-tax restructuring expense of $235 million in both the fiscal third quarter and fiscal nine months, primarily inventory and instrument charges related to market and product exits; $9 million recorded in Restructuring and $226 million in Cost of products sold; total estimated program cost $700-800 million, expected completion by end of fiscal 2025.
2023-10-01divestiture_reductioncompleted2023-05-082023-08-23Consumer Health business (Kenvue)USD 912 (millions)other
f5-10q / GLM-5.3-flash-fp4-HTML		Separation of the Consumer Health business via Kenvue IPO (May 8, 2023) and exchange offer completed August 23, 2023; separation costs of $912 million in the fiscal nine months ($330 million in Q3) recorded in discontinued operations. No employee headcount figures disclosed.
2023-10-01restructuringin_progress2024-12-31GlobalInnovative Medicine — R&D (primarily infectious diseases and vaccines)USD 424 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pre-tax restructuring expense of $424M for nine months ($149M in Q3) for R&D program exits including RSV adult vaccine, hepatitis and HIV development. Total estimated program cost $500–600M. No employee count disclosed.
2023-10-01restructuringin_progress2023-07-032025-12-31GlobalMedTech — Orthopaedics franchiseUSD 235 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program initiated in Q3 2023 to streamline operations by exiting certain markets, product lines and distribution network arrangements; $235M charge ($9M in Restructuring, $226M in Cost of products sold). Total estimated program cost $700–800M. No employee count disclosed.
2023-10-01divestiture_reductioncompleted2023-05-082023-08-23GlobalConsumer Health (Kenvue)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Kenvue IPO completed May 8, 2023; exchange offer completed Aug 23, 2023 deconsolidating Consumer Health. Separation costs of $912M for nine months ($330M in Q3) recorded in discontinued operations. No employee count disclosed.
2023-10-01restructuringin_progress2023-07-012024-12-31GlobalInnovative MedicineUSD 149 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Prioritization of R&D investment; exit of certain programs in infectious diseases and vaccines. Estimated total costs $500-600 million.
2023-10-01restructuringin_progress2023-07-012025-12-31GlobalMedTechUSD 235 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Orthopaedics franchise streamlining; exiting certain markets, product lines, and distribution networks. Estimated total costs $700-800 million.
2023-10-01restructuringin_progress2023-07-012024-12-31Innovative MedicineUSD 149 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Prioritization of R&D investment; exit of certain programs in infectious diseases and vaccines. Estimated total costs $500-$600 million.
2023-10-01restructuringin_progress2023-07-012025-12-31MedTechUSD 235 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Orthopaedics franchise restructuring; exiting certain markets, product lines, and distribution networks. Estimated total costs $700-$800 million.
2023-10-01divestiture_reductioncompleted2023-08-232023-08-23Consumer Healthdiscontinued_operations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Separation of Consumer Health business into Kenvue. Employee headcount transferred not explicitly disclosed.
2023-10-01restructuringin_progressUSD 158,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-10-01restructuringin_progressInnovative Medicine [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-10-01restructuringin_progressMedTech [Member]USD 200,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-10-01restructuringin_progressR&D Restructuring Plan [Member]USD 149,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-10-01restructuringin_progressOrthopaedics Restructuring Plan [Member]USD 235,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-10-01restructuringin_progressOperating Segments [Member] / Innovative Medicine [Member]USD 149,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-10-01restructuringin_progressOperating Segments [Member] / MedTech [Member]USD 235,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-10-01restructuringin_progressOperating Segments [Member]USD 384,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-10-01restructuringin_progressRestructuring Charges [Member] / MedTech [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-10-01restructuringin_progressCosts of Goods and Services Sold [Member] / MedTech [Member]USD 226,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-07-02restructuringin_progressPharmaceuticalUSD 0 (billions)MD&A
f5-10q / GLM-5.3-flash-fp4-HTML		R&D portfolio prioritization in Pharmaceutical segment; exits in infectious diseases and vaccines including RSV adult vaccine program, hepatitis and HIV development; includes termination of partnered and non-partnered program costs and asset impairments. No employee counts disclosed.
2023-07-02restructuringin_progressPharmaceuticalUSD 0 (billions)MD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Year-to-date pre-tax restructuring charge for the same R&D prioritization program; no employee counts disclosed.
2023-07-02divestiture_reductionin_progress2023-05-08Consumer Health (Kenvue)other
f5-10q / GLM-5.3-flash-fp4-HTML		Kenvue IPO completed May 8, 2023; J&J retains ~89.6% and continues consolidating. On July 24, 2023 announced intent to split off at least 80.1% of Kenvue via exchange offer. No headcount figures disclosed.
2023-07-02restructuringin_progressGlobalPharmaceuticalUSD 0 (billions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		R&D portfolio prioritization in the fiscal first and second quarters of 2023; exits of certain programs, primarily in infectious diseases and vaccines, including the RSV adult vaccine, hepatitis and HIV programs. Pre-tax charge of approximately $0.1 billion in Q2 and $0.3 billion in the fiscal six months, covering program termination costs and asset impairments. No employee count disclosed.
2023-07-02divestiture_reductionannounced2023-07-24GlobalConsumer Health (Kenvue)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter announcement of intent to split off at least 80.1% of Kenvue shares via an exchange offer; upon completion Kenvue becomes a separate company and its results move to discontinued operations. No workforce impact quantified in the filing.
2023-07-02restructuringin_progress2023-04-01GlobalPharmaceuticalUSD 145 (millions)MD&A
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Pre-tax restructuring charge of $0.1 billion in Q2 2023 related to R&D prioritization, including discontinuation of RSV adult vaccine, hepatitis, and HIV programs. Includes termination of partnered/non-partnered program costs and asset impairments.
2023-07-02restructuringin_progress2023-01-01GlobalPharmaceuticalUSD 300 (millions)MD&A
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Pre-tax restructuring charge of $0.3 billion in fiscal six months ended July 2, 2023. Includes Q1 and Q2 charges related to R&D prioritization.
2023-07-02restructuringin_progressPharmaceuticalUSD 0 (billions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Pre-tax charge of approx $0.1 billion in Q2 2023 related to R&D program prioritization and exits in infectious diseases and vaccines.
2023-07-02restructuringin_progressPharmaceuticalUSD 0 (billions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Pre-tax charge of approx $0.3 billion in fiscal six months 2023 related to R&D program prioritization and exits in infectious diseases and vaccines.
2023-07-02restructuringin_progressUSD 145,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-07-02restructuringin_progressPharmaceutical [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-04-02restructuringcompletedPharmaceutical — R&DUSD 0 (billions)MD&A
f5-10q / GLM-5.3-flash-fp4-HTML		R&D investment prioritization led to exit of certain programs including RSV adult vaccine, HIV and hepatitis; charge includes termination of partnered and non-partnered program costs and asset impairments. No employee count disclosed.
2023-04-02restructuringcompleted2023-04-02GlobalPharmaceutical — Research & DevelopmentUSD 0 (billions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Completed in Q1 2023: R&D portfolio prioritization exiting RSV adult vaccine, HIV and hepatitis programs; includes terminated partnered/non-partnered program costs and asset impairments. No employee count disclosed.
2023-04-02divestiture_reductioncompleted2021-11-012023-04-05GlobalConsumer Health (Kenvue separation)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Consumer Health business transferred to Kenvue on April 5, 2023 (subsequent to quarter end); Kenvue IPO roadshow launched April 24, 2023. No headcount associated with the separation disclosed in this filing.
2023-04-02restructuringcompleted2023-01-022023-04-02GlobalPharmaceuticalUSD 0 (billions)MD&A
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Pre-tax charge of approximately $0.1 billion related to prioritization of R&D investment, including discontinuation of RSV adult vaccine and HIV/hepatitis programs.
2023-04-02restructuringcompleted2023-01-022023-04-02GlobalMedTechUSD 0 (billions)MD&A
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Pre-tax charge of approximately $0.1 billion related to Pulsar Vascular acquisition IPR&D write-down.
2023-04-02restructuringcompletedPharmaceuticalUSD 0 (billions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Prioritization of R&D investment; exit of certain programs including RSV adult vaccine, HIV, and hepatitis. Charge includes termination of partnered/non-partnered program costs and asset impairments.
2023-04-02restructuringcompletedMedTechUSD 0 (billions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Restructuring related charge disclosed in segment earnings analysis.
2023-04-02restructuringin_progressUSD 130,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-01-01restructuringcompleted20182023-01-01GlobalGlobal Supply ChainUSD 1 (billions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year Global Supply Chain program announced fiscal Q2 2018; completed in fiscal Q4 2022 (fiscal year ended 2023-01-01). Fiscal 2022 pre-tax charge of $0.5 billion, recorded as $0.3B restructuring, $0.1B other (income) expense, and $0.1B cost of products sold. Cumulative project costs ~$2.2 billion; ~$0.8 billion in annualized pre-tax savings achieved. Headcount affected not quantified in this filing. Severance reserve of $75 million at fiscal year-end 2022 (no new severance charges in 2022; $37 million severance cash settlements); footnote notes severance charges may continue beyond program completion.
2023-01-01divestiture_reductionin_progress2021-112023GlobalConsumer Health (planned New Consumer Health Company, Kenvue)USD 1,089 (millions)MD&A
f5-10k / GLM-5.3-flash-HTML		Planned separation of the Consumer Health business into an independent publicly traded company (Kenvue), targeted by end of fiscal 2023; separation not yet executed as of the filing date. Consumer Health separation costs of $1,089 million expensed in fiscal 2022 (of which ~$1.0 billion in Other (income) expense); the Company also incurred ~$0.5 billion of net incremental international tax costs in fiscal 2022 related to the legal separation. Employee headcount affected not disclosed.
2023-01-01acquisition_additioncompleted2022-12-222022-12-22GlobalMedTech — Interventional Solutions (Heart Recovery portfolio)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition of Abiomed, Inc. completed via tender offer on December 22, 2022; upfront consideration $380.00 per share (~$17.1 billion net of cash acquired) plus non-tradeable contingent value rights of up to $35.00 per share (~$1.6 billion aggregate). Results included in the MedTech segment from the acquisition date. Human Capital section confirms Abiomed headcount is included in fiscal 2022 employee counts (155,800 headcount); number of employees added not disclosed.
2023-01-01restructuringcompleted2018-062022-12-31WorldwideGlobal Supply ChainUSD 500 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Global Supply Chain program announced in fiscal Q2 2018 and completed in fiscal Q4 2022. FY2022 pre-tax charge of $0.5B ($0.3B restructuring, $0.1B other (income) expense, $0.1B cost of products sold); cumulative program costs of approximately $2.2B since announcement. Employees affected not disclosed; severance reserve of $75M remained at year-end.
2023-01-01acquisition_additioncompleted2022-12-222022-12-22United StatesMedTechbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Abiomed, Inc. completed December 22, 2022 for $17.1B cash plus contingent value rights; results included in MedTech from acquisition date. Headcount added not disclosed.
2023-01-01divestiture_reductionannounced2021-112023-12-31WorldwideConsumer HealthItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Planned separation of the Consumer Health business as Kenvue, a new publicly traded company, targeted by end of fiscal year 2023. Separation costs of $1.0B recorded in FY2022 within Other (income) expense; $1,089M of Consumer Health separation costs deducted from segment earnings. Headcount to be separated not disclosed.
2023-01-01restructuringcompleted2018-04-012022-12-31GlobalGlobal Supply ChainUSD 1 (billions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Global Supply Chain restructuring program completed in Q4 2022. Total project costs of approximately $2.2 billion recorded since announcement. $0.5 billion pre-tax charge recorded in 2022.
2023-01-01restructuringcompleted2018-04-012022-12-31WorldwideGlobal Supply ChainUSD 1 (billions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Global Supply Chain restructuring program announced in Q2 2018. Completed in Q4 2022. Fiscal 2022 pre-tax charge of $0.5 billion ($0.3B restructuring, $0.1B other expense, $0.1B COGS). Total project costs approx $2.2 billion since announcement. Employee count not disclosed.
2023-01-01acquisition_additioncompleted2022-12-222022-12-22WorldwideMedTechUSD 18 (billions)business_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Abiomed, Inc. completed Dec 22, 2022. Headcount included in total employee count. Specific employee count not disclosed.
2023-01-01restructuringin_progressUSD 321,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-01-01restructuringin_progressConsumer Health [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-01-01restructuringin_progressConsumer [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-01-01restructuringin_progressMedTech [Member]USD 300,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-01-01restructuringin_progressSupply Chain [Member]USD 500,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-01-01restructuringin_progressRestructuring Charges [Member] / Supply Chain [Member]USD 300,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-01-01restructuringin_progressOther Income Expense Net [Member] / Supply Chain [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-01-01restructuringin_progressCost of Sales [Member] / Supply Chain [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-01-01restructuringin_progressEmployee Severance [Member] / Supply Chain [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-01-01restructuringin_progressAsset Write-off [Member] / Supply Chain [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-01-01restructuringin_progressOther Restructuring [Member] / Supply Chain [Member]USD 448,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-10-02restructuringin_progress2018-04-012022-12-31GlobalGlobal Supply ChainUSD 123 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2022 net pre-tax charge of $123 million ($82M restructuring, $13M cost of products sold, $28M other expense). Program announced fiscal Q2 2018; ~$2.1 billion of ~$2.2-2.3 billion total charges recorded to date. No employee counts disclosed in this filing.
2022-10-02restructuringin_progress2018-04-012022-12-31GlobalGlobal Supply ChainUSD 323 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine-month 2022 net pre-tax charge of $323 million ($237M restructuring, $46M cost of products sold, $40M other expense). Severance reserve balance of $84 million at October 2, 2022; severance cash outlays expected to be substantially paid by program completion in December 2022.
2022-10-02restructuringin_progress20182022-12-31GlobalGlobal Supply ChainUSD 323 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Net pre-tax charge of $323M recorded in fiscal nine months 2022 ($237M restructuring, $46M cost of products sold, $40M other income/expense). Severance reserve balance $84M at quarter-end. No employee-affected count disclosed. Program expected to generate $0.7–0.8B annual pre-tax cost savings; total charges of ~$2.2–2.3B expected by completion in December 2022.
2022-10-02restructuringin_progressGlobalGlobal Supply ChainUSD 82 (millions)financial_statements
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Q3 2022 restructuring charge of $82 million recorded. Employee count not disclosed.
2022-10-02restructuringin_progressGlobalGlobal Supply ChainUSD 237 (millions)financial_statements
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		YTD 2022 restructuring charge of $237 million recorded. Employee count not disclosed.
2022-10-02restructuringin_progress2018-04-012022-12-31GlobalGlobal Supply ChainUSD 323 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Global Supply Chain actions announced in Q2 2018. Net pre-tax charge of $323 million recorded in fiscal nine months ended Oct 2, 2022 ($237M in restructuring line). Program expected to complete Dec 2022. Employee count not disclosed.
2022-10-02restructuringin_progressUSD 82,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-10-02restructuringin_progressMedical Devices [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-10-02restructuringin_progressSupply Chain [Member]USD 123,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-10-02restructuringin_progressRestructuring Charges [Member] / Supply Chain [Member]USD 82,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-10-02restructuringin_progressCost of Sales [Member] / Supply Chain [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-10-02restructuringin_progressOther Income Expense Net [Member] / Supply Chain [Member]USD 28,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-10-02restructuringin_progressEmployee Severance [Member] / Medical Devices [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-10-02restructuringin_progressAsset Write-off [Member] / Medical Devices [Member]USD -4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-10-02restructuringin_progressOther Restructuring [Member] / Medical Devices [Member]USD 327,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-07-03restructuringin_progress2018-04-012022-12-31Global Supply ChainUSD 128 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Global Supply Chain restructuring program announced fiscal Q2 2018; net pre-tax charge of $128 million in fiscal Q2 2022 ($85M restructuring, $17M cost of products sold, $26M other income/expense). Total project costs of approximately $2.0 billion recorded since announcement; expects $2.1-$2.3 billion total by December 2022 completion and $0.6-$0.8 billion annual pre-tax savings. No employee counts disclosed; severance reserve balance of $89 million at July 3, 2022.
2022-07-03divestiture_reductionannounced2021-11-01Consumer HealthUSD 370 (millions)MD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Planned separation of Consumer Health business into a new publicly traded company, announced November 2021, targeted completion 18-24 months after announcement. Separation costs of $370 million recorded in fiscal six months 2022 ($268 million in Q2). Additional incremental tax costs of approximately $0.3 billion recognized subsequent to quarter-end. No headcount figures disclosed.
2022-07-03restructuringin_progress2018-04-012022-12-31GlobalGlobal Supply ChainUSD 200 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Global Supply Chain program announced in fiscal Q2 2018; YTD 2022 net pre-tax charge of $200M ($155M restructuring, $33M COGS, $12M other). Total program charges expected $2.1–2.3B by Dec 2022; ~$2.0B recorded to date. Severance reserve balance $111M at quarter-end. No employee headcount affected disclosed.
2022-07-03restructuringin_progressUSD 85 (millions)consolidated_statements_of_earnings
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Restructuring charges of $85 million recorded for the fiscal second quarter ended July 3, 2022. Employee count not disclosed.
2022-07-03restructuringin_progressUSD 155 (millions)consolidated_statements_of_earnings
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Restructuring charges of $155 million recorded for the fiscal six months ended July 3, 2022. Employee count not disclosed.
2022-07-03restructuringin_progress2018-04-012022-12-31GlobalGlobal Supply ChainUSD 128 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal Q2 2022 net pre-tax charge of $128M ($85M restructuring, $17M COGS, $26M other). Program announced in Q2 2018. Total expected charges $2.1B-$2.3B by Dec 2022. Employee count not disclosed.
2022-07-03restructuringin_progress2018-04-012022-12-31GlobalGlobal Supply ChainUSD 200 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal YTD 2022 net pre-tax charge of $200M ($155M restructuring, $33M COGS, $12M other). Program announced in Q2 2018. Total expected charges $2.1B-$2.3B by Dec 2022. Employee count not disclosed.
2022-07-03restructuringin_progressUSD 85,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-07-03restructuringin_progressMedical Devices [Member]USD 200,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-07-03restructuringin_progressSupply Chain [Member]USD 128,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-07-03restructuringin_progressRestructuring Charges [Member] / Supply Chain [Member]USD 85,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-07-03restructuringin_progressCost of Sales [Member] / Supply Chain [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-07-03restructuringin_progressOther Income Expense Net [Member] / Supply Chain [Member]USD 26,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-07-03restructuringin_progressEmployee Severance [Member] / Medical Devices [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-07-03restructuringin_progressAsset Write-off [Member] / Medical Devices [Member]USD -11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-07-03restructuringin_progressOther Restructuring [Member] / Medical Devices [Member]USD 211,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-04-03restructuringin_progress2018-07-012022-12-31Global Supply ChainUSD 72 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing Global Supply Chain program announced fiscal Q2 2018; Q1 2022 net pre-tax charge of $72 million ($70M restructuring, $16M cost of products sold, $14M income from property sales in other income/expense). Total project costs of approximately $1.8 billion recorded since announcement; expected total pre-tax charges of $2.1-$2.3 billion by program completion in December 2022. No employee counts disclosed in this filing.
2022-04-03restructuringin_progress20182022-12-31GlobalGlobal Supply ChainUSD 72 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Global Supply Chain actions announced in fiscal Q2 2018; Q1 2022 net pre-tax charge of $72M ($70M restructuring, $16M COGS, $14M income in other income/expense). Severance reserve $115M at 2022-04-03; ~$1.8B cumulative charges; total program expected $2.1-2.3B with $0.6-0.8B annual pre-tax savings by end of 2022. No employee-affected count disclosed.
2022-04-03restructuringin_progress2018-06-012022-12-31GlobalGlobal Supply ChainUSD 72 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Fiscal Q2 2018 announced Global Supply Chain actions. Q1 2022 recorded net pre-tax charge of $72M ($70M restructuring, $16M COGS, $14M gain in other income). Total project costs approx $1.8B recorded since announcement. Expected annual savings $0.6B-$0.8B.
2022-04-03restructuringin_progress2018-04-012022-12-31GlobalGlobal Supply ChainUSD 72 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Global Supply Chain actions announced in Q2 2018. Q1 2022 net pre-tax charge of $72 million recorded. Total expected charges $2.1B-$2.3B by Dec 2022. Employee count not disclosed.
2022-04-03restructuringin_progressUSD 70,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-04-03restructuringin_progressMedical Devices [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-04-03restructuringin_progressSupply Chain [Member]USD 72,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-04-03restructuringin_progressRestructuring Charges [Member] / Supply Chain [Member]USD 70,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-04-03restructuringin_progressCost of Sales [Member] / Supply Chain [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-04-03restructuringin_progressOther Income Expense Net [Member] / Supply Chain [Member]USD -14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-04-03restructuringin_progressEmployee Severance [Member] / Medical Devices [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-04-03restructuringin_progressAsset Write-off [Member] / Medical Devices [Member]USD -23,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-04-03restructuringin_progressOther Restructuring [Member] / Medical Devices [Member]USD 95,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-01-02restructuringin_progress20182022-12-31GlobalGlobal Supply ChainUSD 473 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year Global Supply Chain program announced in fiscal Q2 2018 to optimize the supply chain network; no employees-affected count disclosed. Fiscal 2021 pre-tax charge of $473 million comprised $53 million asset write-offs and $420 million other project expense — no new severance charges in 2021 (severance reserve declined from $135 million to $112 million via $23 million cash settlements). Cumulative pre-tax costs of approximately $1.8 billion recorded since inception against expected total charges of $2.1–$2.3 billion; expected annual pre-tax savings of $0.6–$0.8 billion substantially delivered by end of 2022. Charge figures are fiscal-2021-only; cumulative figures noted as 'cumulative through fiscal year-end' in MD&A.
2022-01-02divestiture_reductionannounced2021-11GlobalConsumer HealthUSD 0 (billions)Item_1_Business
f5-10k / GLM-5.3-flash-HTML		Structural separation of the Consumer Health business into a new, publicly traded company, targeted for completion 18–24 months after the November 2021 announcement (specific completion date not stated). Not a headcount reduction in the layoff sense — the Consumer Health workforce is expected to transfer to the new company; affected employee count not quantified. Separation costs of $0.1 billion were recorded in 2021 and costs in future years are expected to be significantly higher.
2022-01-02restructuringin_progress2018-06-302022-12-31WorldwideGlobal Supply ChainUSD 1 (billions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Global Supply Chain program announced in fiscal Q2 2018. FY2021 pre-tax charge of $0.5B ($0.3B restructuring, $0.1B other (income) expense, $0.1B cost of products sold); cumulative project costs of approximately $1.8B recorded since announcement. Total program expected to generate $0.6–0.8B annual pre-tax cost savings with total expected charges of $2.1–2.3B; approximately 70% of cumulative pre-tax costs expected to be cash. Employees affected not disclosed.
2022-01-02divestiture_reductionannounced2021-11WorldwideConsumer HealthItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Company announced intention to separate the Consumer Health business into a new publicly traded company, targeting completion in 18 to 24 months after announcement. FY2021 separation costs of $0.1B recorded in other (income) expense; costs in future years expected to be significantly higher. Headcount impact not disclosed.
2022-01-02restructuringin_progress2018-04-012022-12-31GlobalGlobal Supply ChainUSD 500 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Announced in Q2 2018. In 2021, Company recorded pre-tax charge of $0.5 billion ($0.3B restructuring, $0.1B other income/expense, $0.1B cost of products sold). Total project costs recorded since announcement approx $1.8 billion. Program set to be completed at end of 2022.
2022-01-02restructuringin_progress2018-06-302022-12-31GlobalGlobal Supply ChainUSD 1 (billions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Global Supply Chain restructuring announced in Q2 2018. $0.5 billion pre-tax charge recorded in 2021. Program expected to be completed by end of 2022. Employee count not disclosed for this specific year's activity.
2022-01-02restructuringin_progressUSD 252,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-01-02restructuringin_progressConsumer [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-01-02restructuringin_progressPharmaceutical [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-01-02restructuringin_progressMedical Devices [Member]USD 300,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-01-02restructuringin_progressSupply Chain [Member]USD 500,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-01-02restructuringin_progressRestructuring Charges [Member] / Supply Chain [Member]USD 300,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-01-02restructuringin_progressOther Income Expense Net [Member] / Supply Chain [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-01-02restructuringin_progressCost of Sales [Member] / Supply Chain [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-01-02restructuringin_progressEmployee Severance [Member] / Supply Chain [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-01-02restructuringin_progressAsset Write-off [Member] / Supply Chain [Member]USD 53,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-01-02restructuringin_progressOther Restructuring [Member] / Supply Chain [Member]USD 420,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-10-03restructuringin_progress2018-01-012022-12-31GlobalGlobal Supply ChainUSD 121 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing Global Supply Chain program announced fiscal Q2 2018; Q3 2021 pre-tax charge of $121 million ($60M restructuring, $18M cost of products sold, $43M other income/expense); nine-month charge $333 million; total project costs ~$1.6 billion since announcement; expected total charges $1.9-$2.3 billion with $0.6-$0.8 billion annual savings substantially delivered by 2022. No employee counts disclosed in this filing.
2021-10-03restructuringin_progress2018GlobalGlobal Supply ChainUSD 121 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Global Supply Chain actions announced in fiscal Q2 2018; Q3 2021 pre-tax charge of $121M ($60M restructuring, $18M cost of products sold, $43M other expense); YTD 2021 charge $333M; severance reserve $152M at 2021-10-03; ~$1.6B recorded to date of a planned $1.9–2.3B; employees affected not disclosed; savings of $0.6–0.8B annually expected substantially delivered by 2022.
2021-10-03restructuringin_progress2018-04-012022-12-31GlobalGlobal Supply ChainUSD 169 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Global Supply Chain actions announced in Q2 2018. Q3 2021 pre-tax charge of $121M ($60M restructuring, $18M COGS, $43M other). YTD 2021 pre-tax charge of $333M ($169M restructuring, $65M COGS, $99M other). Total project costs approx $1.6B since announcement. Expected annual savings $0.6-0.8B substantially delivered by 2022. Total expected pre-tax charges $1.9-2.3B over 4-5 years. Employee count not disclosed.
2021-10-03restructuringin_progressUSD 60,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-10-03restructuringin_progressConsumer [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-10-03restructuringin_progressPharmaceutical [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-10-03restructuringin_progressMedical Devices [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-10-03restructuringin_progressSupply Chain [Member]USD 121,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-10-03restructuringin_progressRestructuring Charges [Member] / Supply Chain [Member]USD 60,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-10-03restructuringin_progressCost of Sales [Member] / Supply Chain [Member]USD 18,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-10-03restructuringin_progressOther Income Expense Net [Member] / Supply Chain [Member]USD 43,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-10-03restructuringin_progressEmployee Severance [Member] / Medical Devices [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-10-03restructuringin_progressAsset Write-off [Member] / Medical Devices [Member]USD 38,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-10-03restructuringin_progressOther Restructuring [Member] / Medical Devices [Member]USD 295,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-07-04restructuringin_progress2018-04-012022-12-31Global Supply ChainUSD 108 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q2 2021 pre-tax charge of $108M ($56M restructuring, $20M cost of products sold, $32M other income/expense); YTD charge $212M; total project costs ~$1.5B since 2018; expected total charges $1.9B-$2.3B with $0.6B-$0.8B annual savings substantially delivered by 2022. Severance reserve balance $123M at July 4, 2021; no employee counts disclosed.
2021-07-04restructuringin_progress2018-04-01GlobalGlobal Supply ChainUSD 212 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Fiscal six months 2021 pre-tax charge of $212M ($109M restructuring, $47M COGS, $56M other income/expense). Severance reserve balance $123M at quarter-end. Program announced fiscal Q2 2018; total project costs ~$1.5B to date; expected total charges $1.9–2.3B over 4–5 years; expected annual pre-tax savings $0.6–0.8B substantially delivered by 2022. No employee headcount affected disclosed.
2021-07-04restructuringin_progressUSD 56 (millions)financial_statements
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Restructuring charges of $56 million recorded for the fiscal second quarter ended July 4, 2021. Employee count not disclosed.
2021-07-04restructuringin_progressUSD 109 (millions)financial_statements
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Restructuring charges of $109 million recorded for the fiscal six months ended July 4, 2021. Employee count not disclosed.
2021-07-04restructuringin_progress2018-04-012022-12-31GlobalGlobal Supply ChainUSD 108 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Global Supply Chain actions announced in Q2 2018. Q2 2021 pre-tax charge of $108M ($56M restructuring, $20M COGS, $32M other). Total project costs ~$1.5B recorded since announcement. Expected annual savings $0.6-0.8B by 2022. Employee count not disclosed.
2021-07-04restructuringin_progressUSD 56,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-07-04restructuringin_progressMedical Devices [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-07-04restructuringin_progressSupply Chain [Member]USD 108,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-07-04restructuringin_progressRestructuring Charges [Member] / Supply Chain [Member]USD 56,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-07-04restructuringin_progressCost of Sales [Member] / Supply Chain [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-07-04restructuringin_progressOther Income Expense Net [Member] / Supply Chain [Member]USD 32,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-07-04restructuringin_progressEmployee Severance [Member] / Medical Devices [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-07-04restructuringin_progressAsset Write-off [Member] / Medical Devices [Member]USD 26,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-07-04restructuringin_progressOther Restructuring [Member] / Medical Devices [Member]USD 186,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-04-04restructuringin_progress2018-04-012022-12-31Global Supply ChainUSD 104 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing Global Supply Chain program announced fiscal Q2 2018; Q1 2021 pre-tax charge of $104 million recorded across restructuring ($53M), cost of products sold ($27M) and other (income) expense ($24M). Cumulative charges of approximately $1.4 billion; expected total charges of $1.9-$2.3 billion with annual pre-tax savings of $0.6-$0.8 billion substantially delivered by 2022. No employee counts disclosed in this filing.
2021-04-04restructuringin_progress2018GlobalGlobal Supply ChainUSD 104 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2021 pre-tax charge of $104M ($53M restructuring, $27M COGS, $24M other income/expense); severance reserve balance $130M at quarter-end. No employee count disclosed. Program announced fiscal Q2 2018; ~$1.4B cumulative charges; expected total $1.9–2.3B with savings of $0.6–0.8B annually by 2022.
2021-04-04restructuringin_progress2018-04-012022-12-31GlobalGlobal Supply ChainUSD 104 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-NVFP4-MTP-HTML		Fiscal Q1 2021 pre-tax charge of $104 million recorded. Total project costs of approximately $1.4 billion recorded since announcement. Expected annual pre-tax cost savings of $0.6 to $0.8 billion substantially delivered by 2022. Cash outlays for severance expected to be substantially paid over next 18 months.
2021-04-04restructuringin_progress2018-04-012022-12-31GlobalGlobal Supply ChainUSD 104 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Global Supply Chain actions announced in Q2 2018. Q1 2021 pre-tax charge of $104 million includes $53 million in restructuring, $27 million in cost of products sold, and $24 million in other expense. Total project costs recorded since announcement are approx $1.4 billion. Expected to generate $0.6-$0.8 billion in annual pre-tax cost savings substantially delivered by 2022. Employee count affected not disclosed in this period.
2021-04-04restructuringin_progressUSD 53,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-04-04restructuringin_progressMedical Devices [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-04-04restructuringin_progressSupply Chain [Member]USD 104,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-04-04restructuringin_progressRestructuring Charges [Member] / Supply Chain [Member]USD 53,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-04-04restructuringin_progressCost of Sales [Member] / Supply Chain [Member]USD 27,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-04-04restructuringin_progressOther Income Expense Net [Member] / Supply Chain [Member]USD 24,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-04-04restructuringin_progressEmployee Severance [Member] / Medical Devices [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-04-04restructuringin_progressAsset Write-off [Member] / Medical Devices [Member]USD 14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-04-04restructuringin_progressOther Restructuring [Member] / Medical Devices [Member]USD 90,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-01-03restructuringin_progress20182022GlobalGlobal Supply Chain (all segments)USD 0 (billions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year Global Supply Chain program announced fiscal Q2 2018; employee count not disclosed. FY2020 pre-tax charge $0.4B ($0.2B restructuring line, $0.1B other (income) expense, $0.1B cost of products sold); cumulative charges ~$1.3B since announcement; total expected charges $1.9-2.3B with ~70% cash; expects $0.6-0.8B annual pre-tax savings substantially delivered by 2022. Severance reserve of $135M (of $144M total reserve) at January 3, 2021.
2021-01-03othercompleted2018Medical Devices — Ethicon Endo-Surgery and DePuy Synthes manufacturing operationsother
f5-10k / GLM-5.3-flash-HTML		Strategic collaboration with Jabil Inc. (binding offer accepted fiscal 2018) included transfer of employees and manufacturing sites; transfers completed in fiscal year 2020. Note 20 links pension net actuarial losses to the employee transfers to Jabil. Headcount transferred not disclosed.
2021-01-03acquisition_additioncompleted2020-10-01PharmaceuticalUSD 6 (billions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition of Momenta Pharmaceuticals, Inc. completed October 1, 2020 for approximately $6.1B net of cash acquired (purchase price shown as associated value); headcount added not disclosed.
2021-01-03acquisition_additioncompleted2020PharmaceuticalUSD 1 (billions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Fiscal Q1 2020 acquisition of rights to investigational compound bermekimab from XBiotech Inc. for $0.8B, along with certain employees from XBiotech Inc.; number of employees transferred not disclosed.
2021-01-03acquisition_additioncompleted2020Medical Devicesbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Fiscal Q1 2020 acquisition of all outstanding shares in Verb Surgical Inc. (robotics and data science capabilities), including shares previously held by Verily; headcount added not disclosed.
2021-01-03restructuringin_progress20182022-12-31WorldwideGlobal Supply ChainUSD 0 (billions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Announced in fiscal second quarter 2018; exact announcement date not disclosed. FY2020 pre-tax charge of $0.4B ($0.2B restructuring, $0.1B other (income) expense, $0.1B cost of products sold); cumulative project costs of approximately $1.3B since announcement. Program expected to generate $0.6B-$0.8B annual pre-tax savings substantially delivered by 2022, with total expected charges of $1.9B-$2.3B. No employees-affected count disclosed; severance reserve balance was $135M of a $144M total reserve at fiscal year-end.
2021-01-03othercompleted20182021-01-03WorldwideMedical Devices (Ethicon Endo-Surgery, DePuy Synthes)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Strategic manufacturing collaboration with Jabil Inc. involving transfer of employees and manufacturing sites; transfers completed during fiscal 2020. Binding offer accepted in fiscal 2018; number of employees transferred not disclosed.
2021-01-03acquisition_additioncompleted2020-10-01PharmaceuticalUSD 6 (billions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Momenta Pharmaceuticals, Inc. for approximately $6.1B net of cash acquired; $6.0B allocated to IPR&D and $1.2B to goodwill. Headcount added not disclosed.
2021-01-03acquisition_additioncompletedPharmaceuticalUSD 1 (billions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of all rights to bermekimab and certain employees from XBiotech Inc. for $0.8B, completed in fiscal first quarter 2020 (exact date not disclosed). Headcount added not quantified.
2021-01-03acquisition_additioncompletedMedical DevicesUSD 0 (billions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of all outstanding shares in Verb Surgical Inc., completed in fiscal first quarter 2020 (exact date not disclosed); $0.4B allocated to IPR&D and $0.2B to goodwill. Headcount added not disclosed.
2021-01-03divestiture_reductioncompletedUnited StatesConsumer HealthMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Baby Center divestiture in the U.S. cited as a driver of the 9.4% Baby Care franchise sales decline in fiscal 2020; timing and headcount not disclosed.
2021-01-03divestiture_reductioncompletedInternational (outside U.S.)PharmaceuticalUSD 1 (billions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Subsequent to fiscal 2020, two brands outside the U.S. divested in separate transactions for combined proceeds of approximately $0.6B; to be reflected in 2021 results. Headcount not disclosed.
2021-01-03restructuringin_progress2018-06-012022-12-31GlobalSupply ChainUSD 400 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Global supply chain restructuring announced in Q2 2018. $400 million pre-tax charge recorded in 2020. Total expected pre-tax charges $1.9-$2.3 billion. Savings expected by 2022.
2021-01-03restructuringin_progress2018-06-302022-12-31WorldwideGlobal Supply ChainUSD 0 (billions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Announced in Q2 2018. Fiscal 2020 pre-tax charge of $0.4 billion recorded. Total expected pre-tax charges $1.9-$2.3 billion. Savings substantially delivered by 2022. Employee count not explicitly disclosed for FY2020 activity.
2021-01-03restructuringin_progressUSD 247,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-01-03restructuringin_progressPharmaceutical [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-01-03restructuringin_progressMedical Devices [Member]USD 300,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-01-03restructuringin_progressSupply Chain [Member]USD 400,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-01-03restructuringin_progressRestructuring Charges [Member] / Supply Chain [Member]USD 200,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-01-03restructuringin_progressOther Income Expense Net [Member] / Supply Chain [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-01-03restructuringin_progressCost of Sales [Member] / Supply Chain [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-01-03restructuringin_progressEmployee Severance [Member] / Supply Chain [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-01-03restructuringin_progressAsset Write-off [Member] / Supply Chain [Member]USD 43,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-01-03restructuringin_progressOther Restructuring [Member] / Supply Chain [Member]USD 405,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-09-27restructuringin_progress2018-04-012022-12-31GlobalGlobal Supply ChainUSD 130 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2020 pre-tax charge of $130M ($68M restructuring, $32M cost of products sold, $30M other income/expense); program targets $0.6-$0.8B annual pre-tax savings substantially delivered by 2022, with total expected charges of $1.9-$2.3B over 4-5 years; ~$1.2B recorded since announcement; severance reserve of $146M at quarter-end, cash outlays expected over next 2 years; no employee counts disclosed
2020-09-27restructuringin_progress2018-04-012022-12-31GlobalGlobal Supply ChainUSD 363 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Fiscal nine months 2020 pre-tax charge of $363M ($187M restructuring, $69M cost of products sold, $107M other income/expense); part of the same Global Supply Chain program
2020-09-27divestiture_reductionin_progress2018-07-012020-12-31GlobalEthicon Endo-Surgery and DePuy Synthesbusiness_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Strategic collaboration with Jabil Inc. includes transfer of certain employees and manufacturing sites; majority of transfers completed in 2019 with a minor amount remaining in 2020; assets held for sale of $0.1B inventory and PP&E at quarter-end
2020-09-27restructuringin_progress2018-06-302022-12-31GlobalGlobal Supply ChainUSD 363 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Global Supply Chain program; $363M pre-tax charge in fiscal nine months 2020 ($130M in Q3). Severance reserve balance of $156M at 2020-09-27. No employee counts disclosed; total program charges expected $1.9–2.3B with $0.6–0.8B annual savings by 2022.
2020-09-27acquisition_additionannounced2020-10-012020-10-01United StatesPharmaceuticalUSD 6,500 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Momenta Pharmaceuticals completed 2020-10-01 for ~$6.5B, primarily allocated to IPR&D; headcount added not disclosed.
2020-09-27acquisition_additioncompleted2020-03-312020-03-31United StatesPharmaceuticalUSD 800 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Fiscal Q1 2020 acquisition of bermekimab rights and certain employees from XBiotech Inc. for $0.8B; headcount added not disclosed.
2020-09-27acquisition_additioncompleted2020-03-312020-03-31United StatesMedical Devicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Fiscal Q1 2020 acquisition of all outstanding shares in Verb Surgical Inc.; headcount added not disclosed.
2020-09-27divestiture_reductioncompleted2019-04-012019-04-01GlobalMedical Devicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		ASP divestiture to Fortive completed 2019-04-01; referenced in current-period MD&A as a prior-year divestiture gain. Headcount removed not disclosed.
2020-09-27restructuringin_progress2018-04-012022-12-31GlobalGlobal Supply ChainUSD 130 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q3 2020 pre-tax charge of $130M ($68M restructuring, $32M COGS, $30M other). Program announced in Q2 2018. Total expected charges $1.9B-$2.3B. Employee count not disclosed.
2020-09-27acquisition_additioncompleted2020-01-012020-01-01GlobalPharmaceuticalUSD 800 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of bermekimab rights and certain employees from XBiotech Inc. in Q1 2020. Employee count not disclosed.
2020-09-27acquisition_additioncompleted2020-01-012020-01-01GlobalMedical DevicesUSD 400 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of all outstanding shares in Verb Surgical Inc. in Q1 2020. Employee count not disclosed.
2020-09-27restructuringin_progressUSD 68,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-27restructuringin_progressConsumer [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-27restructuringin_progressOperating Segments [Member] / Pharmaceutical [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-27restructuringin_progressMedical Devices [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-27restructuringin_progressSupply Chain [Member]USD 130,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-27restructuringin_progressRestructuring Charges [Member] / Supply Chain [Member]USD 68,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-27restructuringin_progressCost of Sales [Member] / Supply Chain [Member]USD 32,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-27restructuringin_progressOther Income Expense Net [Member] / Supply Chain [Member]USD 30,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-27restructuringin_progressEmployee Severance [Member] / Medical Devices [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-27restructuringin_progressAsset Write-off [Member] / Medical Devices [Member]USD 55,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-27restructuringin_progressOther Restructuring [Member] / Medical Devices [Member]USD 308,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-28restructuringin_progress2018-04-012022-12-31GlobalGlobal Supply ChainUSD 233 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Global Supply Chain program announced Q2 2018; $233M pre-tax charge in fiscal six months 2020 ($115M in Q2). Total project costs ~$1.1B recorded since announcement; expected total charges $1.9-2.3B over 4-5 years with $0.6-0.8B annual pre-tax savings substantially delivered by 2022. Severance reserve balance of $152M at June 28, 2020; no employee counts disclosed.
2020-06-28divestiture_reductionin_progress2018-07-012020-12-31GlobalEthicon Endo-Surgery and DePuy Synthesbusiness_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Strategic collaboration with Jabil Inc. includes transfer of certain employees and manufacturing sites; majority of transfers completed in 2019 with a minor amount remaining in 2020. Assets held for sale of $0.1 billion at June 28, 2020. Pension-related actuarial losses associated with the employee transfer recorded in restructuring.
2020-06-28restructuringin_progress2018-06-012022-12-31GlobalGlobal Supply ChainUSD 233 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Global Supply Chain restructuring announced in Q2 2018; H1 2020 charge of $233M ($119M restructuring, $37M COGS, $77M other). Total program charges expected $1.9–2.3B; ~$1.1B recorded to date. No employee headcount affected disclosed.
2020-06-28acquisition_additioncompleted2020-03-312020-03-31United StatesPharmaceuticalUSD 800 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of bermekimab and related assets from XBiotech Inc. for $0.8B; certain employees acquired. Headcount added not disclosed.
2020-06-28acquisition_additioncompleted2020-03-312020-03-31United StatesMedical Devicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of all outstanding shares of Verb Surgical Inc. (robotics and data science). Headcount added not disclosed.
2020-06-28divestiture_reductionin_progress2018-09-012020-12-31GlobalMedical Devices — Ethicon Endo-Surgery and DePuy Synthesother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Strategic collaboration with Jabil Inc. involving transfer of certain employees and manufacturing sites; majority completed in 2019 with minor amount remaining in 2020. Headcount transferred not disclosed.
2020-06-28restructuringin_progress2018-07-012022-12-31GlobalGlobal Supply ChainUSD 115 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q2 2020 pre-tax charge of $115M ($61M restructuring, $22M COGS, $32M other). Program announced Q2 2018. Total expected charges $1.9B-$2.3B over 4-5 years. Employee count not disclosed.
2020-06-28acquisition_additioncompleted2020-03-312020-03-31GlobalPharmaceuticalUSD 800 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of bermekimab rights and certain employees from XBiotech Inc. in Q1 2020. Purchase price $0.8B. Employee count not disclosed.
2020-06-28acquisition_additioncompleted2020-03-312020-03-31GlobalMedical DevicesUSD 400 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of all outstanding shares in Verb Surgical Inc. in Q1 2020. Fair value allocated primarily to IPR&D ($0.4B). Employee count not disclosed.
2020-06-28restructuringin_progress2018-07-012022-12-31GlobalGlobal Supply ChainUSD 233 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2020 pre-tax charge of $233M ($119M restructuring, $37M COGS, $77M other). Part of Global Supply Chain actions announced Q2 2018. Employee count not disclosed.
2020-06-28restructuringin_progressUSD 61,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-28restructuringin_progressMedical Devices [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-28restructuringin_progressSupply Chain [Member]USD 115,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-28restructuringin_progressRestructuring Charges [Member] / Supply Chain [Member]USD 61,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-28restructuringin_progressCost of Sales [Member] / Supply Chain [Member]USD 22,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-28restructuringin_progressOther Income Expense Net [Member] / Supply Chain [Member]USD 32,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-28restructuringin_progressEmployee Severance [Member] / Medical Devices [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-28restructuringin_progressAsset Write-off [Member] / Medical Devices [Member]USD 27,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-28restructuringin_progressOther Restructuring [Member] / Medical Devices [Member]USD 206,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-29restructuringin_progress2018-04-012022-12-31GlobalGlobal Supply ChainUSD 118 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2020 pre-tax charge of $118M ($58M restructuring, $15M cost of products sold, $45M other income/expense); ~$1.0B cumulative charges since 2018 announcement; program targets $0.6-$0.8B annual pre-tax savings substantially delivered by 2022, with total expected charges of $1.9-$2.3B over 4-5 years. No employee counts disclosed.
2020-03-29divestiture_reductionin_progress2018-07-012020-12-31GlobalEthicon Endo-Surgery and DePuy Synthesbusiness_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Strategic collaboration with Jabil Inc. includes transfer of certain employees and manufacturing sites; majority of transfers completed in 2019 with a minor amount remaining in 2020. Q1 2020 restructuring table notes pension-related actuarial losses tied to the employee transfer to Jabil.
2020-03-29restructuringin_progressWorldwideGlobal Supply ChainUSD 118 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Global Supply Chain actions announced in fiscal Q2 2018 (exact date not disclosed). Q1 2020 pre-tax charge of $118M ($58M restructuring, $15M COGS, $45M other income/expense); ~$1.0B recorded since announcement; program expected to total $1.9B–$2.3B over 4–5 years, with $0.6B–$0.8B annual pre-tax savings substantially delivered by 2022. Severance reserve balance $165M at 2020-03-29, expected to be paid out over the next 2 years. No employee headcount affected is disclosed.
2020-03-29divestiture_reductionin_progressWorldwideEthicon Endo-Surgery and DePuy Synthes (manufacturing)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Strategic collaboration with Jabil Inc. involving transfer of certain employees and manufacturing sites; majority of transfers completed in 2019 with a minor amount remaining in 2020. No employee count disclosed. Related pension actuarial losses of $3M recorded in Q1 2020 restructuring reserve roll-forward.
2020-03-29restructuringin_progress2018-06-012022-12-31GlobalGlobal Supply ChainUSD 118 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q1 2020 pre-tax charge of $118M ($58M restructuring, $15M COGS, $45M other). Total project costs ~$1.0B recorded since announcement. Expected annual savings $0.6B-$0.8B by 2022. Employee count not disclosed.
2020-03-29acquisition_additioncompleted2020-03-292020-03-29GlobalPharmaceuticalUSD 800 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of bermekimab rights and certain employees from XBiotech Inc. for $0.8B. Employee count not disclosed.
2020-03-29acquisition_additioncompleted2020-03-292020-03-29GlobalMedical DevicesUSD 400 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of all outstanding shares in Verb Surgical Inc. for $0.4B (IPR&D) + $0.2B goodwill. Employee count not disclosed.
2020-03-29divestiture_reductionin_progress2018-09-012020-12-31GlobalMedical Devicesbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Strategic collaboration with Jabil Inc. to transfer certain employees and manufacturing sites. Majority of transfers completed in 2019 with minor amount remaining in 2020. Employee count not disclosed.
2020-03-29restructuringin_progressUSD 58,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-29restructuringin_progressMedical Devices [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-29restructuringin_progressSupply Chain [Member]USD 118,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-29restructuringin_progressRestructuring Charges [Member] / Supply Chain [Member]USD 58,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-29restructuringin_progressCost of Sales [Member] / Supply Chain [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-29restructuringin_progressOther Income Expense Net [Member] / Supply Chain [Member]USD 45,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-29restructuringin_progressEmployee Severance [Member] / Medical Devices [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-29restructuringin_progressAsset Write-off [Member] / Medical Devices [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-29restructuringin_progressOther Restructuring [Member] / Medical Devices [Member]USD 107,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-12-29restructuringin_progress20182022GlobalGlobal Supply Chain (Consumer, Pharmaceutical, Medical Devices)USD 611 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Global Supply Chain actions announced in fiscal Q2 2018. FY2019 pre-tax charge of $611M ($0.3B restructuring line, $0.2B other income/expense, $0.1B cost of products sold); cumulative project costs ~$0.8B; total expected pre-tax charges $1.9–2.3B over 4–5 years, with $0.6–0.8B annual savings substantially delivered by 2022. Includes transfer of employees and manufacturing sites to Jabil Inc. under a strategic collaboration (majority of transfers completed in 2019). No new severance charges in 2019; severance reserve of $164M at year-end to be substantially paid out over the next 2 years. Number of employees affected not disclosed.
2019-12-29divestiture_reductioncompleted2019GlobalMedical Devices — Advanced Sterilization Products (ASP)other
f5-10k / GLM-5.3-flash-HTML		ASP business sold to Fortive Corporation during fiscal Q2 2019 for an aggregate value of approximately $2.8B ($2.7B cash plus $0.1B retained receivables), producing a ~$2.0B pre-tax gain. Employee headcount transferring with the business not disclosed.
2019-12-29acquisition_additioncompleted2019Japan; United StatesConsumer (DR. CI:LABO); Medical Devices (Auris Health)USD 5,800 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		FY2019 business combinations totaled $5.8B cash with $1.4B liabilities assumed; primarily DR. CI:LABO (Japan, Consumer, ~$2.1B, ownership completed June 2019) and Auris Health (US robotic technologies, Medical Devices, ~$3.4B net of cash, closed April 1, 2019), plus Taris Biomedical and JointPoint assets. Value shown is purchase consideration, not a workforce charge; employee headcount acquired not disclosed.
2019-12-29acquisition_additioncompleted2019-12-30Pharmaceutical — bermekimab (dermatological indications)USD 800 (millions)subsequent_events
f5-10k / GLM-5.3-flash-HTML		Acquisition of bermekimab rights and certain XBiotech Inc. employees closed December 30, 2019, one day after fiscal year-end, and is disclosed as a subsequent event. Purchase price $0.8B is consideration, not a workforce charge; employee count not quantified.
2019-12-29restructuringin_progress20182022WorldwideGlobal Supply Chain (all segments)USD 600 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2019 pre-tax charge of $0.6B split across the restructuring line, other (income) expense, and cost of products sold; cumulative project costs of approximately $0.8B since the program was announced in fiscal Q2 2018. Program targets $0.6–0.8B of annual pre-tax savings substantially delivered by 2022, with total expected charges of $1.9–2.3B over 4–5 years. Employees affected not disclosed; severance reserve balance was $164M at fiscal year-end.
2019-12-29acquisition_additioncompleted2019-01-172019-01-17JapanConsumerbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Ci:z Holdings Co., Ltd. (DR. CI:LABO) for approximately $2.1B; headcount added not disclosed.
2019-12-29acquisition_additioncompleted2019-04-012019-04-01United StatesMedical Devicesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Auris Health, Inc. for approximately $3.4B net of cash, with contingent payments up to $2.35B; headcount added not disclosed.
2019-12-29divestiture_reductioncompleted20192019WorldwideMedical Devicesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Divestiture of Advanced Sterilization Products (ASP) to Fortive for approximately $2.8B with a pre-tax gain of about $2.0B recognized in fiscal Q2 2019; headcount removed not disclosed.
2019-12-29otherin_progress20182020WorldwideEthicon Endo-Surgery and DePuy Synthes manufacturingbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Strategic manufacturing collaboration with Jabil Inc. involving transfer of employees and manufacturing sites; most transfers completed in 2019 with a small remainder in 2020. Employees transferred not disclosed.
2019-12-29acquisition_additioncompleted2019-12-302019-12-30United StatesPharmaceuticalsubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Subsequent to fiscal year-end, acquired rights to the investigational compound bermekimab along with certain employees from XBiotech Inc. for $0.8B; number of employees not disclosed.
2019-12-29restructuringin_progress2018-04-012022-12-31GlobalSupply ChainUSD 1 (billions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Global supply chain actions announced in Q2 2018. In 2019, the Company recorded a pre-tax charge of $0.6 billion ($0.3B in restructuring, $0.2B in other income/expense, $0.1B in cost of products sold). Total project costs of approximately $0.8 billion have been recorded since announcement. Expected to generate $0.6-$0.8 billion in annual pre-tax cost savings by 2022.
2019-12-29acquisition_additioncompleted2019-01-172019-01-17JapanConsumerbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of DR. CI:LABO (Ci:z Holdings Co., Ltd.) completed January 17, 2019. Purchase price approximately $2.1 billion. Employee count not explicitly disclosed in filing.
2019-12-29acquisition_additioncompleted2019-04-012019-04-01United StatesMedical Devicesbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Auris Health, Inc. completed April 1, 2019. Purchase price approximately $3.4 billion. Employee count not explicitly disclosed in filing.
2019-12-29divestiture_reductioncompleted2019-06-012019-06-01GlobalMedical Devicesdiscontinued_operations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Divestiture of Advanced Sterilization Products (ASP) business to Fortive Corporation. Aggregate value approximately $2.8 billion. Employee count not explicitly disclosed.
2019-12-29restructuringin_progress2018-01-012020-12-31GlobalSupply Chainbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Strategic collaboration with Jabil Inc. to transfer employees and manufacturing sites. Majority of transfers completed in 2019 with minor amount remaining in 2020. Specific employee count not disclosed.
2019-12-29restructuringin_progress2018-04-012022-12-31WorldwideGlobal Supply ChainUSD 600 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Announced in Q2 2018. In 2019, recorded pre-tax charge of $0.6 billion. Total expected pre-tax charges $1.9-$2.3 billion. Savings substantially delivered by 2022. Employee count not explicitly disclosed for 2019 activity.
2019-12-29acquisition_additioncompleted2019-01-172019-06-30JapanConsumerbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of DR. CI:LABO completed June 2019. Headcount not disclosed.
2019-12-29acquisition_additioncompleted2019-04-012019-04-01United StatesMedical Devicesbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Auris Health, Inc. completed April 2019. Headcount not disclosed.
2019-12-29divestiture_reductioncompleted2019-01-012019-12-29WorldwideMedical Devicesdiscontinued_operations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Divestiture of Advanced Sterilization Products (ASP) business. Headcount not disclosed.
2019-12-29restructuringin_progressUSD 266,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-29restructuringin_progressConsumer [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-29restructuringin_progressPharmaceutical [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-29restructuringin_progressMedical Devices [Member]USD 400,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-29restructuringin_progressSupply Chain [Member]USD 600,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-29restructuringin_progressRestructuring Charges [Member] / Supply Chain [Member]USD 300,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-29restructuringin_progressOther Income Expense Net [Member] / Supply Chain [Member]USD 200,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-29restructuringin_progressCost of Sales [Member] / Supply Chain [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-29restructuringin_progressEmployee Severance [Member] / Supply Chain [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-29restructuringin_progressAsset Write-off [Member] / Supply Chain [Member]USD 151,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-29restructuringin_progressOther Restructuring [Member] / Supply Chain [Member]USD 460,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-09-29restructuringin_progress2018-04-172022-12-31GlobalGlobal Supply ChainUSD 128 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2019 pre-tax charge of $128M ($20M in cost of products sold, $39M in other income/expense); nine-month charge $360M; cumulative project costs ~$598M; expected total charges $1.9-$2.3B with $0.6-$0.8B annual pre-tax savings substantially delivered by 2022; includes transfer of certain employees and manufacturing sites to Jabil Inc. under strategic collaboration; severance reserve of $180M at quarter-end
2019-09-29restructuringin_progress2018-04-172022-12-31GlobalGlobal Supply ChainUSD 360 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Nine-month 2019 pre-tax charge of $360M (Q3 2019 charge $128M); severance reserve $180M at 2019-09-29. No employee count disclosed. Program targets $0.6–0.8B annual savings by 2022; total expected charges $1.9–2.3B over 4–5 years.
2019-09-29otherin_progress2018-09-302019-12-31GlobalEthicon Endo-Surgery; DePuy Synthesother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Strategic collaboration with Jabil Inc. involves transfer of certain employees and manufacturing sites; most transfers expected complete by year-end 2019. Announcement date is fiscal Q3 2018 quarter-end; exact date not stated. No employee count disclosed.
2019-09-29acquisition_additioncompleted2019-04-012019-04-01United StatesMedical Devicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Auris Health, Inc. acquired for ~$3.4B net of cash; up to $2.35B additional contingent payments. No headcount added disclosed.
2019-09-29acquisition_additioncompleted2019-01-172019-06-30JapanConsumerbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ci:z Holdings Co., Ltd. (Dr. Ci:Labo) acquisition completed 2019-01-17; legal ownership with tender offer completed June 2019. No headcount added disclosed.
2019-09-29acquisition_additioncompleted2019-09-272019-09-27United StatesMedical Devicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of assets of JointPoint, Inc. (hip navigation software). No headcount added disclosed.
2019-09-29divestiture_reductioncompleted2019-04-012019-04-01GlobalMedical Devicesother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		ASP (Advanced Sterilization Products) business divested to Fortive for ~$2.8B; pre-tax gain of ~$2.0B recognized. No headcount reduction disclosed.
2019-09-29restructuringin_progress2018-04-012022-12-31GlobalSupply ChainUSD 0 (billions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Global supply chain restructuring announced in Q2 2018. Q3 2019 pre-tax charge of $128 million recorded. Total expected charges $1.9-$2.3 billion. Completion by 2022.
2019-09-29divestiture_reductioncompleted2019-04-012019-04-01GlobalMedical Devicesbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Divestiture of Advanced Sterilization Products (ASP) business to Fortive Corporation completed April 1, 2019.
2019-09-29acquisition_additioncompleted2019-04-012019-04-01GlobalMedical Devicesbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Auris Health, Inc. completed April 1, 2019.
2019-09-29acquisition_additioncompleted2019-01-172019-01-17JapanConsumerbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Ci:z Holdings Co., Ltd. (Dr. Ci:Labo) completed January 17, 2019.
2019-09-29acquisition_additioncompleted2019-09-272019-09-27United StatesMedical Devicesbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of assets of JointPoint, Inc. completed September 27, 2019.
2019-09-29restructuringin_progressUSD 69,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-29restructuringin_progressConsumer [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-29restructuringin_progressPharmaceutical [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-29restructuringin_progressMedical Devices [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-29restructuringin_progressSupply Chain [Member]USD 128,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-29restructuringin_progressCost of Sales [Member] / Supply Chain [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-29restructuringin_progressOther Income Expense Net [Member] / Supply Chain [Member]USD 39,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-29restructuringin_progressEmployee Severance [Member] / Medical Devices [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-29restructuringin_progressAsset Write-off [Member] / Medical Devices [Member]USD 81,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-29restructuringin_progressOther Restructuring [Member] / Medical Devices [Member]USD 279,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progress2018-04-17GlobalGlobal Supply ChainUSD 142 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Global supply chain restructuring announced April 2018. Q2 2019 pre-tax charge of $142 million ($38 million in cost of products sold, $47 million in other income/expense); six-month charge $232 million. Approximately $500 million of project costs recorded since announcement. Company expects $1.9-$2.3 billion total pre-tax charges over 4-5 years and $0.6-$0.8 billion annual pre-tax savings substantially delivered by 2022. Severance reserve balance of $187 million at June 30, 2019; no employee counts disclosed.
2019-06-30restructuringin_progress2018-10-232019-12-31GlobalEthicon Endo-Surgery and DePuy Synthesother
f5-10q / GLM-5.3-flash-fp4-HTML		Strategic collaboration with Jabil Inc. includes transfer of employees and manufacturing sites; certain sites transferred in first six months of 2019 with additional sites expected to transfer in remainder of 2019. Part of the global supply chain restructuring. No employee counts disclosed.
2019-06-30restructuringin_progress2018-04-012022-12-31GlobalGlobal Supply ChainUSD 0 (billions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Company announced global supply chain actions in Q2 2018. Q2 2019 recorded $142M pre-tax charge. Total expected charges $1.9B-$2.3B. Employee count not disclosed.
2019-06-30divestiture_reductioncompleted2019-04-01GlobalMedical Devicesbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Divestiture of ASP business to Fortive completed April 1, 2019. Employee count not disclosed.
2019-06-30acquisition_additioncompleted2019-04-01GlobalMedical Devicesbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Auris Health, Inc. completed April 1, 2019. Employee count not disclosed.
2019-06-30acquisition_additioncompleted2019-01-17JapanConsumerbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Ci:z Holdings Co., Ltd. (Dr. Ci: Labo) completed January 17, 2019. Employee count not disclosed.
2019-06-30divestiture_reductionin_progress2019-12-31GlobalMedical Devicesbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Strategic collaboration with Jabil Inc. involves transfer of employees and manufacturing sites. Some sites transferred in first six months of 2019, additional sites expected to transfer in remainder of 2019. Employee count not disclosed.
2019-06-30restructuringin_progressUSD 57,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressMedical Devices [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressSupply Chain [Member]USD 142,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressCost of Sales [Member] / Supply Chain [Member]USD 38,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressOther Income Expense Net [Member] / Supply Chain [Member]USD 47,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressEmployee Severance [Member] / Medical Devices [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressAsset Write-off [Member] / Medical Devices [Member]USD 61,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressOther Restructuring [Member] / Medical Devices [Member]USD 171,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progress2018-04-172022-12-31GlobalGlobal Supply ChainUSD 90 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2019 pre-tax charge of $90 million ($23M in cost of products sold, $31M in other (income) expense); cumulative charges of $0.3 billion since announcement. Program expected to generate $0.6-$0.8 billion annual pre-tax savings substantially delivered by 2022, with total expected pre-tax charges of $1.9-$2.3 billion over 4-5 years. Includes transfer of certain manufacturing sites to Jabil Inc. under a strategic collaboration; no employee counts disclosed.
2019-03-31restructuringin_progress2018-04-17GlobalGlobal Supply ChainUSD 90 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2019 pre-tax charge of $90M ($23M in cost of products sold, $31M in other (income) expense); $0.3B total charges since announcement. Program expected to generate $0.6–0.8B annual pre-tax savings substantially delivered by 2022, with total pre-tax charges of $1.9–2.3B over 4–5 years. Severance reserve balance $193M at 2019-03-31. No employee headcount affected disclosed.
2019-03-31acquisition_additioncompleted2018-10-232019-01-17JapanConsumerbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Ci:z Holdings Co., Ltd. (Dr. Ci: Labo) completed 2019-01-17 for approximately $2.1B; Company acquired 89% of outstanding shares, paying ~$1.6B net of cash acquired by quarter-end. No headcount added disclosed.
2019-03-31divestiture_reductionin_progress2018-07-01GlobalMedical Devices — manufacturing (Ethicon Endo-Surgery, DePuy Synthes)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Strategic collaboration with Jabil Inc. involving transfer of employees and manufacturing sites; certain sites transferred in Q1 2019 with additional sites expected during remainder of 2019. Announcement date approximate (binding offer accepted during fiscal Q3 2018). No employee count disclosed.
2019-03-31acquisition_additioncompletedUnited StatesMedical Devicessubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Subsequent to Q1 2019, completed acquisition of Auris Health, Inc. for approximately $3.4B net of cash acquired, plus contingent payments up to $2.35B on predetermined milestones. Robotic technology developer focused on lung cancer. No headcount added disclosed; announcement date not stated in filing.
2019-03-31divestiture_reductioncompletedGlobalMedical Devices — Advanced Sterilization Products (ASP)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Subsequent to Q1 2019, completed divestiture of ASP business to Fortive Corporation for aggregate value of approximately $2.8B ($2.7B cash proceeds plus $0.1B retained net receivables). Assets held for sale at 2019-03-31 included $0.2B inventory, $0.1B PP&E, $0.3B goodwill. No employee count disclosed; announcement date not stated in filing.
2019-03-31restructuringin_progress2018-04-012022-12-31GlobalGlobal Supply ChainUSD 0 (billions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Company announced global supply chain actions in Q2 2018. Q1 2019 recorded $90M pre-tax charge. Total expected charges $1.9B-$2.3B. Employee count not disclosed.
2019-03-31divestiture_reductioncompleted2019-04-012019-04-01GlobalMedical Devicessubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Divestiture of Advanced Sterilization Products (ASP) business to Fortive completed subsequent to quarter end. Employee count not disclosed.
2019-03-31acquisition_additioncompleted2019-04-012019-04-01GlobalMedical DevicesUSD 3 (billions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Auris Health, Inc. completed subsequent to quarter end for approx $3.4B. Employee count not disclosed.
2019-03-31acquisition_additioncompleted2019-01-172019-01-17JapanConsumerUSD 2 (billions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Ci:z Holdings Co., Ltd. (Dr. Ci: Labo) completed Jan 17, 2019. Employee count not disclosed.
2019-03-31restructuringin_progressOther Income Expense Net [Member] / Supply Chain [Member]USD 31,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressCost of Sales [Member] / Supply Chain [Member]USD 23,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressSupply Chain [Member]USD 90,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressUSD 36,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressAsset Write-off [Member] / Medical Devices [Member]USD 23,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressEmployee Severance [Member] / Medical Devices [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressOther Restructuring [Member] / Medical Devices [Member]USD 67,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressMedical Devices [Member]USD 90,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-12-30restructuringcompleted20162018-12-30Medical DevicesUSD 462 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Program announced Q1 2016 to streamline go-to-market model and operations; completed in fiscal Q4 2018. FY2018 pre-tax charge of $462M ($46M in cost of products sold, $227M in other (income) expense); cumulative project costs ~$2.5B since announcement; ~$0.7B annualized pre-tax savings achieved in 2018. Disclosure notes ~2,375 individuals received separation payments cumulatively since both this program and the 2018 Global Supply Chain announcements (combined figure, not attributable to this program alone).
2018-12-30restructuringin_progress2018-04-172022-12-31Worldwide (global supply chain actions)All segments (Global Supply Chain)USD 238 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		FY2018 pre-tax charge of $238M ($59M in cost of products sold, $117M in other (income) expense). Program expects total pre-tax charges of $1.9B-$2.3B over 4-5 years, ~70% cash, with $0.6B-$0.8B annual savings substantially delivered by 2022; includes strategic collaborations (e.g., Jabil) and network optimization. The ~2,375 separation-payment figure disclosed is cumulative across both restructuring announcements and not attributable to this program alone.
2018-12-30divestiture_reductioncompleted2018-12-30WorldwideMedical Devices — Diabetes Care (LifeScan)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		LifeScan Inc. business divested during fiscal 2018 (completed fiscal Q4) for approximately $2.1B, with certain net liabilities retained; pre-tax gain of ~$0.5B. Headcount transferring with the business not disclosed.
2018-12-30divestiture_reductionannounced20182019Medical Devices — Advanced Sterilization Productsbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Binding offer from Fortive Corporation to acquire the Advanced Sterilization Products business for ~$2.7B accepted in 2018; expected to close in 2019. At fiscal year-end, $0.2B inventory, $0.1B PP&E and $0.3B goodwill held for sale; Company retains ~$0.1B net receivables. Headcount not disclosed.
2018-12-30divestiture_reductionannounced2018Ethicon Endo-Surgery and DePuy Synthes manufacturing (Medical Devices)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Binding offer accepted in 2018 to form a strategic collaboration with contract manufacturer Jabil Inc., including transfer of employees and manufacturing sites; part of the global supply chain restructuring. Pending at fiscal year-end, with $0.3B inventory and $0.1B PP&E held for sale. Employee count not disclosed.
2018-12-30acquisition_additioncompleted20182018-12-30Consumer, Pharmaceutical and Medical Devicesbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Certain businesses acquired in 2018 for ~$0.9B cash and $0.1B liabilities assumed, primarily Zarbee's Inc. (Consumer), Medical Enterprises Distribution LLC, BeneVir Biopharm, Inc. and Orthotaxy; headcount added through these acquisitions not disclosed.
2018-12-30acquisition_additioncompleted2018-10-232019-01-17JapanConsumersubsequent_events
f5-10k / GLM-5.3-flash-HTML		Agreement announced October 23, 2018 to acquire Ci:z Holdings Co., Ltd. for ~¥230 billion (~$2.1B); completed January 17, 2019 via tender offer acquiring 89% of shares, subsequent to fiscal year-end; remainder to be acquired via share consolidation in H1 2019.
2018-12-30acquisition_additionannounced2019-02-132019-06-30Medical Devices (robotic surgery technologies)subsequent_events
f5-10k / GLM-5.3-flash-HTML		Definitive agreement to acquire Auris Health, Inc. for ~$3.4B cash plus contingent payments up to $2.35B upon milestone achievement; expected to close by end of fiscal Q2 2019 subject to antitrust clearance.
2018-12-30restructuringcompleted2018-12-30WorldwideMedical DevicesUSD 462 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Program announced in Q1 2016 (exact date not disclosed); completed in fiscal Q4 2018. 2018 pre-tax charge of $462M ($46M in cost of products sold, $227M in other (income) expense); cumulative program cost of $2.5B since announcement. Filer discloses approximately 2,375 individuals received separation payments cumulative since the restructuring announcements across both programs; a 2018-specific affected headcount is not given.
2018-12-30restructuringin_progress2018-04-172022-12-31WorldwideGlobal Supply ChainUSD 238 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2018 pre-tax charge of $238M ($59M in cost of products sold, $117M in other (income) expense). Multi-year program: expected total pre-tax charges of $1.9-2.3B over 4-5 years and $0.6-0.8B annual pre-tax savings substantially delivered by 2022; ~70% of cumulative pre-tax costs expected to be cash. Affected headcount not disclosed; discussions subject to consultation requirements.
2018-12-30divestiture_reductioncompleted2018-12-30WorldwideMedical Devices (Diabetes Care)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		LifeScan Inc. divested in fiscal Q4 2018 for approximately $2.1B with certain net liabilities retained; pre-tax divestiture gains across 2018 were approximately $1.2B (including NIZORAL, RoC and certain non-strategic Pharmaceutical products). Headcount removed not disclosed.
2018-12-30divestiture_reductionannounced2019-12-31WorldwideMedical Devices (Advanced Sterilization Products)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Binding offer accepted from Fortive Corporation to acquire the ASP business for approximately $2.7B; expected to close in 2019. Assets held for sale at year-end: $0.2B inventory, $0.1B PP&E, $0.3B goodwill. Headcount not disclosed.
2018-12-30divestiture_reductionannouncedWorldwideMedical Devices (Ethicon Endo-Surgery, DePuy Synthes)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Binding offer accepted in 2018 to form a strategic manufacturing collaboration with Jabil Inc., expanding a 12-year relationship; includes transfer of employees and manufacturing sites. Assets held for sale at year-end: $0.3B inventory, $0.1B PP&E net. Number of employees transferred not disclosed.
2018-12-30acquisition_additioncompleted2018-12-30WorldwideConsumer, Medical Devices, PharmaceuticalUSD 899 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2018 acquisitions totaling $0.9B cash plus $0.1B liabilities assumed: Zarbee's Inc., Medical Enterprises Distribution LLC, BeneVir Biopharm Inc. and Orthotaxy. Headcount added not disclosed.
2018-12-30acquisition_additioncompleted2018-10-232019-01-17JapanConsumerUSD 2,100 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement entered 2018-10-23 to acquire Ci:z Holdings Co., Ltd. for approximately JPY 230 billion (~$2.1B); tender offer completed 2019-01-17 acquiring 89% of shares, with remaining shares to be acquired via share consolidation in H1 2019. Headcount added not disclosed.
2018-12-30acquisition_additionannounced2019-02-132019-06-30United StatesMedical DevicesUSD 3,400 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Auris Health, Inc. for approximately $3.4B cash plus up to $2.35B contingent milestone payments; announced after fiscal year-end, closing subject to antitrust clearance, expected by end of Q2 2019. Headcount added not disclosed.
2018-12-30restructuringcompleted2016-01-012018-12-30WorldwideMedical DevicesUSD 462 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Program announced in Q1 2016, completed in Q4 2018. 2018 pre-tax charge of $462 million. Total project costs since announcement approx $2.5 billion.
2018-12-30restructuringin_progress2018-04-172022-12-31WorldwideGlobal Supply ChainUSD 238 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Announced April 17, 2018. 2018 pre-tax charge of $238 million. Expected total pre-tax charges $1.9-$2.3 billion over 4-5 years.
2018-12-30divestiture_reductioncompleted2018-10-012018-12-30WorldwideMedical Devicesbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Divestiture of LifeScan Inc business completed in Q4 2018.
2018-12-30acquisition_additioncompleted2018-01-012018-12-30WorldwideConsumer, Medical Devices, Pharmaceuticalsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisitions in 2018 included Zarbee's Inc., Medical Enterprises Distribution LLC, BeneVir Biopharm, Inc., and Orthotaxy.
2018-12-30restructuringcompleted2,3752016-03-012018-12-30WorldwideMedical DevicesUSD 462 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Program announced Q1 2016. Completed in fiscal Q4 2018. 2,375 individuals received separation payments since announcement. $462M pre-tax charge recorded in 2018.
2018-12-30restructuringin_progress2018-04-172022-12-31WorldwideGlobal Supply ChainUSD 238 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Announced Q2 2018. Expected to generate $0.6-$0.8B annual savings by 2022. Total expected charges $1.9-$2.3B. $238M pre-tax charge recorded in 2018. Employee count not explicitly disclosed for this specific action in the footnote, though total separations since all announcements is 2,375.
2018-12-30restructuringin_progressUSD 227,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-30restructuringin_progressOther Income Expense Net [Member] / Supply Chain [Member]USD 117,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-30restructuringin_progressOther Income Expense Net [Member] / Medical Devices [Member]USD 227,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-30restructuringin_progressCost of Sales [Member] / Supply Chain [Member]USD 59,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-30restructuringin_progressCost of Sales [Member] / Medical Devices [Member]USD 46,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-30restructuringin_progressAsset Write-off [Member] / Medical Devices [Member]USD 132,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-30restructuringin_progressEmployee Severance [Member] / Medical Devices [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-30restructuringin_progressOther Restructuring [Member] / Medical Devices [Member]USD 568,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-30restructuringin_progressMedical Devices [Member]USD 700,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-30restructuringin_progressSupply Chain [Member]USD 238,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-09-30restructuringin_progress2,6505%2016-01-012018-12-31GlobalMedical DevicesUSD 2,400 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Announced Q1 2016; approximately 2,650 positions eliminated, of which 1,950 received separation payments; represents about 5 percent of the Medical Devices segment's global workforce. Total pre-tax charges of approximately $2.4 billion recorded since announcement; program expected to be completed by end of fiscal 2018 with certain projects and severance charges continuing beyond that date. Q3 2018 pre-tax charge of $101 million.
2018-09-30restructuringin_progress2018-04-172022-12-31GlobalGlobal Supply ChainUSD 1,900 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Global Supply Chain actions announced April 17, 2018; expected annual pre-tax cost savings of $0.6-$0.8 billion substantially delivered by 2022; expected pre-tax charges of approximately $1.9-$2.3 billion over 4-5 years, ~70% cash. $148 million of charges recorded since announcement; Q3 2018 pre-tax charge of $89 million. Includes expanding use of strategic collaborations such as the Jabil collaboration.
2018-09-30divestiture_reductionannounced2018-09-30GlobalMedical Devices — Diabetes Care (LifeScan)USD 2,100 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Divestiture of LifeScan business completed subsequent to the third quarter for approximately $2.1 billion; assets held for sale at September 30, 2018 included inventory, PP&E, intangibles and $1.0 billion of goodwill. Headcount affected not disclosed.
2018-09-30divestiture_reductionannounced2018-09-302019-12-31GlobalMedical Devices — Advanced Sterilization ProductsUSD 2,700 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Binding offer accepted from Fortive Corporation to acquire the Advanced Sterilization Products business for approximately $2.7 billion; transaction expected to close in 2019. Headcount affected not disclosed.
2018-09-30acquisition_additionannounced2018-10-222019-03-31JapanConsumerUSD 2,000 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		All-cash tender offer to acquire outstanding shares of Ci:z Holdings Co., Ltd. not already held for approximately $2 billion (¥230 billion); expected to close in Q1 2019 followed by a squeeze-out. Headcount to be added not disclosed.
2018-09-30restructuringin_progress2,6505%20162018-12-31GlobalMedical Devicesrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cumulative positions eliminated since the Q1 2016 announcement, not a quarterly figure; 1,950 of the 2,650 received separation payments. Program estimated at ~$2.4B pre-tax charges, fully recorded to date; ~5% of Medical Devices global workforce targeted. Severance reserve of $200M at 2018-09-30 covers both restructuring programs combined and is not attributable to this program alone.
2018-09-30restructuringin_progress2018-04-172022-12-31GlobalGlobal Supply Chainrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Global Supply Chain actions including strategic collaborations and network optimization; no employee count disclosed. Expected pre-tax charges of $1.9B–$2.3B over 4–5 years (~70% cash), targeting $0.6B–$0.8B annual pre-tax savings substantially delivered by 2022. $148M charged since announcement; includes the Jabil Inc. manufacturing collaboration.
2018-09-30restructuringin_progress2,6505%2016-01-012018-12-31GlobalMedical DevicesUSD 2,400 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Approximately 2,650 positions eliminated since announcement; 1,950 received separation payments. Program expected to complete by end of fiscal 2018.
2018-09-30restructuringin_progress2018-04-172022-12-31GlobalGlobal Supply ChainUSD 1,900 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Expected pre-tax charges of $1.9B to $2.3B over 4-5 years. No specific headcount reduction disclosed in this filing.
2018-09-30restructuringin_progressUSD 88,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressOther Income Expense Net [Member] / Medical Devices [Member]USD 45,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressOther Income Expense Net [Member] / Supply Chain [Member]USD 34,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressCost of Sales [Member] / Medical Devices [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressCost of Sales [Member] / Supply Chain [Member]USD 14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progress2,650Medical Devices [Member]USD 101,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressSupply Chain [Member]USD 89,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressAsset Write-off [Member] / Medical Devices [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressEmployee Severance [Member] / Medical Devices [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressOther Restructuring [Member] / Medical Devices [Member]USD 373,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-07-01restructuringin_progress2,6002016-01-012018-12-31Medical DevicesUSD 117 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program announced Q1 2016; approximately 2,600 positions eliminated cumulatively, of which 1,900 received separation payments. Q2 2018 pre-tax charge of $117 million ($19M in cost of products sold, $54M in other (income) expense). Cumulative charges of $2.3 billion recorded; total expected approximately $2.4 billion. Position eliminations represent approximately 5 percent of the Medical Devices segment's global workforce. Program expected to be completed by end of fiscal 2018 with certain projects and severance charges continuing beyond that date.
2018-07-01restructuringin_progress2018-04-172022-12-31Global Supply ChainUSD 59 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Actions announced April 17, 2018 to focus resources and increase investments in supply chain capabilities. Q2 2018 pre-tax charge of $59 million ($25M in cost of products sold, $21M in other (income) expense). Expected annual pre-tax cost savings of $0.6-$0.8 billion substantially delivered by 2022; expected pre-tax restructuring charges of $1.9-$2.3 billion over 4-5 years, approximately 70% cash. Subsequent to the quarter, a binding offer was received to form a strategic collaboration with Jabil Inc. for Ethicon Endo-Surgery and DePuy Synthes production.
2018-07-01restructuringin_progress2,60020162018-12-31GlobalMedical DevicesUSD 117 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced in Q1 2016; ~2,600 positions eliminated cumulatively since announcement (1,900 received separation payments), equal to about 5% of the segment's global workforce. $117M pre-tax charge recorded in fiscal Q2 2018 ($19M in cost of products sold, $54M in other (income) expense). Total program estimated at ~$2.4B, with $2.3B recorded to date; expected completion by end of fiscal 2018.
2018-07-01restructuringannounced2018-04-172022GlobalGlobal Supply ChainUSD 59 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Global Supply Chain actions announced 2018-04-17; no employee count disclosed. $59M pre-tax charge in fiscal Q2 2018 ($25M cost of products sold, $21M other (income) expense). Expected pre-tax charges of ~$1.9B-$2.3B over 4-5 years and annual pre-tax savings of ~$0.6B-$0.8B substantially delivered by 2022; ~70% of cumulative costs expected to be cash. Subsequent to the quarter, a binding offer for a strategic manufacturing collaboration with Jabil Inc. was received (North American sites accepted).
2018-07-01divestiture_reductionannounced2018-12-31GlobalMedical Devices — LifeScanother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		During fiscal Q2 2018 the Company accepted Platinum Equity's binding offer to acquire LifeScan for ~$2.1B; no headcount associated with the sale is disclosed. Assets held for sale at 2018-07-01 include ~$0.1B inventory, ~$0.1B PP&E, ~$0.1B intangibles and ~$1.0B goodwill; ~$0.4B of net liabilities retained. Expected close by end of 2018.
2018-07-01divestiture_reductionannounced2019GlobalMedical Devices — Advanced Sterilization Productsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		During fiscal Q2 2018 the Company received Fortive Corporation's binding offer to acquire the ASP business for ~$2.7B; no headcount disclosed. Assets held for sale at 2018-07-01 include ~$0.1B inventory, ~$0.1B PP&E and ~$0.2B goodwill; ~$0.1B of net receivables retained. Expected close in early 2019.
2018-07-01acquisition_additioncompletedUnited StatesPharmaceuticalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of BeneVir Biopharm, Inc. (oncolytic immunotherapies) completed during fiscal Q2 2018; no purchase price or headcount added disclosed in this filing.
2018-07-01reduction_in_forceannounced12018-06-202018-10-01United StatesCorporate — executiveUSD 10 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Individual executive separation; the agreement states the separation qualifies as a reduction in force. Supplemental Severance Pay of $10,000,000 (52 weeks at $192,307.69/week) plus Enhanced Severance Pay of $1,072,500 (52 weeks at $20,625/week) if the agreement is executed and not revoked; Basic Severance otherwise would be $82,500. Pro-rata vesting of 2018 LTI awards permitted.
2018-07-01restructuringin_progress2,6005%2016-03-312018-12-31GlobalMedical DevicesUSD 2,400 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Approximately 2,600 positions eliminated since announcement; 1,900 received separation payments. Total estimated pre-tax charges $2.4 billion.
2018-07-01restructuringin_progress2018-04-172022-12-31GlobalGlobal Supply ChainUSD 2,100 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Expected pre-tax charges of $1.9 billion to $2.3 billion over 4-5 years. Employee count not disclosed.
2018-07-01restructuringin_progressUSD 57,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-07-01restructuringin_progressOther Income Expense Net [Member] / Medical Devices [Member]USD 54,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-07-01restructuringin_progressOther Income Expense Net [Member] / Supply Chain [Member]USD 21,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-07-01restructuringin_progressCost of Sales [Member] / Medical Devices [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-07-01restructuringin_progressCost of Sales [Member] / Supply Chain [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-07-01restructuringin_progress2,600Medical Devices [Member]USD 117,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-07-01restructuringin_progressSupply Chain [Member]USD 59,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-07-01restructuringin_progressAsset Write-off [Member] / Medical Devices [Member]USD 49,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-07-01restructuringin_progressEmployee Severance [Member] / Medical Devices [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-07-01restructuringin_progressOther Restructuring [Member] / Medical Devices [Member]USD 234,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-04-01restructuringin_progress2,5002016-01-012018-12-31Medical DevicesUSD 2,400 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program announced Q1 2016 targeting ~5% of Medical Devices global workforce; ~2,500 positions eliminated to date, of which 1,800 received separation payments; total project costs of $2.1 billion recorded since announcement; Q1 2018 pre-tax charge of $107 million; program expected to be completed by end of fiscal 2018 with certain projects and severance charges continuing beyond that date.
2018-04-01restructuringannounced2018-04-172022-12-31Global Supply ChainUSD 2,100 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Subsequent event: actions across Global Supply Chain to focus resources and increase investments in critical capabilities; expected annual pre-tax cost savings of $0.6-$0.8 billion substantially delivered by 2022; expected pre-tax restructuring charges of approximately $1.9-$2.3 billion over 4-5 years, with ~70% resulting in cash outlays; specific future actions subject to consultation requirements.
2018-04-01restructuringin_progress2,5002016-01-012018-12-31GlobalMedical DevicesUSD 107 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cumulative positions eliminated since program announced in Q1 2016; 1,800 received separation payments. Q1 2018 charge of $107M pre-tax. Program targets ~5% of Medical Devices global workforce; total estimated program charges ~$2.4B.
2018-04-01restructuringannounced2018-04-172022-12-31GlobalGlobal Supply Chainrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Subsequent-event announcement (April 17, 2018). Expected pre-tax restructuring charges of $1.9B–$2.3B over 4–5 years; annual pre-tax cost savings of $0.6B–$0.8B substantially delivered by 2022. No employee count disclosed; ~70% of cumulative pre-tax costs expected to be cash outlays.
2018-04-01divestiture_reductionannounced2018-01-01GlobalMedical Devices — LifeScan (Diabetes Care)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Binding offer from Platinum Equity to acquire LifeScan for ~$2.1B announced during Q1 2018; assets held for sale recorded at April 1, 2018. No headcount associated with the divestiture disclosed.
2018-04-01restructuringin_progress2,5002016-01-012018-12-31GlobalMedical DevicesUSD 107 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Approximately 2,500 positions eliminated in total since announcement; 1,800 received separation payments. Q1 2018 charge of $107M includes $6M in COGS and $59M in other expense. Program expected to complete by end of fiscal 2018.
2018-04-01restructuringannounced2018-04-172022-12-31GlobalGlobal Supply Chainsubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Announced April 17, 2018. Expected pre-tax charges of $1.9B to $2.3B over 4-5 years. Expected annual savings of $0.6B to $0.8B by 2022. Specific employee counts not yet disclosed.
2018-04-01restructuringin_progressOther Income Expense Net [Member] / Medical Devices [Member]USD 59,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-04-01restructuringin_progressCost of Sales [Member] / Medical Devices [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-04-01restructuringin_progressUSD 42,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-04-01restructuringin_progressAsset Write-off [Member] / Medical Devices [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-04-01restructuringin_progressEmployee Severance [Member] / Medical Devices [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-04-01restructuringin_progressOther Restructuring [Member] / Medical Devices [Member]USD 102,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-04-01restructuringin_progress2,500Medical Devices [Member]USD 107,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-12-31restructuringin_progress2,4002016GlobalMedical DevicesUSD 760 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year program announced in Q1 2016 (Medical Devices go-to-market overhaul). Position eliminations are cumulative through fiscal year-end 2017 since program announcement (of which 1,700 received separation payments); filer expects total eliminations of roughly 4-6% of the Medical Devices segment's global workforce over approximately 15 months from the filing date. FY2017 pre-tax charge of $760M ($88M in cost of products sold, $363M in other (income) expense, remainder in restructuring line); cumulative charges of $2.0B recorded against estimated total program charges of $2.0-$2.4B, roughly half cash including ~$400M employee severance. Annualized savings target of $800M-$1.0B, majority by end of 2018; ~$500M realized in 2017.
2017-12-31otherannounced2017Medical Devices — Diabetes Care (Animas insulin pump business)USD 215 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		In fiscal Q4 2017 the Company announced its decision to exit the Animas insulin pump business; Medtronic selected to facilitate transition for patients and providers. Headcount impact not quantified in the filing. The $215M charge is an asset impairment primarily related to the insulin pump business recorded during 2017 in connection with the strategic-options review of the Diabetes Care companies; strategic review of LifeScan, Inc. remained ongoing at year-end.
2017-12-31restructuringin_progress2,4002016WorldwideMedical DevicesUSD 760 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year program announced in Q1 2016; figures are cumulative through fiscal year-end since announcement (approximately 2,400 positions eliminated, of which 1,700 received separation payments). 2017 pre-tax charge of $760M ($88M in cost of products sold, $363M in other (income) expense); total project costs of $2.0B recorded since announcement against an estimated $2.0B-$2.4B program. Program targets position eliminations equal to roughly 4%-6% of the segment's global workforce, with the majority of expected $800M-$1.0B annualized savings realized by end of 2018 (approximately $500M realized in 2017).
2017-12-31acquisition_additioncompleted2017-06-162017-06-16SwitzerlandPharmaceuticalbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Actelion Ltd acquired via all-cash tender offer for $29.6B net of cash acquired; added the Pulmonary Hypertension therapeutic area. No employee headcount disclosed for the acquired workforce.
2017-12-31acquisition_additioncompleted2017-02-272017-02-27United StatesMedical Devicesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Abbott Medical Optics acquired for $4.3B net of cash acquired (ophthalmic products). No employee headcount disclosed for the acquired workforce.
2017-12-31divestiture_reductioncompleted20172017United StatesMedical Devicesdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Codman Neurosurgery divested to Integra LifeSciences; part of approximately $1.3B of 2017 pre-tax divestiture gains. No headcount removed disclosed.
2017-12-31divestiture_reductioncompleted20172017EuropeConsumerdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		COMPEED brand divested to HRA Pharma; MD&A notes a gain of approximately $0.5B in the Consumer segment. No headcount removed disclosed.
2017-12-31otherannounced2017United StatesMedical Devices — Diabetes Care (Animas insulin pump business)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		In Q4 2017 the Company announced its decision to exit the Animas insulin pump business, with patients transitioned to Medtronic; a $0.2B asset impairment charge was recorded in Q2 2017 primarily related to the insulin pump business. Strategic options for LifeScan remained under evaluation at filing. No headcount affected disclosed.
2017-12-31restructuringin_progress2,4002016-03-012018-12-31GlobalMedical DevicesUSD 760 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Announced in Q1 2016. Approximately 2,400 positions eliminated globally in Medical Devices segment. 1,700 received separation payments by year-end. Total pre-tax charges recorded since announcement: $2.0 billion. 2017 charge: $760 million.
2017-12-31acquisition_additioncompleted2017-06-162017-06-16GlobalPharmaceuticalUSD 29,600 (millions)business_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Actelion Ltd. completed June 16, 2017. Purchase price $29.6 billion. Headcount not explicitly disclosed.
2017-12-31acquisition_additioncompleted2017-02-272017-02-27GlobalMedical DevicesUSD 4,300 (millions)business_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Abbott Medical Optics (AMO) completed February 27, 2017. Purchase price $4.3 billion. Headcount not explicitly disclosed.
2017-12-31restructuringin_progress2,4002016-03-012018-12-31GlobalMedical DevicesUSD 760 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Announced Q1 2016. Approximately 4-6% of Medical Devices global workforce. 2,400 positions eliminated total; 1,700 received separation payments through FY2017. Pre-tax charges of $760M recorded in 2017.
2017-12-31restructuringin_progress2,400Medical Devices [Member]USD 284,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressUSD 309,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressOther Income Expense Net [Member] / Medical Devices [Member]USD 363,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressCost of Sales [Member] / Medical Devices [Member]USD 88,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressAsset Write-off [Member] / Medical Devices [Member]USD 194,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressOther Restructuring [Member] / Medical Devices [Member]USD 656,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-10-01restructuringin_progress2,200GlobalMedical DevicesUSD 1,800 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Approximately 2,200 positions eliminated since announcement, of which 1,700 received separation payments. Program targets 4-6% of Medical Devices global workforce over 15 months; cumulative pre-tax charges of $1.8 billion recorded against an estimated total of $2.0-$2.4 billion. Roughly half of cumulative costs are cash (including ~$400 million severance), half non-cash. Fiscal nine months 2017 pre-tax charge of $476 million ($46 million in cost of products sold, $265 million in other (income) expense); fiscal third quarter charge of $187 million ($29 million in cost of products sold, $89 million in other (income) expense). Severance reserve balance of $245 million at October 1, 2017, with a $90 million accrual adjustment in Q2 2017 due to higher-than-anticipated voluntary separations. Expected annualized pre-tax savings of $800 million to $1.0 billion, majority by end of 2018.
2017-10-01otherannounced2017-10Medical Devices — Diabetes Care (Animas insulin pump business)other
f5-10q / GLM-5.3-flash-fp4-HTML		Subsequent to the fiscal third quarter of 2017, the Company announced its decision to exit the Animas insulin pump business; Medtronic plc selected to facilitate patient transition. 2016 annual sales for Animas were approximately $0.2 billion. No headcount disclosed. Related $0.2 billion impairment charge primarily related to the insulin pump business was recorded in fiscal nine months 2017.
2017-10-01divestiture_reductioncompleted2017-10-02Medical Devices — Codman Neurosurgery businesssubsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Divestiture of the Codman Neurosurgery business to Integra LifeSciences Holdings Corporation completed on October 2, 2017 for approximately $1.0 billion. As of October 1, 2017, held-for-sale assets included $63 million of inventory, $33 million of net property, plant and equipment, and $106 million of goodwill. No headcount disclosed.
2017-10-01restructuringin_progress2,200WorldwideMedical DevicesUSD 476 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cumulative positions eliminated since the program announcement (announcement date not stated in this filing); 1,700 of the 2,200 had received separation payments. Program targets position eliminations equal to roughly 4-6% of the Medical Devices segment's global workforce over the next 15 months (no explicit completion date given). Charge shown is the fiscal nine months 2017 pre-tax restructuring charge ($187M recorded in fiscal Q3 2017); total program estimated at $2.0-2.4 billion pre-tax with $1.8 billion recorded since announcement. Severance reserve balance was $245M at 2017-10-01; approximately $400M of cumulative severance expected to be paid in cash.
2017-10-01acquisition_additioncompleted2017-06-16Switzerland / WorldwidePharmaceuticalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Actelion Ltd acquired via all-cash tender offer at $280 per share; $29.1 billion paid net of cash acquired for 98.4% of tendered shares (closed fiscal Q2 2017, within the year-to-date period). No employee headcount disclosed. A $0.5 billion liability remains for untendered shares expected to be paid by end of 2017. Actelion spun out Idorsia Ltd, of which the Company holds 9.9%.
2017-10-01divestiture_reductioncompleted2017-10-02Medical Devices — Codman Neurosurgerysubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Divestiture of the Codman Neurosurgery business to Integra LifeSciences for approximately $1.0 billion, completed 2017-10-02 (one day after quarter end). No headcount disclosed. Held-for-sale amounts at 2017-10-01: $63M inventory, $33M net PP&E, $106M goodwill.
2017-10-01otherannouncedMedical Devices — Diabetes Care (Animas)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Subsequent to fiscal Q3 2017 the Company announced its decision to exit the Animas insulin pump business, selecting Medtronic plc to transition patients; 2016 Animas sales were approximately $0.2 billion. Announcement date not specified in the filing. No headcount disclosed; no assets held for sale at 2017-10-01 related to the announcement. Strategic options for LifeScan, Inc. remain under evaluation.
2017-10-01restructuringin_progress2,200GlobalMedical DevicesUSD 476 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Approximately 2,200 positions eliminated to date; 1,700 received separation payments. Total estimated pre-tax charges $2.0B-$2.4B. YTD charge $476M.
2017-10-01divestiture_reductioncompleted2017-10-02GlobalMedical Devicessubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Divestiture of Codman Neurosurgery business completed Oct 2, 2017. Headcount impact not quantified.
2017-10-01divestiture_reductioncompleted2017-09-30GlobalConsumerbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Divestiture of COMPEED completed in Q3 2017. Headcount impact not quantified.
2017-10-01restructuringin_progressUSD 69,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-10-01restructuringin_progressOther Income Expense Net [Member] / Medical Devices [Member]USD 89,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-10-01restructuringin_progressCost of Sales [Member] / Medical Devices [Member]USD 29,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-10-01restructuringin_progress2,200Medical Devices [Member]USD 187,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-10-01restructuringin_progressAsset Write-off [Member] / Medical Devices [Member]USD 140,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-10-01restructuringin_progressEmployee Severance [Member] / Medical Devices [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-10-01restructuringin_progressOther Restructuring [Member] / Medical Devices [Member]USD 426,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-07-02restructuringin_progress2,100GlobalMedical DevicesUSD 289 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program announced prior to this filing; expected pre-tax charges of $2.0-$2.4 billion, with $1.6 billion recorded to date. Position eliminations of approximately 4-6 percent of the Medical Devices segment global workforce expected over the 18 months following the filing; approximately 2,100 positions eliminated since announcement, of which 1,650 received separation payments. Fiscal six months 2017 pre-tax charge of $289 million ($17 million in cost of products sold, $176 million in other (income) expense); fiscal second quarter charge of $128 million. Includes a $90 million severance accrual adjustment in Q2 2017 due to higher-than-anticipated voluntary separations. Severance reserve balance of $251 million at July 2, 2017.
2017-07-02restructuringin_progress2,1002018-12-31GlobalMedical DevicesUSD 289 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cumulative positions eliminated since program announcement; 1,650 received separation payments. Filing states elimination of roughly 4-6% of the segment's global workforce over the next 18 months. Charge shown is the fiscal six months 2017 pre-tax charge ($128M in Q2 2017); total program estimated at $2.0-2.4B with $1.6B recorded to date. Announcement date not stated in this filing.
2017-07-02acquisition_additioncompleted2017-06-16SwitzerlandPharmaceuticalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Actelion Ltd. acquisition completed June 16, 2017; acquired headcount not disclosed. Actelion's drug discovery operations were spun out to Idorsia Ltd. prior to closing.
2017-07-02acquisition_additioncompleted2017-02-27GlobalMedical Devicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Abbott Medical Optics (AMO) acquisition completed February 27, 2017 for $4.4B net of cash; acquired headcount not disclosed.
2017-07-02divestiture_reductionin_progressGlobalMedical Devicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Binding offer received from Integra LifeSciences to purchase the Codman Neurosurgery business for approximately $1.0B; assets classified as held for sale at quarter end. Headcount affected not disclosed.
2017-07-02otherannounced2017-01-01GlobalDiabetes Care (LifeScan, Animas, Calibra Medical)USD 200 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Strategic options under evaluation for the Diabetes Care companies (partnership, JV, sale or other alternatives); a $0.2B impairment charge, primarily insulin pump business, was recorded in Q2 2017. No headcount reduction quantified. Announcement date reflects fiscal first quarter 2017 (exact date not stated).
2017-07-02restructuringin_progress2,1002017-01-012018-12-31GlobalMedical DevicesUSD 289 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Approximately 2,100 positions eliminated since announcement; 1,650 received separation payments. Total estimated pre-tax charges $2.0B-$2.4B. YTD charge of $289M includes $17M in COGS and $176M in other expense. Completion expected over next 18 months from announcement.
2017-07-02restructuringin_progressUSD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-07-02restructuringin_progressOther Income Expense Net [Member] / Medical Devices [Member]USD 104,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-07-02restructuringin_progressCost of Sales [Member] / Medical Devices [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-07-02restructuringin_progress2,100Medical Devices [Member]USD 128,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-07-02restructuringin_progressAsset Write-off [Member] / Medical Devices [Member]USD 112,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-07-02restructuringin_progressEmployee Severance [Member] / Medical Devices [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-07-02restructuringin_progressOther Restructuring [Member] / Medical Devices [Member]USD 267,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-04-02restructuringin_progressGlobalMedical DevicesUSD 161 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Pre-tax charge of $161 million recorded in fiscal Q1 2017 ($4 million in cost of products sold, $72 million in other (income) expense, remainder in restructuring line). Total expected program charges of approximately $2.0-$2.4 billion pre-tax; $1.4 billion recorded since announcement. Position eliminations of approximately 4 to 6 percent of the Medical Devices segment's global workforce expected over the next 18 months, subject to local consultation procedures. Approximately 1,600 positions eliminated since announcement. Roughly half of cumulative costs expected to be cash, including approximately $500 million of employee severance; other half non-cash (facility rationalization, inventory and intangible write-offs). Severance reserve balance of $355 million at April 2, 2017.
2017-04-02restructuringin_progress1,6002018-12-31GlobalMedical DevicesUSD 161 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cumulative positions eliminated since program announcement; program targets 4-6% of Medical Devices global workforce over 18 months. Q1 2017 charge was $161M; total program estimated at $2.0-2.4B pre-tax with $1.4B recorded to date.
2017-04-02acquisition_additioncompleted2017-02-27GlobalMedical Devicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Abbott Medical Optics (AMO) for $4.4B net of cash acquired; headcount added not disclosed.
2017-04-02acquisition_additioncompleted2017-04-02United StatesMedical Devicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisitions of Torax Medical, Inc. and Megadyne Medical Products, Inc. completed during Q1 2017; headcount added not disclosed.
2017-04-02acquisition_additionannounced2017-01-262017-06-30GlobalPharmaceuticalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Tender offer for Actelion Ltd. at $280/share (~$30.0B); expected to close by end of Q2 2017. Headcount not disclosed.
2017-04-02divestiture_reductionannouncedGlobalMedical Devicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Binding offer received from Integra LifeSciences to purchase Codman Neurosurgery business for ~$1.0B; headcount affected not disclosed.
2017-04-02otherannouncedGlobalMedical Devicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Process announced to evaluate strategic options for Diabetes Care Companies (LifeScan, Animas, Calibra Medical); no assets held for sale as of quarter-end.
2017-04-02acquisition_additioncompleted2017-04-02GlobalMedical Devicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Neuravi Limited completed subsequent to quarter-end; headcount added not disclosed.
2017-04-02restructuringin_progress1,6002016-11-012018-10-01GlobalMedical DevicesUSD 161 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Approximately 1,600 positions eliminated since announcement (4-6% of Med Devices workforce). Q1 2017 charge of $161M includes $4M in COGS and $72M in Other Expense. Total estimated pre-tax charges $2.0B-$2.4B.
2017-04-02acquisition_additioncompleted2017-02-272017-02-27GlobalMedical Devicesbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Abbott Medical Optics (AMO) for $4.4B net of cash. Headcount not explicitly disclosed.
2017-04-02acquisition_additioncompleted2017-04-022017-04-02GlobalMedical Devicesbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Completed acquisition of Torax Medical, Inc. and Megadyne Medical Products, Inc. Headcount not explicitly disclosed.
2017-04-02divestiture_reductionannounced2017-01-26GlobalMedical Devicesbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Received binding offer from Integra LifeSciences to purchase Codman Neurosurgery business for ~$1.0B. Assets held for sale as of April 2, 2017. Headcount not explicitly disclosed.
2017-04-02restructuringin_progressOther Income Expense Net [Member] / Medical Devices [Member]USD 72,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-04-02restructuringin_progressCost of Sales [Member] / Medical Devices [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-04-02restructuringin_progress1,600Medical Devices [Member]USD 161,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-04-02restructuringin_progressUSD 85,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-04-02restructuringin_progressAsset Write-off [Member] / Medical Devices [Member]USD 37,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-04-02restructuringin_progressEmployee Severance [Member] / Medical Devices [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-04-02restructuringin_progressOther Restructuring [Member] / Medical Devices [Member]USD 124,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-01-01restructuringin_progress1,50020152018-12-31GlobalMedical DevicesUSD 685 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year program first announced in fiscal 2015 (Q4 2015 charge $590M). The 1,500 positions eliminated is a cumulative figure since announcement through fiscal 2016; total expected eliminations are approximately 4-6% of the Medical Devices segment's global workforce over roughly two years, subject to local consultation requirements. FY2016 pre-tax charge was $685M ($45M in cost of products sold, $149M in other income/expense, remainder in the restructuring line); cumulative charges $1.275B since announcement against an expected total of $2.0-2.4B, mostly by end of 2017. FY2016 severance cash payments $104M; severance reserve $380M at Jan 1, 2017; total expected severance approximately $500M. Expected annualized pre-tax savings of $800M-$1.0B, majority by end of 2018, with ~$250M realized in 2016.
2017-01-01restructuringin_progress1,5002018-12-31GlobalMedical DevicesUSD 685 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cumulative through fiscal year-end: approximately 1,500 positions eliminated since the program was announced (announcement date not stated in this filing). Program targets position eliminations of about 4-6% of the Medical Devices segment global workforce over two years; a FY2016-specific affected-employee count is not disclosed. FY2016 pre-tax charge of $685M (of a $2.0-2.4B total program estimate, $1.275B recorded to date); reserve balance $381M at year-end. Majority of savings expected by end of 2018.
2017-01-01acquisition_additioncompletedGlobalConsumer; Medical Devicesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2016 acquisitions totaling $4,509M cash: Vogue International LLC, NeuWave Medical Inc., NeoStrata Company Inc., and ex-US rights to RHINOCORT allergy spray. Headcount added not disclosed.
2017-01-01divestiture_reductioncompletedGlobalPharmaceutical; Consumerbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2016 divestitures (approximately $0.6B pre-tax gains): controlled substance raw material and API business, certain anesthetic products in Europe, and certain non-strategic Consumer brands. Headcount removed not disclosed.
2017-01-01acquisition_additioncompleted2017-02-27GlobalMedical Devices (Vision Care)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Abbott Medical Optics Inc. announced during fiscal Q3 2016 for $4.325B cash; transaction closed 2017-02-27, after fiscal year-end. Headcount added not disclosed.
2017-01-01acquisition_additionannounced2017-01-26GlobalPharmaceuticalsubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Subsequent event: all-cash tender offer in Switzerland to acquire Actelion Ltd. at $280 per share, approximately $30.0 billion, with Actelion's discovery operations spun out to R&D NewCo (J&J to hold 16%). Closing subject to demerger, antitrust clearance and customary conditions. Headcount impact not disclosed.
2017-01-01divestiture_reductionannounced2017-01-26GlobalMedical Devices (Diabetes Care — LifeScan, Animas, Calibra Medical)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Subsequent event announced after fiscal year-end: process to evaluate strategic options for the Diabetes Care companies, including partnerships, joint ventures, sale or other alternatives. No assets held for sale at year-end; no assurance a transaction results. Headcount impact not disclosed.
2017-01-01divestiture_reductionannounced2017-02-15GlobalMedical Devices (Codman Neurosurgery)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Subsequent event: binding offer received from Integra LifeSciences to purchase the Codman Neurosurgery business for approximately $1.0 billion. Headcount impact not disclosed.
2017-01-01restructuringin_progress1,5002015-01-012018-12-31GlobalMedical DevicesUSD 685 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Approximately 1,500 positions eliminated since announcement. $685 million pre-tax charge recorded in 2016. Program expected to result in annualized savings of $800 million to $1.0 billion by end of 2018.
2017-01-01restructuringin_progress1,5002016-01-012018-12-31WorldwideMedical DevicesUSD 685 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Approximately 1,500 positions eliminated since announcement. Pre-tax charges of $685 million recorded in 2016. Program expected to result in annualized savings of $800 million to $1.0 billion by end of 2018.
2017-01-01restructuringin_progress1,500Medical Devices [Member]USD 298,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-01-01restructuringin_progressUSD 491,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-01-01restructuringin_progressOther Income Expense Net [Member] / Medical Devices [Member]USD 149,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-01-01restructuringin_progressCost of Sales [Member] / Medical Devices [Member]USD 45,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-01-01restructuringin_progressAsset Write-off [Member] / Medical Devices [Member]USD 249,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-01-01restructuringin_progressEmployee Severance [Member] / Medical Devices [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-01-01restructuringin_progressOther Restructuring [Member] / Medical Devices [Member]USD 436,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-10-02restructuringin_progressGlobalMedical DevicesUSD 2,000 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program expected to eliminate roughly 4 to 6 percent of the Medical Devices segment's global workforce over two years; total pre-tax charges estimated at $2.0-$2.4 billion, roughly half cash (including ~$500 million severance) and half non-cash. Approximately 1,170 positions eliminated since announcement; $977 million of charges recorded to date. Specific announcement date not stated in the filing.
2016-10-02restructuringin_progressGlobalMedical DevicesUSD 109 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Pre-tax charge recorded in the fiscal third quarter of 2016; $3 million in cost of products sold and $44 million in other (income) expense per the footnote, remainder in restructuring line.
2016-10-02restructuringin_progressGlobalMedical DevicesUSD 387 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Pre-tax charge recorded in the fiscal nine months of 2016; $27 million in cost of products sold and $64 million in other (income) expense per the footnote, remainder in restructuring line. Severance reserve balance of $403 million at October 2, 2016, with cash outlays expected over the next 24 months.
2016-10-02restructuringin_progress1,170GlobalMedical DevicesUSD 977 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cumulative positions eliminated since program announcement; program targets elimination of 4-6% of Medical Devices global workforce over two years, total pre-tax charges estimated at $2.0-2.4 billion, with $977 million recorded to date ($109 million in Q3 2016, $387 million in nine months 2016). Announcement date not stated in filing; completion expected over the next two years, with majority of expected $800 million-$1.0 billion annualized savings realized by end of 2018.
2016-10-02restructuringin_progress1,1702016-07-012018-12-31GlobalMedical DevicesUSD 387 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Approximately 1,170 positions eliminated since announcement. Total estimated pre-tax charges $2.0B-$2.4B. $387M charged in fiscal nine months ended Oct 2, 2016. Savings expected by end of 2018.
2016-10-02restructuringin_progressUSD 62,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-10-02restructuringin_progressOther Income Expense Net [Member] / Medical Devices [Member]USD 44,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-10-02restructuringin_progressCost of Sales [Member] / Medical Devices [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-10-02restructuringin_progress1,170Medical Devices [Member]USD 109,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-10-02restructuringin_progressAsset Write-off [Member] / Medical Devices [Member]USD 158,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-10-02restructuringin_progressEmployee Severance [Member] / Medical Devices [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-10-02restructuringin_progressOther Restructuring [Member] / Medical Devices [Member]USD 229,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-07-03restructuringin_progress9002017-12-31Medical DevicesUSD 868 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Approximately 900 positions eliminated since the restructuring was announced; program targets 4-6% of Medical Devices global workforce over two years, with total expected pre-tax charges of $2.0-$2.4 billion, most incurred by 2017. Fiscal six months 2016 charge was $278 million ($141 million in Q2).
2016-07-03restructuringin_progress900GlobalMedical DevicesUSD 278 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		900 is cumulative positions eliminated since program announcement, not a quarterly figure. Program targets 4-6% of Medical Devices global workforce over two years; $278M pre-tax charge recorded in fiscal six months 2016 ($868M cumulative). Announcement date not stated in filing; most charges expected by 2017.
2016-07-03acquisition_additioncompletedGlobalMedical Devicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of NeuWave Medical, Inc. completed in fiscal second quarter 2016; no headcount disclosed.
2016-07-03acquisition_additioncompletedGlobalConsumerbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of NeoStrata Company, Inc. (dermocosmetics) completed in fiscal second quarter 2016; no headcount disclosed.
2016-07-03divestiture_reductioncompletedGlobalPharmaceuticalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Divestiture of controlled substance raw material and API business completed in fiscal second quarter 2016 for $650 million proceeds; no headcount disclosed.
2016-07-03acquisition_additionannouncedUnited StatesConsumerUSD 3,300 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Subsequent to quarter end, acquisition of Vogue International LLC for $3.3 billion in cash; purchase price allocation not yet finalized; no headcount disclosed.
2016-07-03restructuringin_progress900GlobalMedical DevicesUSD 278 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Approximately 900 positions eliminated since announcement; 4-6% of Medical Devices global workforce expected over two years. $278M pre-tax charge recorded in fiscal six months ended July 3, 2016.
2016-07-03restructuringin_progressUSD 114,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-07-03restructuringin_progress900Medical Devices [Member]USD 141,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-07-03restructuringin_progressOther Income Expense Net [Member] / Medical Devices [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-07-03restructuringin_progressCost of Sales [Member] / Medical Devices [Member]USD 24,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-07-03restructuringin_progressAsset Write-off [Member] / Medical Devices [Member]USD 150,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-07-03restructuringin_progressEmployee Severance [Member] / Medical Devices [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-07-03restructuringin_progressOther Restructuring [Member] / Medical Devices [Member]USD 128,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-04-03restructuringin_progress2017-12-31Medical DevicesUSD 2 (billions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program expected to eliminate approximately 4 to 6 percent of the Medical Devices segment's global workforce over the next two years; estimated total pre-tax charges of $2.0 billion to $2.4 billion, most incurred by 2017; approximately half cash (including ~$500 million severance), half non-cash (facility rationalization, inventory and intangible write-offs); expected annualized savings of $800 million to $1.0 billion, majority by end of 2018 including ~$200 million in 2016.
2016-04-03restructuringin_progress400Medical DevicesUSD 137 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Fiscal Q1 2016 pre-tax charge of $137 million ($17 million in cost of products sold); approximately 400 positions eliminated since program announcement; cumulative charges of $727 million recorded to date; severance reserve balance of $467 million at April 3, 2016.
2016-04-03restructuringin_progress400WorldwideMedical DevicesUSD 137 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		400 positions eliminated cumulatively since program announcement (not a Q1-only figure); program targets 4-6% of Medical Devices global workforce over two years; Q1 2016 charge $137M (incl. $17M in COGS); $727M cumulative charges; total program estimated at $2.0B-$2.4B, most by 2017; severance reserve $467M at 2016-04-03, cash outlays expected over next 24 months; announcement date not disclosed in filing
2016-04-03divestiture_reductionin_progress2016-06-30WorldwideControlled substance raw material and active pharmaceutical ingredient (API) businessother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale agreement entered in Q1 2016, expected to close in fiscal Q2 2016; held-for-sale assets disclosed ($236M inventory, $138M PP&E, $10M goodwill) but no headcount impact quantified
2016-04-03acquisition_additioncompletedUnited StatesMedical Devicessubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of NeuWave Medical, Inc. (microwave ablation systems) completed after quarter end; no headcount disclosed. Company also entered a definitive agreement to acquire NeoStrata Company, Inc. (incl. TriStrata) — announced, no headcount disclosed
2016-04-03restructuringin_progress4002018-12-31GlobalMedical DevicesUSD 137 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Approximately 400 positions eliminated since announcement; total program expected to eliminate 4-6% of Medical Devices workforce over two years. Q1 2016 charge of $137 million includes $17 million in cost of products sold. Total estimated pre-tax charges $2.0-$2.4 billion.
2016-04-03restructuringin_progressAsset Write-off [Member] / Medical Devices [Member]USD 99,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-04-03restructuringin_progressEmployee Severance [Member] / Medical Devices [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-04-03restructuringin_progressOther Restructuring [Member] / Medical Devices [Member]USD 38,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-04-03restructuringin_progressUSD 120,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-04-03restructuringin_progressCost of Sales [Member] / Medical Devices [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-04-03restructuringin_progress400Medical Devices [Member]USD 137,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-01-03restructuringin_progress2017-12-31GlobalMedical DevicesUSD 590 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Announced during fiscal 2015; pre-tax charge of $590 million recorded in fiscal Q4 2015 ($484M severance, $86M asset write-offs, $20M other, primarily supply contracts). Position eliminations of approximately 4 to 6 percent of the Medical Devices segment's global workforce expected over the next two years. Total program pre-tax charges estimated at $2.0-$2.4 billion, most incurred by 2017; targeted annualized pre-tax savings of $800 million to $1.0 billion, majority realized by end of 2018. Severance reserve of $484 million at January 3, 2016, with cash outlays expected substantially over 24 months.
2016-01-03divestiture_reductioncompleted2015-10-04Not specifiedMedical Devices — Cardiovascular (Cordis business)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Cordis cardiovascular business sold to Cardinal Health, completed October 4, 2015. Headcount transferred with the business not disclosed. Pre-tax gain of approximately $1.3 billion recorded; Cordis generated about $535 million of net revenues in 2015 prior to divestiture; divestiture reduced Medical Devices segment operational growth by 0.6 percent.
2016-01-03acquisition_additioncompletedNot specifiedPharmaceuticalbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Privately-held biopharmaceutical company developing an anti-thrombin antibody; acquired during fiscal 2015 as part of total 2015 acquisition spend of $954 million (which also included Novira Therapeutics). Employee headcount acquired not disclosed.
2016-01-03acquisition_additioncompletedNot specifiedPharmaceuticalbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Privately-held clinical-stage biopharmaceutical company developing therapies for curative treatment of chronic hepatitis B; acquired during fiscal 2015. Employee headcount acquired not disclosed.
2016-01-03restructuringin_progressWorldwideMedical DevicesUSD 590 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2015 pre-tax charge of $590M ($484M severance, $86M asset write-offs, $20M other), recorded in fiscal Q4 2015; $501M severance/other reserve at year-end. Program totals estimated at $2.0B-$2.4B pre-tax, most by 2017, with position eliminations of about 4%-6% of the Medical Devices global workforce over two years and roughly $200M of savings in 2016. No announcement date or affected-employee count disclosed.
2016-01-03divestiture_reductioncompleted2015-10-04WorldwideMedical Devicesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cordis business divested to Cardinal Health on October 4, 2015; pre-tax gain of about $1.3B recorded in Medical Devices. Cordis annual net revenues were approximately $535M in 2015 and $780M in 2014. Associated headcount not disclosed.
2016-01-03divestiture_reductioncompletedUnited StatesConsumer; Pharmaceuticalbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2015 divestitures of the SPLENDA brand (Consumer, $229M gain) and U.S. license rights to NUCYNTA products (Pharmaceutical, $981M gain). Brand/license transactions; associated headcount not disclosed.
2016-01-03acquisition_additioncompletedWorldwidePharmaceuticalUSD 954 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Certain businesses acquired during 2015 for $954M cash plus $220M liabilities assumed, primarily XO1 Limited and Novira Therapeutics; $839M assigned to in-process R&D. Headcount added through these acquisitions not disclosed.
2016-01-03restructuringin_progress5%2015-10-012017-12-31WorldwideMedical DevicesUSD 2,200 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Company estimates pre-tax restructuring charges of $2.0 billion to $2.4 billion, most incurred by 2017. Position eliminations of approximately 4 to 6 percent of the Medical Devices segment’s global workforce over the next two years. In Q4 2015, recorded pre-tax charge of $590 million.
2016-01-03restructuringin_progress0.05%2015-10-012017-12-31GlobalMedical DevicesUSD 2 (billions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Announced in Q4 2015. Expected to eliminate 4-6% of Medical Devices global workforce over two years. Total estimated pre-tax charges $2.0B-$2.4B. Q4 2015 charge was $590M ($484M severance).
2016-01-03restructuringin_progressCost of Sales [Member] / Medical Devices [Member]USD 81,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-01-03restructuringin_progressContract Termination [Member] / Medical Devices [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-01-03restructuringin_progressEmployee Severance [Member] / Medical Devices [Member]USD 484,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-01-03restructuringin_progressOther Restructuring [Member] / Medical Devices [Member]USD 86,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-01-03restructuringin_progressMedical Devices [Member]USD 590,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-01-03restructuringin_progressUSD 509,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-01-03restructuringin_progressContract Termination [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-01-03restructuringin_progressEmployee Severance [Member]USD 484,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-01-03restructuringin_progressOther Restructuring [Member]USD 86,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-06-28divestiture_reductioncompleted2015-06-30United StatesPharmaceuticalUSD 981 (millions)other
f5-10q / GLM-5.3-flash-fp4-HTML		Divestiture of U.S. license rights to NUCYNTA products completed in fiscal Q2 2015 for approximately $1.05 billion; pre-tax gain of $981 million recognized in Other (income) expense, net. No employee headcount figures disclosed.
2015-06-28divestiture_reductionannounced2015-04-012015-12-31WorldwideMedical Devices (Cordis)other
f5-10q / GLM-5.3-flash-fp4-HTML		Binding offer from Cardinal Health to acquire the Cordis business for approximately $2.0 billion accepted during fiscal Q2 2015; expected to close in second half of 2015. Held-for-sale assets disclosed; no employee headcount figures disclosed.
2015-03-29divestiture_reductionannounced2015-01-012015-12-31WorldwideMedical Devices — Cordis (Cardiovascular Care)USD 2,000 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Binding offer from Cardinal Health to acquire the Cordis business for approximately $2.0 billion; transaction expected to close towards the end of 2015 subject to customary closing conditions and regulatory approvals. Held-for-sale assets disclosed (inventory, PP&E, intangibles, goodwill). No employee headcount figures disclosed.
2015-03-29divestiture_reductioncompleted2015-04-022015-04-02United StatesPharmaceutical — NUCYNTA (tapentadol) product rightsUSD 1,050 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Subsequent to quarter-end, the Company completed the divestiture of its U.S. license rights to NUCYNTA products for approximately $1.05 billion. Assets held for sale relating to the divestiture were immaterial. No employee headcount figures disclosed.
2015-03-29acquisition_additioncompleted2015-01-012015-03-29Pharmaceutical — XO1 Limited (ichorcumab anti-thrombin antibody)USD 233 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		During the fiscal first quarter of 2015, the Company acquired XO1 Limited, a privately-held biopharmaceutical company. Net fair value of acquisitions of $233 million per cash flow statement. No employee headcount figures disclosed.
2014-12-28divestiture_reductioncompleted2014-06-30United States and Europe (seven facilities in the U.S., one in Europe)Medical Devices — Ortho-Clinical Diagnostics business (Diagnostics franchise)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Business sold to The Carlyle Group for approximately $4.0 billion, generating a pre-tax net gain of approximately $1.9 billion. Divestiture included the sale of eight manufacturing facilities. Number of employees transferred is not disclosed.
2014-12-28acquisition_additioncompletedSwitzerlandPharmaceuticalbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Completed during fiscal 2014 as part of $2,129 million of total cash acquisitions. Privately-held biopharmaceutical company developing multispecific protein therapeutics; $225 million of IPR&D assigned. Segment not explicitly stated, inferred from therapeutic focus. No employee headcount disclosed.
2014-12-28acquisition_additioncompletedUnited StatesPharmaceuticalbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Completed during fiscal 2014 as part of $2,129 million of total cash acquisitions. Clinical-stage biopharmaceutical company focused on viral disease therapies (lead compound AL-8176 for RSV); $1,688 million of IPR&D assigned. Segment not explicitly stated, inferred from business focus. No employee headcount disclosed.
2014-12-28divestiture_reductioncompleted2014-06-30GlobalMedical Devices (Diagnostics franchise)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Ortho-Clinical Diagnostics business sold to The Carlyle Group for approximately $4.0 billion; pre-tax net gain of approximately $1.9 billion recorded. No employee count disclosed; some country closings still pending at year-end for local regulatory reasons.
2014-12-28divestiture_reductioncompletedUnited States and select international marketsConsumerbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2014 divestitures of the K-Y brand to Reckitt Benckiser and the BENECOL brand to Raisio; total 2014 divestiture gains of approximately $2.4 billion. No headcount impact disclosed.
2014-12-28acquisition_additioncompletedGlobalPharmaceutical and ConsumerUSD 2,129 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2014 acquisitions of Covagen AG, Alios BioPharma, Inc. and the ORSL beverage brand acquired for $2,129 million cash plus $38 million liabilities assumed. No acquired-employee counts disclosed.
2014-12-28divestiture_reductionannounced2015-01-01United StatesPharmaceuticalUSD 1,050 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement announced in January 2015 to divest U.S. license rights to NUCYNTA products for approximately $1.05 billion; expected to close in fiscal Q2 2015 subject to closing conditions and buyer financing. Announcement month disclosed, day not specified.
2014-09-28divestiture_reductioncompleted2014-06-30WorldwideMedical Devices & Diagnostics (Ortho-Clinical Diagnostics business)USD 1,948 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Divestiture of Ortho-Clinical Diagnostics business to The Carlyle Group for approximately $4.0 billion; pre-tax net gain of approximately $1.9 billion recorded in fiscal third quarter 2014. No employee headcount figures disclosed.
2014-09-28divestiture_reductioncompleted2014-06-30United States and certain other marketsConsumer (K-Y brand, via McNEIL-PPC, Inc.)USD 388 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Divestiture of K-Y brand to Reckitt Benckiser Group PLC; gain of $388 million recognized in Other (income) expense, net in fiscal nine months 2014. No employee headcount figures disclosed.
2014-09-28acquisition_additioncompleted2014-09-28Pharmaceutical (Covagen AG)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Covagen AG, a privately-held biopharmaceutical company, completed during fiscal third quarter 2014. No employee headcount figures disclosed.
2014-09-28acquisition_additionannounced2014-09-302014-12-28Pharmaceutical (Alios BioPharma, Inc.)USD 1,750 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Definitive agreement to acquire Alios BioPharma, a clinical-stage biopharmaceutical company focused on viral disease therapies, for approximately $1.75 billion in cash; expected to close in fiscal fourth quarter 2014. No employee headcount figures disclosed.
2014-09-28divestiture_reductioncompleted2014-06-30GlobalMedical Devices & Diagnostics (Ortho-Clinical Diagnostics business)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Divestiture of Ortho-Clinical Diagnostics to The Carlyle Group for approximately $4.0 billion completed in the fiscal third quarter; no employee counts disclosed. Some country closings still pending local regulatory requirements as of quarter-end.
2014-09-28acquisition_additioncompletedGlobalPharmaceuticalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Covagen AG, a private biopharmaceutical company, completed during the fiscal third quarter; no headcount disclosed.
2014-09-28acquisition_additionannounced2014-09-302014-12-31GlobalPharmaceuticalUSD 1,750 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Subsequent to quarter-end, definitive agreement announced to acquire Alios BioPharma for approximately $1.75 billion in cash; expected to close in fiscal Q4 2014. No headcount disclosed.
2014-09-28divestiture_reductioncompleted2014-09-28WorldwideMedical Devices & Diagnosticsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Completed divestiture of Ortho-Clinical Diagnostics business to The Carlyle Group. Employee count not disclosed.
2014-09-28divestiture_reductioncompleted2014-06-30United States and certain other marketsConsumerbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Completed divestiture of K-Y brand to Reckitt Benckiser Group PLC. Employee count not disclosed.
2014-09-28acquisition_additioncompleted2014-09-28Pharmaceuticalbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Completed acquisition of Covagen AG. Employee count not disclosed.
2014-09-28acquisition_additionannounced2014-09-30PharmaceuticalUSD 2 (billions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Announced definitive agreement to acquire Alios BioPharma, Inc. for approximately $1.75 billion. Employee count not disclosed.
2014-06-29divestiture_reductioncompleted2014-06-30WorldwideMedical Devices and Diagnostics (Ortho-Clinical Diagnostics business)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Divestiture of Ortho-Clinical Diagnostics to The Carlyle Group for approximately $4.0 billion completed June 30, 2014 (day after quarter-end); expected after-tax gain of approximately $1.0 billion in fiscal Q3 2014. No employee headcount figures disclosed.
2014-06-29divestiture_reductioncompleted2014-06-29United States and certain other marketsConsumer (K-Y brand, via McNEIL-PPC, Inc.)USD 332 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Divestiture of K-Y brand to Reckitt Benckiser Group PLC completed during fiscal Q2 2014; gain of $332 million recognized in Other (income) expense, net. No employee headcount figures disclosed.
2014-06-29divestiture_reductioncompleted2014-06-30GlobalMedical Devices & Diagnostics (Ortho-Clinical Diagnostics)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Divestiture of Ortho-Clinical Diagnostics to The Carlyle Group for approximately $4.0 billion, completed June 30, 2014 (day after quarter end); no employee count or workforce impact disclosed. Held-for-sale assets totaled $1.8 billion at quarter end.
2014-06-29divestiture_reductioncompleted2014-06-29United States and certain other marketsConsumer (K-Y brand)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		McNEIL-PPC divested the K-Y brand to Reckitt Benckiser during the fiscal second quarter of 2014, recognizing a $332 million gain; no employee count or workforce impact disclosed.
2014-03-30divestiture_reductionannounced2014-03-312014-06-30WorldwideMedical Devices & Diagnostics — Ortho-Clinical Diagnosticsbusiness_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Binding offer from The Carlyle Group to acquire Ortho-Clinical Diagnostics for approximately $4.0 billion; assets of $1.8 billion classified as held for sale; headcount transfer not quantified. Expected to close mid-year.
2014-03-30divestiture_reductionannounced2014-03-312014-06-30WorldwideConsumer — K-Y brandbusiness_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		McNEIL-PPC, Inc. signed a definitive agreement to sell global rights to the K-Y brand to Reckitt Benckiser Group PLC; headcount impact not quantified. Expected to close mid-year.
2013-12-29divestiture_reductionannounced2014-01GlobalMedical Devices and Diagnostics — Ortho-Clinical Diagnostics (Diagnostics franchise)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Binding offer received from The Carlyle Group to acquire Ortho-Clinical Diagnostics for $4.15 billion (to be reduced ~$0.2 billion at closing for retained working capital). Affected employee count not disclosed. Exploration of strategic alternatives first announced January 2013; closing anticipated mid-2014.
2013-12-29acquisition_additioncompletedUnited States; ChinaPharmaceutical; Consumer; Medical Devices and Diagnosticsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2013 acquisitions (Flexible Stenting Solutions, Shanghai Elsker Mother & Baby, Aragon Pharmaceuticals) for $835 million cash; headcount added not disclosed.
2013-12-29divestiture_reductioncompletedUnited States; Canada; CaribbeanConsumer; Pharmaceuticalbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2013 divestitures included women's sanitary protection products (Energizer), Rolaids (Chattem), DORIBAX rights (Shionogi), and certain consumer/pharmaceutical products; headcount removed not disclosed.
2013-12-29divestiture_reductionannounced2014-012014-06-30United StatesMedical Devices and Diagnostics (Ortho-Clinical Diagnostics)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Binding offer from The Carlyle Group to acquire Ortho-Clinical Diagnostics for $4.15 billion received January 2014, expected to close mid-2014; headcount impact not disclosed. Also referenced in MD&A segment discussion.
2013-12-29restructuringcompleted2011United StatesMedical Devices and DiagnosticsUSD 700 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Cordis Corporation discontinued clinical development program for NEVO Sirolimus-Eluting Coronary Stent and ceased manufacture/marketing of CYPHER and CYPHER SELECT Plus. Pre-tax charge of $0.7 billion recorded in 2011. Program substantially completed.
2013-12-29restructuringin_progressUSD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-06-30acquisition_additionannounced2013-062013-09-30PharmaceuticalUSD 650 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Definitive agreement to acquire Aragon Pharmaceuticals; $650 million upfront cash plus up to $350 million contingent milestone payments; expected to close in fiscal Q3 2013. No headcount figures disclosed.
2013-06-30acquisition_additioncompleted2013-01United StatesMedical Devices & Diagnosticsbusiness_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Completed acquisition of Flexible Stenting Solutions, Inc., developer of peripheral arterial, venous and biliary stents. No headcount figures disclosed.
2013-06-30acquisition_additioncompleted2013-01ChinaConsumerbusiness_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Completed acquisition of Shanghai Elsker Mother & Baby Co., Ltd, a baby care company in China. No headcount figures disclosed.
2013-06-30acquisition_additionannounced2013-09-30United StatesPharmaceuticalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Aragon Pharmaceuticals announced during fiscal Q2 2013; upfront cash payment of $650 million plus up to $350 million contingent on milestones; expected to close in fiscal Q3 2013. No employee headcount disclosed.
2013-03-31acquisition_additioncompletedUnited StatesMedical Devices & DiagnosticsUSD 168 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Flexible Stenting Solutions, Inc., a developer of flexible peripheral arterial, venous and biliary stents; no headcount figures disclosed.
2013-03-31acquisition_additioncompletedChinaConsumerbusiness_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Shanghai Elsker Mother & Baby Co., Ltd, a baby care company in China known for its position in the naturals segment; no headcount figures disclosed.
2013-03-31acquisition_additioncompleted2012-06-14GlobalMedical Devices & Diagnostics (Orthopaedics)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Synthes, Inc. acquisition; purchase price allocation still being finalized during Q1 2013. No employee headcount added disclosed. Integration costs of $258 million recorded in Q1 2013 (recorded in cost of products sold and other (income) expense).
2013-03-31acquisition_additioncompletedUnited StatesMedical Devices & Diagnosticsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Flexible Stenting Solutions, Inc. completed during the fiscal first quarter of 2013; no headcount or consideration disclosed.
2013-03-31acquisition_additioncompletedChinaConsumerbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Shanghai Elsker Mother & Baby Co., Ltd. (baby care) completed during the fiscal first quarter of 2013; no headcount or consideration disclosed.
2012-12-30acquisition_additioncompleted2012-06-14Medical Devices and Diagnostics (Synthes, Inc. — orthopaedics devices)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Synthes, Inc. acquisition completed June 14, 2012 for total consideration of $20.2 billion in cash and stock; employee headcount added through the acquisition is not disclosed. Synthes contributed sales of $2,159 million from acquisition date through fiscal year-end. (Note: the Cordis/CYPHER restructuring program referenced in Note 22 was a 2011 program — $676 million pre-tax charge recorded in fiscal 2011, no restructuring charge in 2012 — and is excluded as prior-year activity.)
2012-12-30acquisition_additioncompleted2012-06-142012-06-14GlobalMedical Devices and DiagnosticsUSD 1,028 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Synthes Inc. acquisition completed June 14, 2012 for $20.2B purchase price. Acquisition-related costs of $1,028M recorded in 2012. No employee headcount added disclosed.
2012-12-30divestiture_reductioncompleted2012-12-30GlobalMedical Devices and Diagnosticsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		DePuy Orthopaedics trauma business divested to Biomet Inc.; transaction closed worldwide as of Dec 30, 2012. No headcount disclosed.
2012-12-30divestiture_reductioncompleted2012-12-30GlobalMedical Devices and Diagnosticsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Therakos business divested to affiliate of Gores Capital Partners III. No headcount disclosed.
2012-12-30divestiture_reductioncompleted2012-12-30GlobalPharmaceuticalbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		BYSTOLIC (nebivolol) IP rights divested to Forest Laboratories. No headcount disclosed.
2012-12-30divestiture_reductioncompleted2012-12-30GlobalMedical Devices and Diagnosticsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		RhoGAM business divested during Q3 2012. No headcount disclosed.
2012-12-30plant_closurein_progressUnited StatesConsumerItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Fort Washington, PA manufacturing site not in operation; McNeil re-siting products to other facilities. Las Piedras, PR and Lancaster, PA facilities operating under FDA consent decree with production volume impacts expected through most of 2013. No headcount disclosed.
2012-12-30restructuringcompleted2011-01-012011-12-31United StatesMedical Devices and DiagnosticsUSD 676 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Cordis Corporation discontinued clinical development program for NEVO Sirolimus-Eluting Coronary Stent and ceased manufacture/marketing of CYPHER products by end of 2011. Charge recorded in 2011. Program substantially completed.
2012-12-30acquisition_additioncompleted2012-06-142012-06-14GlobalMedical Devices and Diagnosticsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Synthes, Inc. completed June 14, 2012. Specific headcount added not disclosed in filing.
2012-12-30restructuringcompleted20112011-12-31WorldwideMedical Devices and DiagnosticsUSD 676 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Discontinuation of NEVO Sirolimus-Eluting Coronary Stent program and cessation of manufacture/marketing of CYPHER stents. Program substantially completed. Charge includes asset write-offs and leasehold/contract obligations. Employee count not disclosed.
2012-12-30acquisition_additioncompleted2012-06-142012-06-14WorldwideMedical Devices and Diagnosticsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Synthes, Inc. completed June 14, 2012. Employee count added not explicitly disclosed in filing.
2012-12-30restructuringin_progressUSD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-09-30acquisition_additioncompleted2012-06-14Medical Devices & DiagnosticsUSD 20,237 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Synthes, Inc. acquired June 14, 2012 for $20.2 billion in cash and stock; headcount added not disclosed. Integration costs of $388 million recorded in the fiscal nine months of 2012.
2012-09-30divestiture_reductioncompletedMedical Devices & Diagnostics — DePuy trauma businessbusiness_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		DePuy Orthopaedics divested certain rights and assets of its trauma business to Biomet, Inc.; initial closing in fiscal Q2 2012, with closings in countries representing nearly all sales completed by end of fiscal Q3 2012. Headcount impact not disclosed.
2012-09-30divestiture_reductioncompletedMedical Devices & Diagnostics — RhoGAM businessbusiness_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Initial closing of the RhoGAM business divestiture completed during fiscal Q3 2012. Headcount impact not disclosed.
2012-09-30divestiture_reductioncompletedUnited States and CanadaConsumerbusiness_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Sale of certain consumer brands to Valeant Pharmaceuticals completed during fiscal Q3 2012. Headcount impact not disclosed.
2012-09-30divestiture_reductionannounced2012-10-112012-12-31Ortho-Clinical Diagnostics — Therakos businessbusiness_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Binding offer from The Gores Group to acquire the Therakos business; expected to close at end of 2012. Headcount impact not disclosed.
2012-09-30restructuringin_progressUSD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-07-01acquisition_additioncompleted2012-06-14GlobalMedical Devices & DiagnosticsUSD 20,237 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Synthes, Inc. completed June 14, 2012 for $20.2 billion in cash and stock; no employee headcount figures disclosed in the filing.
2012-07-01divestiture_reductionin_progressGlobalMedical Devices & Diagnostics (DePuy trauma business)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		DePuy Orthopaedics agreed to divest certain trauma business rights and assets to Biomet, Inc.; initial closing completed in fiscal Q2 2012 covering countries representing the majority of sales. No headcount figures disclosed.
2012-07-01acquisition_additioncompleted2012-06-142012-06-14GlobalMedical Devices & Diagnostics (Orthopaedics)USD 457 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Synthes, Inc. acquired for $20.2B purchase price; no employee headcount added disclosed. $457M pre-tax acquisition-related costs recorded in other income and expense in 2012; integration costs of $192M (Q2) and $223M (YTD) in the segment.
2012-07-01divestiture_reductioncompleted2012-06-302012-06-30GlobalMedical Devices & Diagnostics (DePuy trauma business)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		DePuy agreed to divest certain trauma business rights and assets to Biomet, Inc. as a condition of the Synthes acquisition; initial closing completed in Q2 2012 covering countries representing the majority of sales. No headcount reduction disclosed. Announcement date not stated; completion date approximated to quarter end.
2012-07-01restructuringin_progressUSD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-04-01acquisition_additionannounced2011-04-262012-06-30GlobalMedical Devices & Diagnosticsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Synthes, Inc. for approximately $21.3 billion ($19.3 billion net of cash); expected to close in fiscal Q2 2012. No headcount added disclosed. Related: $31 million of acquisition costs recorded in Medical Devices & Diagnostics operating profit this quarter, and a $148 million currency adjustment in unallocated expense.
2012-04-01divestiture_reductionannounced2012-01-012012-06-30United StatesMedical Devices & Diagnostics (DePuy Orthopaedics trauma business)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to divest DePuy Orthopaedics' trauma business to Biomet, Inc.; subject to regulatory approvals, expected to close fiscal Q2 2012. Intended to address regulatory concerns tied to the pending Synthes acquisition. No headcount reduction disclosed; announcement date not stated in filing (fiscal Q2 2012 per filing narrative).
2012-01-01restructuringcompleted20112011-12-31Medical Devices and Diagnostics — Cordis Corporation (Cardiovascular Care)USD 676 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Filer discontinued the NEVO stent clinical development program and ceased CYPHER/CYPHER SELECT Plus manufacture and marketing by end of 2011. Pre-tax charge of $676 million recorded in fiscal Q2 2011: $512 million asset write-offs (property, plant and equipment $265 million, intangibles $160 million, inventory $87 million — the inventory portion recorded in cost of products sold) and $164 million for leasehold/contract obligations and other expenses. Program described as substantially completed; no employee headcount affected was disclosed.
2012-01-01restructuringcompleted2011-04-302011-12-31GlobalMedical Devices and Diagnostics (Cordis Corporation — Cardiovascular Care)USD 676 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Fiscal Q2 2011 announcement (exact date not disclosed) to discontinue the NEVO stent program and cease manufacture/marketing of CYPHER stents by end of 2011; charge comprises $512M asset write-offs and $164M leasehold/contract obligations, of which ~$164M requires cash payments. Program described as substantially completed; no employee count disclosed.
2012-01-01plant_closurein_progress2010-04United States (Fort Washington, Pennsylvania)Consumer (McNeil Consumer Healthcare)Item_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Fort Washington facility voluntarily shut down April 2010 and remains closed pending rebuild and FDA concurrence with third-party certification; FDA consent decree entered 2011-03-16 covering this and two other McNeil sites. No employee count or charge attributed to the closure disclosed.
2012-01-01divestiture_reductioncompletedGlobalPharmaceutical and Medical Devices and Diagnostics (Animal Health, MONISTAT, Ortho Dermatologics, Codman surgical instruments)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multiple 2011 divestitures with $1.0 billion of aggregate gains; headcount removed through these dispositions not disclosed.
2012-01-01acquisition_additionannounced2011-04-302012-06-30GlobalMedical Devices and Diagnostics (Orthopaedics)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Synthes, Inc. for ~$21.3 billion announced in fiscal Q2 2011; Synthes shareholders approved 2011-12-15, closing expected in first half of 2012. Headcount to be added not disclosed.
2012-01-01restructuringcompleted2011-04-012011-12-31GlobalMedical Devices and DiagnosticsUSD 676 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Cordis Corporation announced discontinuation of NEVO Sirolimus-Eluting Coronary Stent program and cessation of Cypher stents. Charge includes $512M asset write-offs and $164M leasehold/contract obligations. Program substantially completed.
2012-01-01restructuringcompleted2009-10-012011-12-31GlobalAll Segmentsrestructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Global restructuring initiatives announced in 2009 to generate $1.5B annual cost savings. Program substantially completed in 2011.
2012-01-01restructuringcompleted2011-04-022011-12-31GlobalMedical Devices and DiagnosticsUSD 676 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Cordis Corporation discontinued clinical development of NEVO Sirolimus-Eluting Coronary Stent and ceased manufacture/marketing of CYPHER stents. Charge includes asset write-offs and leasehold/contract obligations. Program substantially completed.
2012-01-01restructuringcompleted2009-10-012011-12-31GlobalAll Segmentsrestructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Global restructuring initiatives announced in 2009 expected to generate $1.5 billion in annual cost savings. Accrual recorded in 2009 was substantially completed in 2011.
2012-01-01restructuringin_progressUSD 569,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-01-01restructuringin_progressCordis Restructuring [Member]USD 676,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-01-01restructuringin_progressMedical Devices and Diagnostics [Member]USD 676,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-10-02restructuringin_progress7,5002009-11-01USD 345 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2009 restructuring plan targeting 7,500 position eliminations; approximately 5,800 positions eliminated as of October 2, 2011. Severance reserve of $345 million at January 2, 2011 reduced to $258 million at October 2, 2011 after $87 million of cash outlays during the nine months.
2011-10-02restructuringcompleted2011-04-012011-12-31Medical Devices & Diagnostics — Cardiovascular Care (Cordis Corporation)USD 676 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Cordis discontinued the NEVO stent clinical development program and will cease manufacture and marketing of CYPHER stents by end of 2011. Pre-tax charge of $676 million recorded in fiscal Q2 2011, comprising $512 million asset write-offs (property, plant and equipment $265 million, intangibles $160 million, inventory $87 million) and $164 million leasehold/contract obligations and other expenses; approximately $164 million requires cash payments. Program substantially completed as of October 2, 2011. No employee count disclosed.
2011-10-02restructuringin_progress7,5002009GlobalCompany-widerestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2009 restructuring plan targeted elimination of 7,500 positions; approximately 5,800 eliminated as of 2011-10-02. Severance reserve declined from $345M (2011-01-02) to $258M (2011-10-02) after $87M cash outlays; remaining severance cash outlays to be paid per Company plans and local laws.
2011-10-02restructuringin_progress20112011-12-31GlobalMedical Devices & Diagnostics — Cardiovascular Care (Cordis)USD 676 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cordis discontinued NEVO stent clinical program and will cease manufacture and marketing of CYPHER and CYPHER SELECT Plus stents by end of 2011. $676M pre-tax charge ($512M asset write-offs, $164M leasehold/contract obligations and other); ~$164M requires cash payments. Program substantially completed as of 2011-10-02. No employee count disclosed.
2011-10-02acquisition_additionannounced20112012-06-30GlobalMedical Devices & Diagnostics — Orthopaedicsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Synthes, Inc. for approximately $21.3 billion (~$19.3B net of cash); ~35% cash / ~65% J&J stock. Expected to close in first half of 2012. No headcount disclosed.
2011-10-02acquisition_additioncompleted2011-11-04United StatesMedical Devices & Diagnosticsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Subsequent event: closing of acquisition of SterilMed, Inc., a medical device reprocessing and remanufacturing company, announced 2011-11-04. No headcount disclosed.
2011-10-02divestiture_reductioncompleted2011-10-02GlobalAnimal Health businessother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Divestiture of Animal Health business to Elanco (Eli Lilly) completed during fiscal Q3 2011; part of $578M total divestiture proceeds (with MONISTAT), gains recorded in Other (income)/expense, net. No headcount disclosed.
2011-10-02divestiture_reductioncompleted2011-10-02United StatesConsumer — MONISTATother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Divestiture of MONISTAT in Canada, the U.S. and its territories (including Puerto Rico) completed during fiscal Q3 2011. No headcount disclosed.
2011-10-02restructuringin_progress7,5002009-10-02WorldwideCordis Corporation / Cardiovascular CareUSD 676 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan announced in Q4 2009. 5,800 positions eliminated as of Oct 2, 2011. Includes asset write-offs and leasehold obligations.
2011-10-02restructuringin_progressUSD 589,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-10-02restructuringin_progressMedical Devices and Diagnostics [Member]USD 676,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-07-03restructuringin_progress7,5002009-10-01Company-wideUSD 345 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2009 restructuring plan targeted 7,500 position eliminations; approximately 5,700 positions eliminated as of July 3, 2011. Severance reserve declined from $345 million at January 2, 2011 to $268 million at July 3, 2011 after $77 million of cash outlays.
2011-07-03restructuringin_progress2011-04-042011-12-31Medical Devices & Diagnostics — Cordis Corporation (Cardiovascular Care)USD 676 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Cordis discontinued the NEVO stent clinical development program and will cease manufacture and marketing of CYPHER and CYPHER SELECT Plus stents by end of 2011. Pre-tax charge of $676 million: $512 million asset write-offs (PP&E $265M, intangibles $160M, inventory $87M) and $164 million leasehold/contract obligations and other expenses; approximately $164 million requires cash payments. No employee count disclosed.
2011-07-03divestiture_reductioncompleted2011-07-07Animal Health businesssubsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Company completed divestiture of its Animal Health business to Elanco, a Division of Eli Lilly, on July 7, 2011. No headcount impact disclosed.
2011-07-03divestiture_reductionannounced2011-07-15United StatesOrtho Dermatologics divisionsubsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Definitive agreement announced July 15, 2011 to divest assets of the Ortho Dermatologics division in the U.S. to subsidiaries of Valeant Pharmaceuticals International, Inc. No headcount impact disclosed.
2011-07-03restructuringin_progress2011-04-042011-12-31GlobalCardiovascular Care (Cordis Corporation)USD 676 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cordis discontinued NEVO stent clinical program and will cease CYPHER stent manufacture/marketing by end of 2011. Charge includes $512M asset write-offs and $164M leasehold/contract obligations; ~$164M requires cash payments. No employee count disclosed.
2011-07-03restructuringin_progress5,7002009-10-01GlobalEnterprise-widerestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2009 restructuring plan: 7,500 positions planned for elimination; approximately 5,700 eliminated as of 2011-07-03. Severance reserve balance $268M at quarter-end after $77M cash outlays in H1 2011.
2011-07-03acquisition_additionannounced2011-04-01GlobalMedical Devices & Diagnostics (Orthopaedics)USD 21,300 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Synthes, Inc. for ~$21.3B (~$19.3B net of cash). Consideration ~35% cash / 65% J&J stock. No headcount disclosed.
2011-07-03divestiture_reductionannounced2011-07-072011-07-07GlobalAnimal Healthsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Divestiture of Animal Health business to Elanco (Eli Lilly division) completed 2011-07-07. No headcount disclosed.
2011-07-03divestiture_reductionannounced2011-07-15United StatesOrtho Dermatologicssubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement announced 2011-07-15 to divest Ortho Dermatologics U.S. assets to Valeant Pharmaceuticals. No headcount disclosed.
2011-07-03acquisition_additioncompleted2011-07-142011-07-14RussiaConsumersubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of OTC cough and cold brands in Russia from J.B. Chemicals completed 2011-07-14. No headcount disclosed.
2011-07-03restructuringin_progress2009-10-01Cordis CorporationUSD 676 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Restructuring plan announced in Q4 2009. Q2 2011 charges include $512M asset write-offs and $164M leasehold/contract obligations. Employee count not disclosed.
2011-07-03acquisition_additioncompleted2011-03-31PharmaceuticalUSD 2,000 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired remaining equity of Crucell N.V. in Q1 2011 for net purchase price of $2.0 billion. Employee count not disclosed.
2011-07-03acquisition_additionannounced2011-07-03Medical Devices & DiagnosticsUSD 21,300 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Entered into definitive agreement to acquire Synthes, Inc. for approx $21.3 billion. Employee count not disclosed.
2011-07-03restructuringin_progressUSD 589,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-07-03restructuringin_progressMedical Devices and Diagnostics [Member]USD 676,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-07-03restructuringin_progressCordis Restructuring [Member]USD 676,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-07-03restructuringin_progress7,500Restructuring Plan of 2009 [Member]restructuring_footnote
f5-10q / no-ai-xblr		Expected positions to be eliminated
2011-04-03restructuringin_progress7,5002009-10-01GlobalUSD 1,200 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program announced in fiscal Q4 2009 with $1.2 billion pre-tax charges (severance $748M, asset write-offs $362M, leasehold/contract obligations $76M); approximately 5,500 of the planned 7,500 position eliminations completed as of fiscal Q1 2011. Severance reserve declined from $345M at January 2, 2011 to $304M at April 3, 2011 after $41M of cash outlays.
2011-04-03restructuringin_progress7,5002009-10-01GlobalCompany-wideUSD 1,200 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced Q4 2009 to eliminate ~7,500 positions; ~5,500 eliminated as of Q1 2011. Severance reserve fell from $345M to $304M during the quarter with $41M cash outlays. Total program charge of $1.2B recorded in Q4 2009.
2011-04-03acquisition_additioncompletedGlobalPharmaceuticalUSD 2,049 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of substantially all outstanding equity of Crucell N.V. (vaccines/antibodies) during Q1 2011; net purchase price $2.0B. No headcount added disclosed.
2011-04-03acquisition_additionannounced2011-04-27GlobalMedical Devices & DiagnosticsUSD 21,300 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Synthes, Inc. (orthopaedics) for ~$21.3B (~$19.3B net of cash). No headcount added disclosed.
2011-04-03restructuringin_progress2009-10-01GlobalGlobalrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Company announced global restructuring initiatives in Q4 2009. Q1 2011 filing references the program but does not disclose specific employee counts affected or current quarter charges.
2011-01-02restructuringin_progress5,00020092011GlobalAll segments — Consumer, Pharmaceutical, Medical Devices and DiagnosticsUSD 1,200 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year program announced fiscal Q4 2009 targeting approximately 7,500 position eliminations; cumulative through fiscal year-end 2010 approximately 5,000 positions eliminated. $1.2 billion pre-tax charge (severance $748 million, asset write-offs $362 million, leasehold/contract obligations $76 million) was recorded in fiscal Q4 2009. 2010 activity: $341 million of severance cash outlays, leaving a $345 million severance reserve at January 2, 2011. Program expected to deliver approximately $1.5 billion of annual pre-tax savings when fully implemented in 2011.
2011-01-02restructuringin_progress5,00020092011WorldwideCompany-widerestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cumulative through fiscal year-end: positions eliminated since the program was announced in fiscal Q4 2009; plan targets roughly 7,500 eliminations. The $1.2 billion pre-tax charge (including $748 million severance) was recorded in fiscal 2009, not fiscal 2010. Fiscal 2010 activity: $341 million severance cash outlays, leaving a $345 million reserve at 2011-01-02; program expected to deliver about $1.5 billion annual pre-tax savings when fully implemented in 2011.
2011-01-02otherin_progress2010United States (Fort Washington, Pennsylvania)Consumer — McNeil Consumer Healthcareother
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Production suspended at the Fort Washington facility in fiscal Q2 2010 following OTC recalls; no workforce impact quantified. Alternate supplies planned for the latter half of 2011; Comprehensive Action Plan submitted to FDA on 2010-07-15.
2011-01-02acquisition_additioncompletedUnited StatesMedical Devices and Diagnostics; PharmaceuticalUSD 1,269 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Fiscal 2010 acquisitions of Acclarent, Inc., RespiVert Ltd. and Micrus Endovascular Corporation for $1,269 million cash plus $52 million liabilities assumed; acquired headcount not disclosed.
2011-01-02divestiture_reductioncompletedUnited StatesMedical Devices and Diagnostics — Ethicon Endo-Surgery (Breast Care)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Breast Care business divested in fiscal Q3 2010 with a related gain recorded in other (income) expense; headcount removed through the divestiture not disclosed.
2011-01-02acquisition_additioncompleted20102011-02-22WorldwidePharmaceutical — vaccinesUSD 2,300 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cash tender offer for the roughly 82% of Crucell N.V. not already owned, valued at about $2.3 billion; J&J held about 18% of Crucell at 2011-01-02. Tender offer declared unconditional on 2011-02-22, after fiscal year-end. Headcount not disclosed.
2011-01-02restructuringin_progress7,5002009-10-012011-12-31WorldwideAll SegmentsUSD 1,200 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Global restructuring initiatives announced in Q4 2009. Plans to eliminate approximately 7,500 positions; approximately 5,000 eliminated since announcement. Pre-tax charge of $1.2 billion recorded in 2009, including $748 million severance, $362 million asset write-offs, and $76 million lease/contract obligations. Expected to generate pre-tax annual cost savings of $1.5 billion when fully implemented in 2011.
2011-01-02restructuringcompleted7,5002009-10-012011-12-31GlobalAll segmentsUSD 1,200 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Announced in Q4 2009. Plans to eliminate approximately 7,500 positions. Approximately 5,000 eliminated since announcement. Pre-tax charge of $1.2 billion recorded in 2009.
2010-10-03restructuringin_progress7,5002009-10GlobalCompany-wideUSD 1,200 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program announced Q4 2009; $1.2B pre-tax charge recorded then, including $748M severance, $362M asset write-offs and $76M leasehold/contract obligations. Approximately 4,300 of the planned 7,500 position eliminations completed through fiscal Q3 2010. Severance reserve declined from $686M at January 3, 2010 to $433M at October 3, 2010 after $253M of cash outlays.
2010-10-03plant_closurein_progress2010-04Fort Washington, Pennsylvania, United StatesConsumer — McNeil Consumer Healthcare (OTC Pharmaceuticals and Nutritionals)MD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Production suspended at the Fort Washington facility following voluntary recalls of certain OTC products; estimated impact to 2010 annual sales of approximately $600 million. Alternate supply projected to begin in Q1 2011. No headcount figure disclosed.
2010-10-03restructuringin_progress7,5002009GlobalCompany-wideUSD 1,200 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced in fiscal Q4 2009 targets elimination of approximately 7,500 positions; approximately 4,300 had been eliminated as of 2010-10-03. Charge of $1.2 billion pre-tax recorded in fiscal Q4 2009 (severance $748M, asset write-offs $362M, leasehold/contract obligations $76M), of which about $830M requires cash payments. Severance reserve fell from $686M at 2010-01-03 to $433M at 2010-10-03 after $253M of cash outlays; remaining severance cash outlays expected over the following 12 to 15 months.
2010-10-03acquisition_additioncompletedMedical Devices & Diagnostics (neurovascular)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Micrus Endovascular Corporation completed during fiscal Q3 2010 for a net purchase price of approximately $0.4 billion; headcount added not disclosed.
2010-10-03divestiture_reductioncompletedConsumer / Ethicon Endo-Surgery — Breast Care businessbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Divestiture of the Breast Care business of Ethicon Endo-Surgery, Inc. to Devicor Medical Products, Inc. completed during fiscal Q3 2010; headcount removed not disclosed.
2010-10-03acquisition_additionannounced2010-10-06GlobalPharmaceutical (vaccines and antibodies)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement announced 2010-10-06 to acquire the remaining 81.6% of Crucell N.V. not already owned via a cash tender offer of approximately EUR 1.75 billion; headcount added not disclosed.
2010-10-03restructuringin_progress4,3002009-10-01GlobalGlobalUSD 748 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program announced in Q4 2009. Total plan to eliminate approx. 7,500 positions. 4,300 eliminated as of Oct 3, 2010. Severance reserve balance $433M.
2010-10-03acquisition_additioncompleted2010-07-01GlobalMedical Devices & DiagnosticsUSD 400 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Micrus Endovascular Corporation in Q3 2010 for net purchase price of approx. $0.4 billion. Headcount not disclosed.
2010-10-03acquisition_additioncompleted2010-04-01GlobalPharmaceuticalbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired RespiVert Ltd. in Q2 2010. Headcount and purchase price not disclosed.
2010-10-03acquisition_additioncompleted2010-01-01GlobalMedical Devices & DiagnosticsUSD 800 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Acclarent, Inc. in Q1 2010 for net purchase price of $0.8 billion. Headcount not disclosed.
2010-10-03divestiture_reductioncompleted2010-07-01GlobalMedical Devices & Diagnosticsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Completed divestiture of Breast Care business of Ethicon Endo-Surgery, Inc. to Devicor Medical Products, Inc. in Q3 2010. Headcount not disclosed.
2010-07-04restructuringin_progress7,5002009-10-01GlobalUSD 1,200 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program announced in fiscal Q4 2009; $1.2B pre-tax charge comprising $748M severance, $362M asset write-offs and $76M leasehold/contract obligations. Approximately 3,400 of the planned 7,500 position eliminations completed through fiscal Q2 2010.
2010-07-04restructuringin_progress3,4002009-10-01Globalrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Positions eliminated since the restructuring was announced; part of the 7,500-position program. Severance reserve of $510M remained at July 4, 2010 after $176M of cash outlays in the first six months.
2010-07-04acquisition_additioncompleted2010-01-04United StatesMedical Devices & DiagnosticsUSD 800 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Acclarent, Inc., an ear, nose and throat medical technology company, for a net purchase price of $0.8 billion; headcount added not disclosed.
2010-07-04acquisition_additioncompleted2010-04-05Pharmaceuticalbusiness_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of RespiVert Ltd., a privately held inhaled pulmonary drug discovery company; purchase price and headcount not disclosed.
2010-07-04divestiture_reductioncompleted2010-07-122010-07-12Medical Devices & Diagnostics - Ethicon Endo-Surgerysubsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Ethicon Endo-Surgery completed divestiture of its Breast Care business to Devicor Medical Products, Inc.; headcount transferred not disclosed.
2010-07-04acquisition_additionannounced2010-07-12Medical Devices & DiagnosticsUSD 500 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Definitive agreement to acquire Micrus Endovascular Corporation, maker of minimally invasive stroke devices, for approximately $0.5 billion net; headcount not disclosed.
2010-07-04restructuringin_progress3,4002009GlobalCompany-wideUSD 1,200 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Global restructuring announced in fiscal Q4 2009; program targets elimination of approximately 7,500 positions, of which approximately 3,400 had been eliminated as of this filing. The $1.2 billion pre-tax charge (severance $748M, asset write-offs $362M, leasehold/contract $76M) was recorded in fiscal Q4 2009, not the current period; approximately $830 million requires cash payments. Severance reserve was $510 million at 2010-07-04 (down from $686 million at 2010-01-03 after $176 million of cash outlays), with outlays expected over the next 12 to 18 months. Announcement date disclosed only as fiscal fourth quarter of 2009; no exact date or completion date given.
2010-07-04restructuringin_progress7,5002009-10-01GlobalAll segmentsUSD 748 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program announced in Q4 2009. Plans to eliminate approx. 7,500 positions; approx. 3,400 eliminated through Q2 2010. Total pre-tax charges were $1.2 billion, including $748 million in severance.
2010-04-04restructuringin_progress7,5002009-10GlobalCompany-wideUSD 1,200 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program announced in fiscal Q4 2009 with $1.2 billion pre-tax charges (severance $748M, asset write-offs $362M, leasehold/contract obligations $76M); approximately 3,000 of the planned 7,500 position eliminations completed since announcement.
2010-04-04restructuringin_progress3,0002009-10GlobalCompany-widerestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Positions eliminated to date under the 2009 global restructuring initiative; severance reserve declined from $686 million at January 3, 2010 to $597 million at April 4, 2010 after $89 million of cash outlays.
2010-04-04restructuringin_progress7,5002009GlobalCompany-wideUSD 748 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced in Q4 2009 targets elimination of about 7,500 positions; roughly 3,000 already eliminated as of this filing. Total pre-tax charge of $1.2B (severance $748M, asset write-offs $362M, leasehold/contract $76M) was recorded in fiscal Q4 2009, not this quarter. Severance reserve was $686M at 2010-01-03, reduced by $89M of cash outlays to $597M at 2010-04-04; remaining severance cash outlays expected over the next 12 to 18 months.
2010-04-04acquisition_additioncompletedUnited StatesMedical Devices & Diagnostics (ear, nose and throat devices)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Acclarent, Inc. completed in fiscal Q1 2010 for a net purchase price of $0.8 billion, allocated primarily to $0.7 billion of amortizable intangible assets. No headcount associated with the acquisition is disclosed.
2010-04-04restructuringin_progress3,0002009-10-01GlobalGlobalUSD 748 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Approximately 3,000 of 7,500 planned positions eliminated since announcement in Q4 2009. Total program includes $1.2B pre-tax charges ($748M severance).
2010-01-03restructuringin_progress7,50020092011GlobalUSD 1,186 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Global program announced in fiscal Q4 2009; ~7,500 positions to be eliminated, of which ~700 eliminated by report date. Charge of $1,186M ($1.2B per Note 22 text; $113M recorded in cost of products sold) comprises $748M severance, $362M asset write-offs, $76M leasehold/contract obligations. Segment charge split: Consumer $369M, Pharmaceutical $496M, Medical Devices and Diagnostics $321M. Savings of $1.4–$1.7B expected when fully implemented in 2011.
2010-01-03restructuringin_progress7,5002011-12-31WorldwideConsumer; Pharmaceutical; Medical Devices and DiagnosticsUSD 1,186 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Announced in fiscal fourth quarter of 2009 (exact date not disclosed); program plans to eliminate about 7,500 positions, of which about 700 had been eliminated as of filing. Charge of $1,186M pre-tax (severance $748M, asset write-offs $362M, other $76M); segment charges were $369M Consumer, $496M Pharmaceutical, $321M Medical Devices and Diagnostics. Savings of $1.4-$1.7B expected when fully implemented in 2011.
2010-01-03acquisition_additioncompletedWorldwideConsumer; Pharmaceutical; Medical Devices and Diagnosticsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2009 acquisitions (Mentor Corporation, Cougar Biotechnology, Finsbury Orthopaedics, Gloster Europe, Elan Alzheimer Immunotherapy program) for $2,470M cash; acquired headcount not disclosed.
2010-01-03acquisition_additionannounced2010-01-202010-01-20United StatesMedical Devices and Diagnosticssubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Acclarent Inc. completed 2010-01-20 for approximately $785M net; acquired headcount not disclosed.
2010-01-03restructuringin_progress7,5002009-10-012011-12-31WorldwideAll SegmentsUSD 1,200 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Global restructuring initiatives announced in Q4 2009. Plans to eliminate approximately 7,500 positions. Pre-tax charge of $1.2 billion recorded in Q4 2009.
2010-01-03restructuringin_progress7,5002009-10-012011-12-31WorldwideAll segmentsUSD 1,200 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Announced in Q4 2009. Plans to eliminate approx. 7,500 positions; approx. 700 eliminated since announcement. Total pre-tax charge of $1.2 billion.
2010-01-03restructuringin_progressUSD 1,073,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2009-09-27restructuringannounced2009-11-032011-12-31GlobalCompany-widesubsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Global restructuring initiatives announced November 3, 2009; expected pre-tax annual cost savings of $1.4-$1.7 billion when fully implemented in 2011, with $0.8-$0.9 billion expected in 2010. Pre-tax restructuring charges of $1.1-$1.3 billion expected in Q4 2009 (range, not a single value).
2009-09-27reduction_in_forceannounced6.5%2009-11-032011-12-31GlobalCompany-wideother
f5-10q / GLM-5.3-flash-fp4-HTML		Position eliminations estimated at 6-7 percent of global workforce (midpoint 6.5 recorded here as a range indicator; filer disclosed a range, not a point estimate). Savings from reducing management layers, increasing spans of control, and simplifying business structures.
2009-09-27restructuringin_progress4,2002007-09-30GlobalPharmaceutical segment and Cordis franchise; enterprise-wide functionsUSD 745 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2007 restructuring program: approximately 4,200 positions eliminated; $745 million pre-tax charges recorded in fiscal Q3 2007, including $450 million severance, $272 million asset write-offs, and $23 million leasehold obligations. Severance reserve balance of $70 million as of September 27, 2009, with substantially all remaining outlays expected in Q4 2009.
2009-09-27restructuringin_progress4,2002007GlobalCompany-wide; includes Pharmaceutical segment, Cordis franchise and enterprise functions (HR, finance, IT, procurement)USD 745 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced in the fiscal third quarter of 2007; approximately 4,200 positions eliminated, with $745M pre-tax charges ($450M severance, $272M asset write-offs, $23M leasehold). Severance reserve was $70M at 2009-09-27 after $108M of cash outlays during fiscal 2009 YTD; substantially all remaining severance expected to be paid in Q4 2009.
2009-09-27restructuringannounced2009-11-032011GlobalCompany-widesubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Position eliminations estimated at 6-7 percent of global workforce (count not disclosed). Pre-tax restructuring charge expected in the range of $1.1-$1.3 billion in Q4 2009; expected annual pre-tax cost savings of $1.4-$1.7 billion when fully implemented in 2011, with $0.8-$0.9 billion in 2010. Charge value left null because only a range was disclosed.
2009-09-27acquisition_additioncompletedUnited StatesPharmaceutical (development-stage oncology biopharmaceutical)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cougar Biotechnology, Inc. acquired during the fiscal third quarter of 2009 for a net purchase price of $1.0 billion; headcount added not disclosed. Exact announcement/acquisition date not stated in the filing.
2009-09-27acquisition_additioncompletedGlobalMedical Devices & Diagnostics (aesthetic market products)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Mentor Corporation acquired during the fiscal first quarter of 2009 for a net purchase price of $1.1 billion; headcount added not disclosed. Exact acquisition date not stated in the filing.
2009-09-27restructuringannounced6.5%2009-11-032011-12-31GlobalGlobal operationsUSD 1 (billions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Announced Nov 3, 2009. Position eliminations estimated at 6-7% of global workforce. Pre-tax charges expected in range of $1.1-$1.3 billion in Q4 2009. Savings expected to be fully implemented in 2011.
2009-09-27restructuringin_progress2007-07-01GlobalPharmaceuticals and Medical DevicesUSD 70 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Ongoing program announced in Q3 2007. Severance reserve balance was $70 million as of Sept 27, 2009, down from $178 million at year-end 2008. Original program eliminated approx 4,200 positions.
2009-06-28restructuringin_progress4,4002007-07-01Enterprise-wide; Pharmaceutical segment consolidation, Cordis franchise, and enterprise functions (HR, finance, IT, procurement)USD 745 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program announced Q3 2007 to offset generic competition in Pharmaceutical segment and drug-eluting stent market challenges. Approximately 4,100 of the planned 4,400 position eliminations completed as of Q2 2009. Original pre-tax charge of $745 million included severance of $450 million, asset write-offs of $272 million, and $23 million of leasehold obligations; roughly $500 million expected to require cash payments. Severance reserve declined from $178 million at December 28, 2008 to $97 million at June 28, 2009 after $81 million of cash outlays in the first six months of 2009.
2009-06-28restructuringin_progress4,1002007GlobalEnterprise-wide (Pharmaceutical, Cordis, corporate functions)USD 745 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cumulative positions eliminated since Q3 2007 announcement; program targeted ~4,400 total. Severance reserve fell from $178M to $97M during six months ended 2009-06-28 with $81M cash outlays. Original $745M pre-tax charge included $450M severance, $272M asset write-offs, $23M leasehold.
2009-06-28acquisition_additioncompletedGlobalMedical Devices & Diagnostics (aesthetic market)USD 1,100 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Mentor Corporation acquired in fiscal Q1 2009 for net purchase price of $1.1B; headcount added not disclosed.
2009-06-28acquisition_additioncompleted2009-07-092009-07-09United StatesPharmaceutical (oncology)USD 1,000 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cougar Biotechnology Inc. acquired for approximately $1.0 billion; headcount added not disclosed.
2009-06-28acquisition_additionannounced2009-07-02GlobalPharmaceutical (Alzheimer's Immunotherapy Program)USD 1,000 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement with Elan Corporation for 50.1% ownership of new entity holding Elan's Alzheimer's Immunotherapy Program, plus $1.0B investment for 18.4% of Elan ADRs; headcount not disclosed.
2009-06-28restructuringin_progress4,4002007-09-01WorldwidePharmaceutical, Medical Devices & Diagnostics, Enterprise-wide functionsUSD 450 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Initiated in Q3 2007 to improve cost structure. Plan to eliminate approx. 4,400 positions; 4,100 eliminated as of Q2 2009. Severance reserve balance $97M as of June 28, 2009.
2009-06-28acquisition_additioncompleted2009-01-01GlobalMedical Devices & DiagnosticsUSD 1,100 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Mentor Corporation in Q1 2009 for net purchase price of $1.1 billion. Headcount not disclosed.
2009-06-28acquisition_additioncompleted2009-07-09GlobalPharmaceuticalUSD 1,000 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Completed acquisition of Cougar Biotechnology Inc. on July 9, 2009 for approx. $1.0 billion. Headcount not disclosed.
2009-03-29restructuringin_progress4,4002007-07-01Enterprise-wide; Pharmaceutical segment and Cordis franchiseUSD 745 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program announced in fiscal Q3 2007 to offset generic competition and drug-eluting stent market challenges; approximately 3,800 of the planned 4,400 position eliminations completed as of Q1 2009. Pre-tax charges of $745 million included severance of $450 million, asset write-offs of $272 million and $23 million of leasehold obligations; approximately $500 million expected to require cash payments.
2009-03-29restructuringin_progress2007-07-012009-12-31Severance reserveUSD 125 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance reserve declined from $178 million at December 28, 2008 to $125 million at March 29, 2009 after $53 million of cash outlays in the quarter; substantially all remaining balance expected to be paid out over the remainder of 2009.
2009-03-29restructuringin_progress4,4002007GlobalEnterprise-wide; includes Pharmaceutical segment and Cordis franchiseUSD 745 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced in fiscal Q3 2007 targets elimination of about 4,400 positions; 3,800 already eliminated as of this filing. Original $745M pre-tax charge included $450M severance, $272M asset write-offs, $23M leasehold. Severance reserve fell from $178M (Dec 28, 2008) to $125M (Mar 29, 2009) after $53M of Q1 2009 cash outlays; remaining severance expected to be paid over the remainder of 2009. Positions eliminated specifically during Q1 2009 are not disclosed.
2009-03-29acquisition_additioncompletedGlobalMedical Devices & Diagnostics (Ethicon franchise referenced in MD&A)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Mentor Corporation acquired during fiscal Q1 2009 for a net purchase price of $1.1 billion, allocated primarily to $0.9 billion of amortizable intangibles and $0.4 billion of goodwill. Headcount added through the acquisition is not disclosed.
2009-03-29restructuringin_progress4,4002007-09-01WorldwidePharmaceuticals, Medical Devices & Diagnostics, Enterprise-wide functionsUSD 745 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Initiated Q3 2007. Plans to eliminate approx. 4,400 positions; 3,800 eliminated since announcement. Includes severance, asset write-offs, and leasehold obligations.
2009-03-29acquisition_additioncompleted2009-03-29GlobalMedical Devices & DiagnosticsUSD 1,100 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Mentor Corporation for net purchase price of $1.1 billion. Headcount not disclosed.
2008-12-28restructuringin_progress4,4002007Enterprise-wide; targeted cost-base reduction in the Pharmaceutical segment and the Cordis franchise (Medical Devices and Diagnostics), plus streamlining of enterprise functions (HR, finance, IT, procurement)USD 745 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year program announced in fiscal Q3 2007 to offset generic competition and drug-eluting stent market challenges. Approximately 3,500 of the planned ~4,400 position eliminations had been completed cumulatively since announcement through this filing. The $745M pre-tax charge ($450M severance, $272M asset write-offs, $23M leasehold) was recorded in fiscal Q3 2007; the fiscal 2008 income statement shows no incremental restructuring charges. During fiscal 2008, $226M of severance was paid, leaving a $178M severance reserve at 2008-12-28. MD&A reports approximately $1.6B in achieved annual cost savings under the program.
2008-12-28restructuringin_progress3,500WorldwidePharmaceutical; Medical Devices and Diagnostics (Cordis); enterprise functionsrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Program announced in fiscal Q3 2007 (exact date not stated); figure is cumulative through fiscal 2008 year-end — approximately 3,500 of a planned ~4,400 positions eliminated since announcement. The $745M pre-tax charge (severance $450M, asset write-offs $272M, leasehold $23M) was recorded in fiscal 2007, not the current year; fiscal 2008 activity was $226M of severance cash outlays, leaving a $178M severance reserve at 2008-12-28. Approximately $1.6B in annual cost savings achieved per MD&A.
2008-12-28acquisition_additioncompletedWorldwide (Sweden, China, U.S.)Consumer; Medical Devices and Diagnosticsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2008 acquisitions ($1,214M cash): Amic AB, Beijing Dabao Cosmetics, SurgRx, HealthMedia, LGE Performance Systems, Omrix Biopharmaceuticals (completed 2008-12-30). Headcount added through these acquisitions is not disclosed.
2008-12-28divestiture_reductioncompletedWorldwideMedical Devices and Diagnostics (Ethicon Professional Wound Care)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Divestiture of Ethicon's Professional Wound Care business generated a $536M pre-tax gain recorded in other (income) expense, net in 2008; associated headcount removed is not disclosed.
2008-12-28acquisition_additionannounced2009-01-232009-01-23WorldwideMedical Devices and Diagnostics (aesthetic market)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Mentor Corporation completed 2009-01-23 for a net purchase price of $1.1 billion; headcount added not disclosed.
2008-12-28restructuringin_progress4,4002007-07-01WorldwidePharmaceutical, Medical Devices and Diagnostics, Enterprise-wideUSD 745 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Program announced in Q3 2007. Total pre-tax charge of $745 million recorded in 2007. Approximately 4,400 positions planned for elimination; approximately 3,500 eliminated since announcement. Remaining reserve balance of $178 million as of Dec 28, 2008.
2008-12-28restructuringin_progress4,4002007-07-01WorldwidePharmaceutical, Medical Devices and Diagnostics, CorporateUSD 745 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Program announced in Q3 2007. Total plan to eliminate approx 4,400 positions. As of fiscal year-end 2008, approx 3,500 positions eliminated. Charge recorded in 2007 included $450M severance, $272M asset write-offs, $23M leasehold obligations.
2008-09-28restructuringin_progress4,4002007-09Pharmaceutical segment and Cordis franchise; enterprise-wide functions (HR, finance, IT, procurement)USD 745 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program announced Q3 2007 to offset generic competition in Pharma and drug-eluting stent market challenges. Of ~4,400 planned position eliminations, 3,300 had been eliminated through Q3 2008. Original Q3 2007 charge of $745M comprised $450M severance, $272M asset write-offs, and $23M leasehold obligations; ~$500M expected to require cash. Severance reserve declined from $404M at Dec 30, 2007 to $209M at Sept 28, 2008 after $195M of cash outlays; remaining severance expected to be paid over the next 9-12 months. No restructuring charges recorded in fiscal 2008 periods.
2008-09-28restructuringin_progress4,400WorldwideEnterprise-wide (Pharmaceutical, Medical Devices & Diagnostics, Consumer, and corporate functions)USD 745 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Announced during fiscal Q3 2007 (exact date not stated); charge of $745M pre-tax recorded in fiscal Q3 2007, of which ~$500M expected to require cash payments. Approximately 4,400 positions planned for elimination; 3,300 eliminated as of 2008-09-28. Severance reserve: $404M at 2007-12-30, $(195)M cash outlays, $209M balance at 2008-09-28; remaining cash outlays expected over the next 9-12 months. Charge composition: $450M severance, $272M asset write-offs, $23M leasehold obligations.
2008-09-28acquisition_additioncompletedChinaConsumerbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Beijing Dabao Cosmetics Co., Ltd. completed during fiscal Q3 2008 (personal care brands in China); no headcount disclosed. Contributed to Skin Care franchise growth in the quarter.
2008-09-28acquisition_additioncompletedSwedenMedical Devices & DiagnosticsUSD 40 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Amic AB (in vitro diagnostics developer) completed during fiscal Q2 2008; $40M IPR&D charge recorded before and after tax; no headcount disclosed.
2008-09-28divestiture_reductionannouncedWorldwideEthicon — Professional Wound Care businessbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to sell Ethicon's Professional Wound Care business entered during fiscal Q3 2008; divestiture expected to close in fiscal Q4 2008; no headcount disclosed.
2008-09-28acquisition_additioncompleted2008-10-162008-10-16United StatesMedical Devices & Diagnosticssubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter acquisition of SurgRx, Inc., developer of the ENSEAL advanced bipolar tissue sealing system; no headcount disclosed.
2008-09-28acquisition_additioncompleted2008-10-272008-10-27United StatesNot specifiedsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter acquisition of HealthMedia, Inc., a privately held developer of web-based behavior change interventions; no headcount disclosed.
2008-09-28restructuringin_progress4,4002007-07-01WorldwidePharmaceutical, Medical Devices & Diagnostics, Enterprise-wideUSD 745 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Initiated in Q3 2007. Plans to eliminate approx. 4,400 positions; 3,300 eliminated as of Q3 2008. Total pre-tax charges of $745M recorded in Q3 2007 (severance $450M, asset write-offs $272M, leasehold $23M). Remaining severance reserve of $209M as of Sept 28, 2008.
2008-06-29restructuringin_progress4,4002007-07-01Primarily Pharmaceutical segment and Cordis franchise; enterprise-wide functions (HR, finance, IT, procurement)USD 745 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program announced in fiscal Q3 2007 to offset generic competition in Pharmaceutical segment and drug-eluting stent market challenges. Approximately 2,700 of the ~4,400 planned position eliminations completed since inception as of Q2 2008. Total pre-tax charges of $745 million comprise severance of $450 million, asset write-offs of $272 million, and leasehold obligations of $23 million; approximately $500 million of pre-tax charges expected to require cash payments.
2008-06-29restructuringin_progress2007-07-01Severance reserveUSD 260 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance reserve roll-forward: $404 million balance at December 30, 2007, reduced by $144 million of cash outlays during the first fiscal six months of 2008, leaving $260 million at June 29, 2008. Remaining outlays expected to be substantially paid over the next 12 months.
2008-06-29restructuringin_progress4,4002007WorldwidePharmaceutical; Cordis (Medical Devices & Diagnostics); enterprise-wide functions (HR, finance, IT)USD 745 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced in fiscal Q3 2007 to improve cost structure ahead of generic competition and drug-eluting stent market challenges. Approximately 4,400 positions planned for elimination; 2,700 eliminated since inception as of June 29, 2008. Charge comprises $450M severance, $272M asset write-offs, $23M leasehold obligations; about $500M expected to require cash payments. Severance reserve: $404M at Dec 30, 2007, $(144)M cash outlays, $260M at June 29, 2008, with outlays expected to be substantially paid over the next 12 months.
2008-06-29acquisition_additioncompleted2008-06-29SwedenMedical Devices & Diagnostics (in vitro diagnostics)USD 40 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Amic AB acquired during fiscal Q2 2008 for $44M in cash and debt; $40M IPR&D charge recorded (pre- and after-tax). Headcount added through the acquisition not disclosed.
2008-06-29acquisition_additionannounced2008-07-302008-07-30ChinaConsumersubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Beijing Dabao Cosmetics Co., LTD (personal care brands in China) completed July 30, 2008, after quarter end. Headcount not disclosed.
2008-06-29restructuringin_progress2,7002007-09-01WorldwidePharmaceuticals; Medical Devices & Diagnostics (Cordis); Enterprise-wide functionsUSD 144 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2,700 positions eliminated since plan inception (Q3 2007). $144M severance cash outlays recorded in first six months of 2008. Total program charge was $745M pre-tax.
2008-03-30restructuringin_progress4,4002007-07-01Pharmaceutical segment and Cordis franchise; enterprise-wide functions (HR, finance, IT, procurement)USD 745 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program announced in fiscal Q3 2007 to offset generic competition in Pharma and drug-eluting stent market challenges. Total pre-tax charge of $745M comprises severance $450M, asset write-offs $272M, and leasehold obligations $23M; approximately $500M expected to require cash payments. Approximately 2,200 of the 4,400 positions had been eliminated since inception as of Q1 2008.
2008-03-30reduction_in_forcein_progress2,2002007-07-01Company-widerestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Positions eliminated since the program's inception through the fiscal first quarter of 2008, out of approximately 4,400 planned. Severance reserve balance was $404M at December 30, 2007, reduced by $67M of cash outlays to $337M at March 30, 2008; remaining outlays expected over the next 12 to 15 months.
2008-03-30restructuringin_progress2,200WorldwidePharmaceutical; Medical Devices & Diagnostics (Cordis); enterprise-wide functions (HR, Finance, IT)USD 745 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced in fiscal Q3 2007 (exact announcement date not stated in filing); targets elimination of approximately 4,400 positions, of which 2,200 had been eliminated since inception as of 2008-03-30. Charge comprises $450M severance, $272M asset write-offs, $23M leasehold obligations; approximately $500M expected to require cash payments. Severance reserve: $404M at 2007-12-30, less $67M cash outlays, $337M at 2008-03-30; remaining severance cash outlays expected over the next 12 to 15 months.
2008-03-30restructuringin_progress2,2002007-09-01WorldwidePharmaceuticals, Medical Devices & Diagnostics, Enterprise-wide functionsUSD 450 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program announced in Q3 2007 to eliminate approx. 4,400 positions. 2,200 eliminated since inception. Severance reserve balance $337M as of Mar 30, 2008.
2007-12-30restructuringin_progress4,4002007Enterprise-widePharmaceutical segment cost-base reduction; Cordis franchise (Medical Devices and Diagnostics) business-model integration; enterprise-wide functions (HR, finance, IT, procurement)USD 745 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Program announced in fiscal Q3 2007; approximately 1,400 of the planned ~4,400 position eliminations were completed in 2007. Charge components: $450M severance, $272M asset write-offs, $23M leasehold obligations; ~$500M expected to require cash. Charges by segment (Note 11): $15M Consumer, $429M Pharmaceutical, $301M Medical Devices and Diagnostics. Severance cash outlays of $46M made in 2007, leaving a $404M reserve at year-end, to be paid over the following 12 to 18 months. No explicit completion date disclosed.
2007-12-30restructuringin_progress4,400WorldwidePharmaceutical segment, Cordis franchise (Medical Devices and Diagnostics), Consumer segment, and enterprise-wide support functions (HR, finance, IT, procurement)USD 745 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Announced during fiscal third quarter 2007 (exact date not disclosed). Program plans to eliminate approximately 4,400 positions, of which approximately 1,400 were eliminated in fiscal 2007. Pre-tax charge of $745M comprises $450M severance, $272M asset write-offs and $23M leasehold obligations; approximately $500M expected to require cash payments. Severance cash outlays of $46M in 2007 left a $404M reserve at year-end. Segment charge split per Note 11: Consumer $15M, Pharmaceutical $429M, Medical Devices and Diagnostics $301M. Purpose was to offset generic competition in Pharmaceuticals and drug-eluting stent market challenges.
2007-12-30restructuringin_progress4,4002007-07-01WorldwidePharmaceutical; Medical Devices and DiagnosticsUSD 745 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Approximately 1,400 positions eliminated in 2007; total program plans to eliminate 4,400 positions. Pre-tax charges of $745 million recorded in 2007.
2007-12-30restructuringin_progress4,4002007-09-30WorldwidePharmaceutical; Medical Devices and Diagnostics (Cordis)USD 745 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Company plans to eliminate approximately 4,400 positions. Approximately 1,400 were eliminated in 2007. Total pre-tax charges of $745 million recorded in Q3 2007.
2007-09-30restructuringin_progress4,4002007-07-31Primarily Pharmaceutical segment and Cordis franchise of Medical Devices and Diagnostics segment; also operations and certain facilities consolidationUSD 745 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program aims to improve cost structure and offset generic competition and drug-eluting stent market challenges; expected pre-tax annual savings of $1.3-$1.6 billion for 2008. Charges comprise $450 million severance, $272 million asset write-offs, and $23 million leasehold obligations; approximately $500 million of charges expected to require cash payments. Severance cash outlays expected over next 12 to 18 months; severance reserve of $442 million at September 30, 2007 after $8 million of cash outlays.
2007-09-30restructuringin_progress2007-07-31Pharmaceutical segmentUSD 429 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring charges recorded in the fiscal third quarter of 2007 attributable to the Pharmaceutical segment.
2007-09-30restructuringin_progress2007-07-31Medical Devices and Diagnostics segment (Cordis franchise)USD 301 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring charges recorded in the fiscal third quarter of 2007 attributable to the Medical Devices and Diagnostics segment.
2007-09-30restructuringin_progress2007-07-31Consumer segmentUSD 15 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring charges recorded in the fiscal third quarter of 2007 attributable to the Consumer segment.
2007-09-30restructuringin_progress4,4002007-07-31GlobalPrimarily Pharmaceutical segment and the Cordis franchise of the Medical Devices and Diagnostics segmentUSD 745 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pre-tax charge comprises $450M severance, $272M asset write-offs, $23M leasehold obligations; approximately $500M expected to require cash payments. Severance reserve balance at 2007-09-30 was $442M after $8M cash outlays, with severance payouts expected over the following 12 to 18 months. Program aims to offset generic competition in Pharmaceuticals and drug-eluting stent market challenges; expected pre-tax annual cost savings of $1.3–$1.6 billion for 2008. Charges by segment: Consumer $15M, Pharmaceutical $429M, Medical Devices & Diagnostics $301M (employee counts not broken out by segment).
2007-09-30acquisition_additioncompletedUnited StatesMedical Devices & Diagnostics (cardiovascular)USD 1,400 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Conor Medsystems, Inc. completed in fiscal first quarter 2007 for $1.4 billion in cash; headcount added not disclosed. Related IPR&D charge of $807M recorded in the nine months ended 2007-09-30.
2007-09-30divestiture_reductioncompletedUnited StatesConsumerUSD 410 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Divestiture of KAOPECTATE, UNISOM, CORTIZONE, BALMEX and ACT consumer products to Chattem, Inc. for $410 million cash in fiscal first quarter 2007; headcount removed not disclosed.
2007-09-30restructuringin_progress4,4002007-07-31WorldwidePharmaceutical; Medical Devices and Diagnostics (Cordis)USD 745 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Initiatives to improve cost structure, offset generic competition and stent market challenges. Includes severance, asset write-offs, and leasehold obligations.
2007-07-01restructuringannounced2007-07-31USD 650 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Company announced initiatives targeting pre-tax annual cost savings of $1.3-$1.6 billion for 2008; expected pre-tax restructuring charges of $550-$750 million in the second half of 2007. No headcount figures disclosed.
2007-07-01restructuringannounced2007-07-31Not specifiedCompany-wideUSD 550 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Initiatives expected to generate pre-tax annual cost savings of $1.3-$1.6 billion for 2008; no employee count disclosed.
2007-07-01acquisition_additioncompletedNot specifiedMedical Devices & Diagnostics (cardiovascular devices)USD 1,400 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Conor Medsystems, Inc. acquired for $1.4 billion cash in fiscal Q1 2007; headcount added not disclosed.
2007-07-01divestiture_reductioncompletedNot specifiedConsumerUSD 410 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Divestiture of KAOPECTATE, UNISOM, CORTIZONE, BALMEX and ACT consumer products to Chattem, Inc. for $410 million cash in fiscal Q1 2007; headcount removed not disclosed.
2007-07-01restructuringannounced2007-07-31WorldwideAll segmentsUSD 650 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Initiatives expected to generate pre-tax annual cost savings of $1.3-$1.6 billion for 2008. Associated pre-tax restructuring charges estimated at $550-$750 million in second half of 2007. Employee count not disclosed.
2007-04-01acquisition_additioncompletedUnited StatesMedical Devices & DiagnosticsUSD 807 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Conor Medsystems, Inc., a cardiovascular device maker, acquired for $1.4 billion cash in Q1 2007; purchase price allocation still being finalized. No headcount disclosed; charge shown is the non-deductible in-process R&D charge, not a severance charge.
2007-04-01divestiture_reductioncompletedUnited StatesConsumerbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Divestiture of KAOPECTATE, UNISOM, CORTIZONE, BALMEX and ACT consumer products to Chattem, Inc. for $410 million cash; no headcount impact disclosed.
2006-12-31acquisition_additioncompleted2006-12-20GlobalConsumerUSD 16,600 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Completed acquisition of the Consumer Healthcare business of Pfizer Inc. for $16.6 billion in cash (purchase price, not a severance/restructuring charge); allocated $6.6 billion goodwill and $8.9 billion intangibles to the Consumer segment. No employee headcount assumed was disclosed; operating results to be reported beginning fiscal 2007. Total 2006 acquisition spend of $18.0 billion also included Animas, Hand Innovations, Future Medical Systems, Vascular Control Systems, Groupe Vendôme, ColBar LifeScience and Ensure Medical, none with disclosed headcount.
2006-12-31acquisition_additioncompleted2006-12-202006-12-20GlobalConsumerUSD 16,600 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Pfizer Inc. Consumer Healthcare business for $16.6 billion cash; acquired headcount not disclosed. Operating results excluded from FY2006 financials (immaterial post-close period) and excluded from management's ICFR assessment (26% of total assets).
2006-12-31acquisition_additioncompleted2006-12-31GlobalPharmaceutical; Medical Devices and Diagnostics; ConsumerUSD 18,023 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Aggregate 2006 acquisitions of $18.0 billion cash (including the Pfizer Consumer Healthcare deal) covering Animas, Hand Innovations, Future Medical Systems, Vascular Control Systems, Groupe Vendôme, ColBar LifeScience and Ensure Medical; headcount added not disclosed.
2006-12-31divestiture_reductioncompleted2006-12-20GlobalConsumerbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Divestiture of the ZANTAC product completed as a condition of regulatory approval for the Pfizer Consumer Healthcare acquisition; headcount removed not disclosed.
2006-12-31divestiture_reductioncompleted2007-01-02United StatesConsumerUSD 410 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Divestiture of KAOPECTATE, UNISOM, CORTIZONE, BALMEX and ACT products to Chattem, Inc. for $410 million cash, completed 2007-01-02 (within FY2006 balance sheet date window) and announced as a closing in fiscal Q1 2007; headcount removed not disclosed.
2006-12-31acquisition_additioncompleted2007-03-31GlobalMedical Devices and DiagnosticsUSD 1,400 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Conor Medsystems, Inc., a cardiovascular device company, for $1.4 billion cash, completed during fiscal first quarter 2007 (after FY2006 period end); headcount added not disclosed.
2005-07-03acquisition_additioncompleted2005-04-042005-04-04United StatesPharmaceuticalUSD 50 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of TransForm Pharmaceuticals for $230 million; $50 million one-time IPR&D charge expensed. Employee count added not disclosed.
2005-07-03acquisition_additioncompleted2005-06-032005-06-03United StatesMedical Devices and DiagnosticsUSD 51 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of CLOSURE Medical for a net purchase price of $364 million; approximately $51 million one-time IPR&D charge expensed. Employee count added not disclosed.
2005-07-03acquisition_additioncompleted2005-06-302005-06-30United StatesPharmaceuticalUSD 252 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Peninsula Pharmaceuticals for approximately $245 million; approximately $252 million one-time IPR&D charge expensed. Employee count added not disclosed.
2005-07-03acquisition_additionannounced2004-12-15United StatesMedical Devices and DiagnosticsUSD 25,400 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pending acquisition of Guidant Corporation at $25.4 billion fully diluted equity value; regulatory review ongoing with FTC and EU, targeted fiscal third quarter close. Employee count to be added not disclosed.
2005-01-02acquisition_additionannounced2004-12-152005-09-30United StatesMedical Devices and Diagnosticssubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Guidant Corporation for $25.4 billion in fully diluted equity value; expected to close in Q3 2005 subject to regulatory and shareholder approvals. No headcount associated with the transaction is disclosed.
2005-01-02acquisition_additioncompletedUnited States; EuropeConsumer; Pharmaceutical; Medical Devices and Diagnosticsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2004 acquisitions totaling $455 million cash plus $15 million liabilities assumed (including Merck's 50% stake in the J&J-Merck European OTC joint venture, Egea Biosciences, Artemis Medical, Scott Lab rights, Biapharm SAS, Micomed assets, AMBI brand). No employee counts disclosed for any transaction.
2005-01-02voluntary_separationcompleted2003-10-012004-06-30United StatesAll segmentsUSD 95 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Retirement Enhancement Program offered to eligible U.S. employees age 55+ with 10+ years service. $95 million expensed in Q4 2003.
2004-03-28divestiture_reductioncompletedMedical Devices and Diagnostics (DePuy)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		DePuy's Castings business was divested in the fiscal first quarter of 2004; filing states no material effect on results, cash flows or financial position and discloses no employee count.
2003-12-28voluntary_separationin_progress2003United StatesCompany-wide; eligible U.S. regular, full-time employeesUSD 95 (millions)other
f5-10k / GLM-5.3-flash-HTML		Retirement Enhancement Program (REP): enhanced pension (early-reduction elimination) plus a special termination benefit of one week of pay per year of credited service, for U.S. regular full-time employees age 55+ with 10+ years of pension credited service by June 30, 2004. The $95 million was recognized in fiscal 2003 U.S. pension expense (shown as special termination benefits); program offered in the fourth quarter of fiscal 2003. Number of participating employees not disclosed.
2003-12-28voluntary_separationcompleted2003-10-012004-06-30United StatesAll segmentsUSD 95 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Retirement Enhancement Program (REP) offered to eligible US full-time employees aged 55+ with 10+ years pension service by June 30, 2004; eliminated early retirement reduction and added special termination benefit of one week pay per year of service; $95M pre-tax charge in 2003 ($61M after tax per quarterly data); employee count not disclosed
2003-12-28acquisition_additioncompletedUnited StatesPharmaceuticalbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Scios Inc. acquired April 2003 for $2.8B total cash acquisitions; headcount added not disclosed
2003-12-28acquisition_additioncompletedUnited StatesMedical Devices and Diagnosticsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Link Spine Group, Orquest assets, and OraPharma acquired during 2003; headcount added not disclosed
2003-12-28voluntary_separationcompleted2003-10-012003-12-31United StatesAll SegmentsUSD 95 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Retirement enhancement program offered in Q4 2003 to eligible U.S. regular, full-time employees. Cost of $95 million charged to income. Specific headcount not disclosed.
2003-12-28voluntary_separationcompleted2003-10-012004-06-30United StatesAll SegmentsUSD 95 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Retirement Enhancement Program offered in Q4 2003 to eligible U.S. regular, full-time employees attaining age 55 with 10 years service by June 30, 2004. Charge of $95 million recorded in 2003.
2003-06-29acquisition_additioncompleted2003-04-29United StatesPharmaceuticalUSD 730 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Scios Inc. acquired for approximately $2.1 billion net of cash; IPR&D charge of $730M. No headcount disclosed.
2003-06-29acquisition_additioncompleted2003-06-03United StatesMedical Devices & DiagnosticsUSD 170 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Link Spine Group acquired for $325M upfront; IPR&D charge of $170M. No headcount disclosed.
2003-06-29acquisition_additioncompleted2003-05-09United StatesMedical Devices & DiagnosticsUSD 26 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Inscope intraluminal clip applier technology acquired for $26M. No headcount disclosed.
2003-06-29acquisition_additioncompleted2003-04-17United StatesConsumerUSD 37 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		CORTAID anti-itch brand business acquired from Pharmacia for approximately $37M. No headcount disclosed.
2003-06-29acquisition_additioncompleted2003-02-10United StatesPharmaceuticalUSD 11 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		OraPharma acquired for approximately $85M net of cash; IPR&D charge of $11M before tax. No headcount disclosed.
2003-06-29acquisition_additioncompleted2003-03-28United StatesPharmaceuticalUSD 7 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		3-Dimensional Pharmaceuticals acquired for approximately $88M net of cash; IPR&D charge of $7M. No headcount disclosed.
2003-06-29acquisition_additioncompleted2003-01-29United StatesMedical Devices & Diagnosticsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Orquest, Inc. assets acquired (biotech orthopedic/spine implants). No headcount or transaction value disclosed.
2003-06-29divestiture_reductioncompleted2003-05-01United StatesMedical Devices & DiagnosticsMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ethicon Endo-Surgery divested Vascular Access product line to Medex Inc. in May 2003; no headcount disclosed. Announcement date approximate (month only).
2003-03-30acquisition_additioncompleted2003-01-292003-01-29United StatesMedical Devices & Diagnosticsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of assets of Orquest, Inc., a biotechnology company; no headcount disclosed.
2003-03-30acquisition_additioncompleted2003-02-102003-02-10United StatesPharmaceuticalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Orapharma, Inc., valued at approximately $85 million net of cash; no headcount disclosed.
2003-03-30acquisition_additioncompleted2003-03-282003-03-28United StatesPharmaceuticalUSD 7 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of 3-Dimensional Pharmaceuticals, Inc., valued at approximately $88 million net of cash, with a pre-tax in-process R&D charge of about $7 million; no headcount disclosed.
2003-03-30acquisition_additionannounced2003-04-292003-04-29United StatesPharmaceuticalsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Completed acquisition of Scios Inc. in a cash-for-stock exchange valued at approximately $2.4 billion net of cash; expected pre-tax in-process R&D charge of $700-800 million in Q2 2003; no headcount disclosed.
2003-03-30acquisition_additionannounced2003-05-062003-06-30United StatesMedical Devices & DiagnosticsUSD 325 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Link Spine Group, Inc. with $325 million upfront payment plus contingent milestone payments; anticipated in-process R&D charge of about $175 million; expected to close in Q2 2003; no headcount disclosed.
2002-12-29acquisition_additioncompletedPharmaceuticalUSD 320 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Completed during Q2 2002; anti-viral biopharmaceutical developer incl. HIV compounds; $150 million IPR&D charge recognized; acquired headcount not disclosed.
2002-12-29acquisition_additioncompletedMedical Devices & Diagnosticsbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Privately held maker of adjustable gastric band for morbid obesity; acquired in Q2 2002; individual price not disclosed; $39 million IPR&D charge; headcount not disclosed.
2002-12-29acquisition_additioncompletedbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired during 2002; blood-typing reagent maker; individual purchase price not disclosed (aggregate 2002 acquisition cash outlay was $478 million); headcount not disclosed.
2002-12-29acquisition_additioncompletedPharmaceuticalUSD 85 (millions)MD&A
f5-10k / GLM-5.3-flash-HTML		Definitive agreement announced in Q4 2002 for oral health care specialty pharmaceuticals; ~$85 million net of cash; closed in Q1 2003; headcount not disclosed.
2002-12-29acquisition_additionannounced2003-02-10PharmaceuticalUSD 2,400 (millions)subsequent_events
f5-10k / GLM-5.3-flash-HTML		Cash-for-stock acquisition at $45.00 per share, ~$2.4 billion net of cash; expected to close in Q2 2003 with ~$700 million anticipated IPR&D charge; headcount not disclosed.
2002-12-29acquisition_additioncompleted2002-06-302002-06-30BelgiumPharmaceuticalUSD 320 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Biopharmaceutical company focused on anti-viral treatments including HIV. Headcount not disclosed.
2002-12-29acquisition_additioncompleted2002-12-312003-03-31United StatesPharmaceuticalUSD 85 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Announced Q4 2002, closed Q1 2003. Specialty pharmaceutical company in oral health care. Headcount not disclosed.
2002-12-29acquisition_additionannounced2003-02-102003-06-30United StatesPharmaceuticalUSD 2,400 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Subsequent event disclosed in Note 22. Expected to close Q2 2003. Anticipated IPR&D charge of approximately $700 million. Headcount not disclosed.
2002-09-29acquisition_additioncompleted2002-03-14Medical Devices & Diagnostics (Ortho Clinical Diagnostics)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cash purchase of Micro Typing Systems, Inc. for approximately $30 million; no headcount added disclosed.
2002-09-29acquisition_additioncompleted2002-04-18PharmaceuticalUSD 150 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Tibotec-Virco NV acquisition valued at approximately $320 million in cash and debt; after-tax in-process R&D charge of about $150 million ($0.05 per share) recorded in Q2 2002; no headcount added disclosed.
2002-09-29acquisition_additioncompleted2002-06-27SwitzerlandMedical Devices & Diagnostics (Ethicon Endo-Surgery)USD 39 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Obtech Medical AG acquired for approximately $110 million in cash; after-tax in-process R&D charge of about $39 million ($0.01 per share) recorded in Q2 2002; no headcount added disclosed.
2002-06-30acquisition_additioncompleted2002-03-12United StatesMedical Devices & Diagnosticsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Micro Typing Systems, Inc., valued at approximately $30 million in cash; no headcount disclosed.
2002-06-30acquisition_additioncompleted2002-04-18BelgiumPharmaceuticalUSD 150 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Tibotec-Virco NV, valued at approximately $320 million in cash and debt; after-tax IPR&D charge of $150 million ($0.05/share); no headcount disclosed.
2002-06-30acquisition_additioncompleted2002-06-27SwitzerlandMedical Devices & DiagnosticsUSD 39 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Obtech Medical AG, valued at approximately $110 million in cash; after-tax IPR&D charge of $39 million ($0.01/share); no headcount disclosed.
2002-03-31acquisition_additioncompleted2002-03-122002-03-12United StatesMedical Devices and Diagnosticsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Micro Typing Systems, Inc., maker of ID-MTS blood typing reagents and instruments; no headcount disclosed.
2002-03-31acquisition_additioncompleted2002-03-222002-04-18BelgiumPharmaceuticalUSD 145 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Tibotec-Virco NV acquisition valued at ~$320M cash and debt; $145M after-tax in-process R&D charge in Q2 2002 (not a severance charge); no headcount disclosed.
2001-12-30acquisition_additioncompleted2001-06-22United StatesPharmaceuticalUSD 147 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Merger with ALZA Corporation completed June 22, 2001; accounted for as pooling of interests with roughly 234 million J&J shares issued. Employee headcount added was not disclosed. Pretax ALZA merger costs of $147 million ($126 million after tax) were charged in 2001 (transaction costs, not severance).
2001-12-30acquisition_additioncompleted2001-11-27Medical Devices & Diagnostics — blood glucose monitoring (LifeScan)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition completed November 2001 (completion announced via Form 8-K filed November 27, 2001); Inverness combined with LifeScan to form the blood glucose monitoring franchise. Preliminary allocation included $784 million patents/technology and $714 million goodwill. Headcount added not disclosed.
2001-12-30acquisition_additioncompleted2001Medical Devices & Diagnosticsbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Heartport, a developer and manufacturer of products for less invasive cardiac surgery, acquired during 2001 as part of $1.7 billion of purchase acquisitions. Headcount added not disclosed.
2001-12-30acquisition_additioncompleted2001Medical Devices & Diagnostics — Cordisbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Early-stage medical device company developing catheter-based stent-graft systems for abdominal aortic aneurysms; completed in the fourth quarter of 2001. Included in the $105 million IPR&D charge (shared with Inverness). Headcount added not disclosed.
2001-12-30acquisition_additioncompleted2001business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Babycenter.com, an internet content and commerce site for expectant and new mothers, acquired during 2001. Headcount added not disclosed.
2001-12-30acquisition_additioncompleted2001Consumer — McNeil Nutritionalsbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Chewable calcium supplement product line purchased from Mead Johnson Nutritionals (Bristol-Myers Squibb); product-line transaction with no workforce transfer disclosed. Headcount added not disclosed.
2001-12-30acquisition_additioncompleted2001-06-222001-06-22United StatesPharmaceuticalUSD 147 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		ALZA Corporation merger completed 2001-06-22, accounted for as pooling-of-interests; $147M pretax merger costs incurred in 2001; headcount added not disclosed
2001-12-30acquisition_additioncompleted2001-11-272001-11-27United StatesMedical Devices & Diagnosticsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Inverness Medical Technology diabetes care products business acquired; part of $1.7B total 2001 acquisitions; headcount added not disclosed
2001-12-30acquisition_additioncompleted2001-12-312001-12-31United StatesMedical Devices & Diagnosticsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		TERAMed Inc. acquired in Q4 2001; early-stage medical device company; headcount added not disclosed
2001-12-30acquisition_additioncompleted2001-12-312001-12-31United StatesMedical Devices & Diagnosticsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Heartport, Inc. acquired during 2001; minimally invasive heart surgery products; headcount added not disclosed
2001-12-30acquisition_additioncompleted2001-12-312001-12-31United StatesConsumerbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Babycenter.com acquired during 2001; internet content and commerce site; headcount added not disclosed
2001-12-30acquisition_additioncompleted2001-12-312001-12-31United StatesConsumerbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		VIACTIV calcium supplement product line acquired from Bristol-Myers Squibb; product line acquisition, headcount impact not disclosed
2001-12-30acquisition_additioncompleted2001-06-222001-06-22United StatesPharmaceuticals (ALZA Corporation)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Merger of ALZA into Johnson & Johnson completed 2001-06-22 (0.98 J&J shares per ALZA share); no headcount added through the acquisition is disclosed. Plan to continue through at least 2001-12-31 with no employer contributions expected after 2001-12-31.
2001-09-30acquisition_additioncompleted2001-06-222001-06-22United StatesPharmaceuticalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Merger with ALZA Corporation accounted for by pooling of interests; financial statements restated retroactively. No headcount disclosed.
2001-09-30acquisition_additioncompleted2001-04-182001-04-18United StatesMedical Devices & Diagnosticsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Stock-for-stock purchase of Heartport valued at approximately $81 million; no headcount disclosed.
2001-09-30acquisition_additionannounced2001-05-092001-12-31United StatesMedical Devices & Diagnosticsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive merger agreement to acquire Inverness Medical Technologies (excluding certain businesses) in a stock-for-stock exchange; expected to close in Q4 2001, subject to European regulatory approvals. No headcount disclosed.
2001-09-30divestiture_reductioncompleted2001-06-042001-06-04WorldwideConsumerbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Johnson & Johnson Medical's Worldwide Packs, Gowns and Wearing Apparel business to Molnlycke Health Care AG; no headcount disclosed.
2001-09-30restructuringin_progress2001-06-22United StatesCorporateUSD 126 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Special charges of $126 million after-tax for restructuring and deal costs related to the ALZA merger; no employee count disclosed.
2001-09-30restructuringcompletedWorldwideCorporate / ALZA Merger IntegrationUSD 126 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Special charges of $126 million after-tax for restructuring and deal costs related to the ALZA merger.
2001-09-30acquisition_additioncompleted2001-03-02United StatesConsumerUSD 10 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired BabyCenter, Inc. for approximately $10 million cash.
2001-09-30acquisition_additioncompleted2001-04-18United StatesMedical Devices & DiagnosticsUSD 81 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Completed purchase of Heartport, valued at approximately $81 million.
2001-09-30acquisition_additioncompleted2001-06-22WorldwidePharmaceuticalbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Completed merger with ALZA Corporation in a tax-free stock exchange.
2001-09-30divestiture_reductioncompleted2001-06-04WorldwideMedical Devices & Diagnosticsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sold Worldwide Packs, Gowns and Wearing Apparel business to Molnlycke Health Care AG.
2001-07-01restructuringin_progress2001-06-22PharmaceuticalUSD 109 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Special charges of $109M for restructuring and deal costs related to the ALZA merger; no employee count disclosed. MD&A separately cites $102M after-tax special charges for the same program.
2001-07-01acquisition_additioncompleted2001-06-222001-06-22Pharmaceuticalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		ALZA Corporation merger completed 2001-06-22 under pooling of interests; no headcount added disclosed.
2001-07-01acquisition_additioncompleted2001-04-182001-04-18Medical Devices & Diagnosticsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Heartport, Inc. merger completed 2001-04-18, valued at approximately $81 million; no headcount added disclosed.
2001-07-01acquisition_additionannounced2001-05-092001-12-31Medical Devices & Diagnosticsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive merger agreement to acquire Inverness Medical Technologies announced 2001-05-09; expected to close Q4 2001 subject to European regulatory approvals; no headcount disclosed.
2001-07-01restructuringcompleted2001-06-22WorldwidePharmaceuticalUSD 109 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Special charges for restructuring and deal costs related to the ALZA merger.
2001-07-01acquisition_additioncompleted2001-03-02United StatesConsumerUSD 10 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of BabyCenter, Inc. from eToys, Inc.
2001-07-01acquisition_additioncompleted2001-04-18United StatesMedical Devices & DiagnosticsUSD 81 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Merger with Heartport, valued at approximately $81 million.
2001-07-01acquisition_additioncompleted2001-06-22WorldwidePharmaceuticalbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Merger with ALZA Corporation completed. Accounted for by pooling of interests.
2001-07-01acquisition_additionannounced2001-05-092001-12-31WorldwideMedical Devices & Diagnosticssubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Definitive merger agreement to acquire Inverness Medical Technologies. Expected to close in Q4 2001.
2001-04-01acquisition_additioncompleted2001-03-022001-03-02United StatesConsumerbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		All-cash purchase of BabyCenter, Inc. from eToys, Inc., valued at approximately $10 million; no employee count disclosed
2001-04-01acquisition_additionannounced2001-03-272001-07-31United StatesPharmaceuticalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Stock-for-stock merger agreement with ALZA Corporation at 0.49 J&J shares per ALZA share (0.98 post-split); expected to close by early Q3 2001, subject to ALZA shareholder approval; no employee count disclosed
2001-04-01acquisition_additioncompleted2001-04-182001-04-18United StatesMedical Devices & Diagnosticssubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Merger with Heartport, Inc. completed post-quarter, valued at approximately $81 million; J&J intends to repurchase shares issued within 90 days; no employee count disclosed
2001-04-01acquisition_additionannounced2001-05-09United StatesMedical Devices & Diagnosticssubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Advanced discussions announced regarding stock-for-stock acquisition of Inverness Medical Technology (excluding certain non-diabetes businesses); no definitive agreement yet; no employee count disclosed
2000-12-31restructuringcompleted4,1001998-12-312000-12-31WorldwideConsumer, Pharmaceutical, Professional (manufacturing and operations)USD 553 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year global manufacturing network reconfiguration announced Q4 1998, completed at year-end 2000. Cumulative headcount reduction of ~4,100 employees and closure of 35 manufacturing facilities across the full program. The $553M restructuring charge was recorded in 1998; 2000 activity included $33M accrual reversal to income and $18M remaining accrual. An additional $60M inventory write-off was recorded in cost of sales in 1998.
2000-12-31acquisition_additioncompletedUnited StatesProfessional (medical devices)USD 158 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2000 acquisitions included Innovasive Devices, Atrionix Inc., Medtrex, and the St. Joseph aspirin business for $158M total. Headcount added through these acquisitions was not disclosed.
2000-12-31acquisition_additionannounced2001-03-272001-09-30United StatesPharmaceuticalsubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive merger agreement with ALZA Corporation announced March 27, 2001 (after fiscal year-end). Fixed exchange ratio of 0.49 JNJ shares per ALZA share; ~295 million ALZA shares outstanding on fully diluted basis. Expected to close early Q3 2001. Headcount impact not disclosed.
2000-12-31acquisition_additionannounced2001-01-262001-06-30United StatesProfessional (cardiac surgery products)USD 81 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Heartport Inc. announced January 26, 2001 (after fiscal year-end), valued at approximately $81 million. Expected completion Q2 2001. Headcount impact not disclosed.
2000-12-31restructuringcompleted4,1001998-12-312000-12-31WorldwideManufacturing and OperationsUSD 553 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Plan approved in Q4 1998 to reconfigure global manufacturing network. Completed at year-end 2000. Total headcount reduction approx 4,100 employees worldwide. Charge includes employee separations, asset impairments, and other exit costs.
2000-10-01restructuringin_progress2,8001998-10-012000-12-31GlobalManufacturing and operationsUSD 613 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan approved in Q4 1998 to reconfigure global manufacturing network; substantially complete with full completion expected by year-end 2000. Headcount reduction of approximately 2,800 employees through October 1, 2000, primarily in manufacturing and operations facilities. Manufacturing facilities reduced by 36, from 159 to 123 plants. Charge comprises $161M employee separations, $322M asset impairments, $52M intangible impairments, and $78M other exit costs. Remaining severance and exit cost accrual of $71M at October 1, 2000.
2000-10-01divestiture_reductioncompleted2000-07-01United StatesProfessional / DePuy OrthoTechMD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Company sold its DePuy OrthoTech business (knee braces and related rehabilitation products) to dj Orthopaedics LLC during the third quarter. No headcount figures disclosed.
2000-10-01acquisition_additioncompleted2000-01-01USD 7 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		First-quarter acquisitions of Innovasive Devices (sports medicine surgery devices) and Medtrex (electrosurgical generators and disposable products); net cash payments of $7 million. No headcount figures disclosed.
2000-10-01restructuringin_progress2,80019982000-12-31WorldwideManufacturing and operationsUSD 613 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Global network reconfiguration approved in Q4 1998; 2,800 is cumulative headcount reduction through 2000-10-01, not a quarterly figure. Estimated plan cost $613M includes $161M employee separations, $322M asset impairments, $52M intangible impairments, $78M other exit costs. Remaining severance accrual $58M and other exit accrual $13M at 2000-10-01; $42M of separations paid YTD 2000.
2000-10-01plant_closurein_progress19982000-12-31WorldwideManufacturingrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Component of the same restructuring program: manufacturing plant count reduced by 36, from 159 to 123; no separate headcount allocated to closures. Approximately 2,800 employees reduced overall under the plan.
2000-10-01acquisition_additioncompleted2000Professional (medical devices)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Innovasive Devices (sports medicine surgery devices) and Medtrex (electrosurgical generators) acquired during first quarter 2000; no headcount disclosed. Pro forma results not materially different from reported.
2000-10-01divestiture_reductioncompleted2000-07Professional (DePuy OrthoTech — knee braces and rehabilitation products)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		DePuy OrthoTech sold to dj Orthopaedics LLC during the third quarter (MD&A states July); no headcount transferred disclosed.
2000-10-01restructuringin_progress2,8001998-10-012000-12-31WorldwideManufacturing and operationsUSD 613 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in Q4 1998 to reconfigure global network. Headcount reduction of approx 2,800 employees through Oct 1, 2000. Total estimated cost $613M including $161M employee separations.
2000-10-01acquisition_additioncompleted2000-03-31ProfessionalUSD 82 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Innovasive Devices and Medtrex in Q1 2000. Net cash payments $7M; fair value of assets acquired $83M. Employee count not disclosed.
2000-10-01divestiture_reductioncompleted2000-07-01Professionalbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sold DePuy OrthoTech business to dj Orthopaedics LLC in Q3 2000. Employee count not disclosed.
2000-07-02restructuringin_progress2,4001998-102000-12-31GlobalManufacturing and operationsUSD 613 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan approved Q4 1998 to reconfigure global manufacturing network; targeted completion in 2000. Total estimated cost $613M comprising $161M employee separation costs, $322M asset impairments, $52M intangible impairments, and $78M other exit costs. Headcount reduction through July 2, 2000 approximately 2,400 employees; manufacturing plants reduced by 36, from 159 to 123. Cumulative cash outlays through July 2, 2000 of $45M against $140M accrued separation and exit costs, leaving $95M remaining accrual.
2000-07-02restructuringin_progress2,4001998-12-312000-12-31WorldwideManufacturing and operationsUSD 613 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cumulative headcount reduction of approximately 2,400 employees through 2000-07-02 since plan approval in Q4 1998; plan reduces manufacturing plants from 159 to 123; $45M cash outlays in first half 2000 for severance and exit costs; remaining accrual $95M at quarter end
2000-07-02acquisition_additioncompletedMedical devicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisitions of Innovasive Devices and Medtrex completed in Q1 2000; no headcount disclosed for either acquisition
2000-07-02restructuringin_progress2,4001998-Q42000-12-31WorldwideManufacturing and operations facilitiesUSD 613 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in Q4 1998 to reconfigure global network. Headcount reduction of approx 2,400 employees through July 2, 2000. Includes plant closures (159 to 123 plants).
2000-07-02acquisition_additioncompleted2000-Q1Professional (Medical Devices)USD 82 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Innovasive Devices and Medtrex in Q1 2000. Net cash payment $7 million; fair value of assets acquired $83 million. Headcount not disclosed.
2000-04-02restructuringin_progress1,9001998-Q42000GlobalManufacturing and operationsUSD 613 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan approved Q4 1998 to reconfigure global manufacturing network; targeted completion in 2000. Charge comprises $161M employee separations, $322M asset impairments, $52M intangible impairments, $78M other exit costs. Headcount reduction through April 2, 2000 approximately 1,900 employees; manufacturing plants reduced from 159 to 123. Cash outlays of $26M in the quarter against $140M accrual at January 2, 2000.
2000-04-02acquisition_additioncompleted2000-01-032000-04-02Professional segment / sports medicine and electrosurgeryUSD 7 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Company completed acquisitions of Innovasive Devices (sports medicine surgical devices) and Medtrex (electrosurgical generators and disposables) during the quarter; net cash payments of $7 million. No headcount figures disclosed.
2000-04-02restructuringin_progress1,9001998-10-012000-12-31WorldwideManufacturing and operationsUSD 613 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Global network reconfiguration approved Q4 1998; ~1,900 headcount reduction is cumulative through 2000-04-02, not quarter-only. Charge comprises $161M separations, $322M asset impairments, $52M intangible impairments, $78M other exit costs. Remaining accrual $114M at quarter-end after $26M outlays in the quarter. Plan includes closure of 36 plants (159 to 123).
2000-04-02acquisition_additioncompletedUnited StatesProfessional (medical devices)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Completed acquisitions of Innovasive Devices (sports medicine surgical devices) and Medtrex (electrosurgical generators) during the quarter; no headcount added disclosed. Net cash payments for acquisitions were $7M in the quarter.
2000-04-02restructuringin_progress1,9001998-Q42000-12-31WorldwideManufacturing and operationsUSD 613 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in Q4 1998 to reconfigure global network. Headcount reduction of approx 1,900 employees through April 2, 2000. Total estimated cost $613M.
2000-04-02acquisition_additioncompleted2000-04-022000-04-02United StatesProfessionalUSD 7 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Completed acquisition of Innovasive Devices and Medtrex. Net cash payment $7M. Employee count not disclosed.
2000-01-02restructuringin_progress1,6001998-10-012000-12-31WorldwideManufacturing and operationsUSD 613 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Program approved Q4 1998 to reconfigure global manufacturing network; 1,600 is current-year (FY1999) headcount reduction only. Program total charge $613M includes $553M restructuring charge and $60M inventory write-offs in COGS. Cumulative program involves closure of 36 manufacturing facilities (from 159 to 123 plants). Current-year cash outlays $96M; remaining accrual $140M at year-end. Targeted for completion in 2000.
2000-01-02acquisition_additioncompleted1999-10-061999-10-06WorldwidePharmaceuticalbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Centocor, Inc. merger completed October 6, 1999, accounted for as pooling-of-interests; approximately 45 million J&J shares issued. No employee headcount addition disclosed for this transaction.
2000-01-02acquisition_additioncompleted1999-12-311999-12-31United StatesConsumerbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		AVEENO dermatological skin care business acquired from S.C. Johnson during 1999; no headcount disclosed. Other 1999 acquisitions include AngioGuard, Cygnus drug delivery assets, Medscand TVT assets, and Horizon Health Services — none with disclosed headcount.
2000-01-02restructuringin_progress1,6001998-10-012000-12-31WorldwideManufacturing and OperationsUSD 161 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Headcount reduction for the year ended January 2, 2000 was approximately 1,600 employees. Part of a plan approved in Q4 1998 to reconfigure global manufacturing network. Employee separation costs of $161 million recorded in 1998.
1999-10-03restructuringin_progress5,1001998-12-311999-12-31GlobalManufacturing and operationsUSD 613 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan approved Q4 1998 to reconfigure global manufacturing network; expected completion over the twelve months following approval. Charge comprises $161M employee separations, $322M asset impairments, $52M intangible impairments, $78M other exit costs. Approximately 1,500 of the ~5,100 affected employees had been separated as of 1999-10-03; $59M of the $236M accrual paid through nine months. Program reduces manufacturing plants from 159 to 123 (36 closures).
1999-10-03acquisition_additioncompleted1999-10-061999-10-06United StatesPharmaceuticalUSD 5,000 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Merger with Centocor, Inc. completed October 6, 1999, accounted for as a pooling of interests; ~45 million J&J shares issued (~53 million on a fully diluted basis). No headcount figures disclosed.
1999-10-03acquisition_additionannounced1999-11-08United StatesProfessional (sports medicine devices)USD 85 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Definitive agreement to acquire Innovasive Devices, Inc. under the purchase method; subject to shareholder approval and Hart-Scott-Rodino clearance. No headcount figures disclosed.
1999-10-03restructuringin_progress5,1001998WorldwideManufacturing and operationsUSD 613 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan approved in Q4 1998 (exact date not disclosed) to reconfigure the global manufacturing/operating network; includes closure of 36 plants (159 to 123). Approximately 5,100 employee separations planned, of which 1,500 had occurred by 1999-10-03. Employee separation component $161M of the $613M total estimated cost; severance/exit accrual $236M at start of 1999, $59M paid through nine months, $177M remaining. Filer expects completion over the next twelve months; no specific completion date stated.
1999-10-03acquisition_additioncompleted1999-10-06United StatesBiopharmaceuticalsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Centocor merger completed 1999-10-06, valued at approximately $5 billion, accounted for as a pooling of interests; definitive agreement announced during the quarter (exact date not disclosed). About 45 million J&J shares issued (about 53 million fully diluted); no headcount added disclosed.
1999-10-03acquisition_additionannounced1999-11-08United StatesMedical devices — sports medicine surgerysubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive merger agreement to acquire Innovasive Devices, Inc., valued at approximately $85 million, purchase method; pending shareholder approval and Hart-Scott-Rodino clearance. No headcount disclosed.
1999-10-03acquisition_additioncompletedUnited States, Canada and Western EuropeConsumerbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of the S.C. Johnson & Son dermatological skin care business (primary brand AVEENO) completed during the first quarter of 1999; exact dates not disclosed. Pro forma results reported as not materially different; no headcount added disclosed.
1999-10-03restructuringin_progress5,1001998-10-012000-10-03WorldwideManufacturing and operationsUSD 161 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in Q4 1998 to reconfigure global manufacturing network. Total estimated cost $613M. Employee separations reflect termination of approx 5,100 employees; 1,500 separated as of Oct 3, 1999. Plan expected to complete over next twelve months from report date.
1999-10-03acquisition_additioncompleted1999-10-061999-10-06United StatesPharmaceuticalUSD 5,000 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Merger with Centocor, Inc. completed Oct 6, 1999. Valued at approx $5 billion. Accounted for as pooling of interests. Headcount not disclosed.
1999-10-03acquisition_additionannounced1999-11-08United StatesProfessionalUSD 85 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Definitive merger agreement to acquire Innovasive Devices, Inc. announced Nov 8, 1999. Valued at approx $85 million. Headcount not disclosed.
1999-07-04restructuringin_progress5,1001998-01-012000-07-04GlobalManufacturing and operationsUSD 613 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan approved in 1998 to reconfigure global manufacturing/operating network; expected completion over next twelve months from filing. Charge comprises $161M employee separations (~5,100 employees, 800 separated as of 1999-07-04), $322M asset impairments, $52M intangible impairments, $78M other exit costs. Remaining severance accrual of $236M at period start, $36M cash outlays in first six months of 1999.
1999-07-04restructuringin_progress5,10019982000-07-04WorldwideManufacturing and operationsUSD 613 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Global network reconfiguration approved in 1998; estimated cost $613M comprises $161M employee separations, $322M asset impairments, $52M intangible impairments, $78M other exit costs. Approximately 800 of the ~5,100 planned separations completed as of 1999-07-04; remaining accrual $200M. Completion expected over the following twelve months (date approximate).
1999-07-04acquisition_additioncompletedUnited States, Canada, Western EuropeConsumerbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		First-quarter acquisition of S.C. Johnson & Son dermatological skin care business (AVEENO); no headcount added disclosed.
1999-07-04acquisition_additionannounced1999-07-21United StatesPharmaceuticalsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to merge with Centocor, Inc. in stock-for-stock exchange, total equity value $4.9 billion; closing subject to Centocor shareholder approval, HSR clearance and other conditions. No headcount impact disclosed.
1999-07-04restructuringin_progress5,1001998-01-012000-01-01GlobalManufacturing and operationsUSD 613 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in 1998 to reconfigure global network. Total estimated cost $613M. 800 of 5,100 employees separated as of July 4, 1999. Expected completion over next twelve months from report date.
1999-07-04acquisition_additioncompleted1999-01-011999-01-01U.S., Canada, Western EuropeConsumerbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired dermatological skin care business of S.C. Johnson & Son, Inc. in first quarter. Headcount not disclosed.
1999-07-04acquisition_additionannounced1999-07-21GlobalPharmaceuticalUSD 4,900 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Announced merger with Centocor, Inc. Total equity value $4.9 billion. Headcount not disclosed.
1999-04-04restructuringin_progress5,1001998-01-012000-07-04GlobalManufacturing and operations facilitiesUSD 613 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan to reconfigure global manufacturing/operating network; includes facility closures, business exits, and employee separations. Charge comprises $161M employee separations, $322M asset impairments, $52M intangible impairments, $78M other exit costs. Expected completion over next fifteen months from filing.
1999-04-04reduction_in_forcein_progress5,1001998-01-012000-07-04GlobalManufacturing and operationsUSD 161 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Employee separation component of restructuring plan; 750 of approximately 5,100 affected employees separated as of April 4, 1999. Remaining severance accrual of $150M at quarter-end.
1999-04-04restructuringin_progress5,1001998WorldwideManufacturing and operations facilitiesUSD 613 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Global facility reconfiguration plan approved in 1998; ~5,100 employee terminations planned, 750 separated as of 1999-04-04. Charge comprises separations $161M, asset impairments $322M, intangible impairments $52M, other exit costs $78M. Expected completion over the next fifteen months per filing; remaining severance accrual $150M and other exit accrual $69M at quarter end
1999-04-04acquisition_additioncompletedUnited States, Canada, Western EuropeConsumer — dermatological skin care (AVEENO)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of S.C. Johnson & Son dermatological skin care business completed during the quarter; headcount added not disclosed
1999-04-04restructuringin_progress5,1001998-01-012000-04-01GlobalManufacturing and operationsUSD 161 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in 1998 to reconfigure global network. Total estimated cost $613M. Employee separation costs $161M for approx 5,100 employees. 750 separated as of April 4, 1999. Plan expected to complete over 15 months from approval.
1999-04-04acquisition_additioncompleted1999-04-041999-04-04U.S., Canada, Western EuropeConsumerbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired dermatological skin care business of S.C. Johnson & Son, Inc., including AVEENO brand. Headcount not disclosed.
1999-01-03restructuringin_progress2,5501998WorldwideConsumerUSD 85 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Component of global reconfiguration plan approved in Q4 fiscal 1998 (total plan cost $613 million; closures representing about 10% of manufacturing capacity; completion expected over roughly 18 months). Consumer segment total special pre-tax charge was $244 million: $85 million severance, $133 million asset write-downs, $26 million other exit costs. Company-wide actual headcount reduction in fiscal 1998 was approximately 225 employees; most planned separations not yet executed at year-end.
1999-01-03restructuringin_progress2501998WorldwidePharmaceuticalUSD 18 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Same Q4 fiscal 1998 reconfiguration program as Consumer and Professional components. Pharmaceutical segment total special pre-tax charge was $65 million: $18 million severance and $47 million asset write-downs.
1999-01-03restructuringin_progress2,3001998WorldwideProfessionalUSD 58 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Same Q4 fiscal 1998 reconfiguration program. Professional segment restructuring charge was $304 million: $58 million severance, $194 million asset write-downs, $52 million other exit costs. The segment also carried a separate $164 million purchased in-process R&D write-off from 1998 acquisitions (non-workforce charge, not captured here).
1999-01-03restructuringannouncedWorldwideProfessional — DePuy orthopaedicsbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Plan to reconfigure and integrate DePuy operations (acquisition completed November 1998) was being finalized at filing; expected to result in employee terminations and facility closures, to be recorded as opening balance sheet adjustments and not expected to be material. Targeted for completion within one year of the acquisition date.
1999-01-03restructuringin_progress2,5501998-10-012000-06-30WorldwideConsumerUSD 85 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Part of global manufacturing reconfiguration plan approved Q4 1998; Consumer segment total special charge $244M including $133M asset write-down and $26M other exit costs; announcement date approximate (Q4 1998); completion within 18 months of approval
1999-01-03restructuringin_progress2501998-10-012000-06-30WorldwidePharmaceuticalUSD 18 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Part of global manufacturing reconfiguration plan approved Q4 1998; Pharmaceutical segment total special charge $65M including $47M asset write-down; announcement date approximate (Q4 1998)
1999-01-03restructuringin_progress2,3001998-10-012000-06-30WorldwideProfessionalUSD 58 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Part of global manufacturing reconfiguration plan approved Q4 1998; Professional segment total restructuring charge $304M including $194M asset write-down and $52M other exit costs; announcement date approximate (Q4 1998)
1999-01-03acquisition_additioncompleted1998-11-30WorldwideProfessionalbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of DePuy, Inc. completed November 1998 for $3.7 billion; headcount added not disclosed; also acquired FemRx during 1998
1999-01-03restructuringin_progress2251998-Q41999-Q4WorldwideManufacturing and OperationsUSD 613 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Headcount reduction for the year ended Jan 3, 1999 was approx 225 employees. Plan expected to be completed over next 18 months. Charge includes $161M employee separations, $322M asset impairments, $52M intangible impairments, $78M other exit costs.
1999-01-03acquisition_additioncompleted1998-11-01WorldwideProfessional (Orthopaedics)USD 3,700 (millions)business_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of DePuy, Inc. completed in Nov 1998 for $3.7B. Specific headcount added not disclosed in filing.
1999-01-03restructuringin_progress2251998-10-011999-10-01WorldwideManufacturing and OperationsUSD 613 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Plan approved in Q4 1998 to reconfigure global manufacturing facilities. Expected completion over 18 months. Headcount reduction of approx 225 employees for the year ended Jan 3, 1999. Charge includes $161M employee separations, $322M asset impairments, $52M intangible impairments, $78M other exit costs.
1999-01-03restructuringin_progress2,5501998-10-011999-10-01WorldwideConsumerUSD 244 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Consumer segment portion of restructuring plan. Includes $85M severance for approx 2,550 employees, $133M impaired assets, $26M other exit costs.
1999-01-03restructuringin_progress2501998-10-011999-10-01WorldwidePharmaceuticalUSD 65 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Pharmaceutical segment portion of restructuring plan. Includes $18M severance for approx 250 employees, $47M impaired assets.
1999-01-03restructuringin_progress2,3001998-10-011999-10-01WorldwideProfessionalUSD 304 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Professional segment portion of restructuring plan. Includes $58M severance for approx 2,300 employees, $194M impaired assets, $52M other exit costs. Excludes $164M IPR&D write-off.
1998-09-27acquisition_additioncompleted1998-07-211998-11-04United StatesProfessional (Orthopaedics)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of DePuy, Inc. at $35.00 per share (~$3.5 billion); tender offer expired 1998-10-29 and merger completed 1998-11-04, both after quarter end. No employee headcount added disclosed; company anticipates a one-time charge for in-process R&D and restructuring.
1998-06-28acquisition_additionannounced1998-07-21United StatesOrthopaedic productssubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire DePuy, Inc. at $35.00 per share (~$3.5 billion aggregate); tender offer commenced 1998-07-27. Filing anticipates a one-time charge for in-process R&D and restructuring after close. No employee count disclosed.
1998-06-28acquisition_additioncompletedMedical devices (coronary stent)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		First-quarter acquisition of IsoStent, Inc. (BX Stent intellectual property and specific assets). No headcount disclosed; pro forma results reported as not materially different.
1997-09-28acquisition_additioncompleted1997-07-311997-07-31United StatesProfessional (medical devices)USD 276 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Stock-for-stock merger with Biopsys Medical, Inc. valued at $276 million net of cash acquired; accounted for as a pooling of interests. No employee count disclosed.
1997-09-28acquisition_additioncompleted1997-09-281997-09-28not disclosedProfessional (hospital consulting)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of McFaul & Lyons, a hospital operations design and materials management consulting firm, completed during the quarter; exact date not stated. No employee count or purchase price disclosed.
1997-09-28acquisition_additionannounced1997-09-28not disclosedProfessional (women's health devices)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Merger agreement with Gynecare, Inc. signed and announced during the quarter, stock-for-stock; no employee count disclosed.
1997-09-28acquisition_additionannounced1997-09-28not disclosedProfessional (medical sensor technology)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Merger agreement with Biosense, Inc. signed and announced during the quarter, stock-for-stock; no employee count disclosed.
1997-06-29acquisition_additioncompletedUnited StatesConsumer (eyecare/lens products); Medical Devices (endovascular devices)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Two first-quarter acquisitions (Innotech, Inc. and Nitinol Development Corporation) completed for an aggregate purchase price of $158 million; no headcount added disclosed. Pro forma results reported as not materially different.
1997-06-29acquisition_additioncompleted1997-06-29not disclosedConsumerbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Second-quarter announcement of acquisition of Pharmacia & Upjohn's Motrin (ibuprofen) brand via a product exchange of several smaller consumer brands; no headcount or transaction value disclosed.
1997-06-29acquisition_additioncompleted1997-06-291997-07-31United StatesProfessional (breast biopsy systems)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Stock-for-stock merger with Biopsys Medical, Inc. (NASDAQ:BIOP) valued at $276 million net of cash acquired, effective 1997-07-31 (after quarter end); no headcount added disclosed.
1996-12-29acquisition_additioncompleted1996-02-231996-02-23United StatesProfessionalbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cordis Corporation merger completed February 23, 1996, accounted for as pooling of interests. Approximately 17.6 million Cordis shares outstanding on a fully diluted basis at merger. No employee headcount disclosed for the acquired workforce.
1996-12-29acquisition_additioncompletedUnited StatesProfessionalUSD 233 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		1996 acquisitions totaling $233 million including Indigo Medical, Inc. and Lactaid trademarks. No employee headcount disclosed for acquired businesses.
1996-03-31acquisition_additioncompleted1996-02-231996-02-23Professional (interventional cardiology)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Cordis merger completed February 23, 1996, accounted for as pooling of interests; added approximately 18.6 million J&J shares issued. Cordis had about 17.6 million fully diluted shares outstanding. No employee headcount figure disclosed.
1996-03-31acquisition_additioncompleted1996-02-23Professional (interventional cardiology)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cordis Corporation merger completed 1996-02-23; accounted for as a pooling of interests with total value net of cash of approximately $1.8 billion. No employee or headcount figures disclosed; announcement date not stated in this filing (merger previously announced).
1995-10-01acquisition_additionannounced1995-11-13United StatesMedical Devices (Cordis Corporation)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Stock-for-stock merger agreement at $109 per share, roughly $1.8 billion equity value net of cash; no employee counts or workforce impact disclosed. Shareholder vote expected in about 90 days.